

Tuesday, August 19, 2025

Volume 56 No. 8



NOTICE – Items in this issue will be listed online weekly and printed monthly.

NEW COMPANY DESCRIPTIONS

(For details on individual listings, see the News Section of this issue)

RSE Collection LLC
RSE Innovation LLC

10X GENOMICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	327,791	294,110
Cost & expenses	336,993	397,345
Operating income	(9,202)	(103,235)
Other income (expense), net	4,739	(1,096)
Net before taxes	3,491	(94,882)
Income taxes	3,311	2,964
Net income	180	(97,846)
Earnings common share		
Primary	\$(0.82)	\$(0.82)
Fully Diluted	\$(0.82)	\$(0.82)
Common Shares:		
Full Diluted	124,258	119,461
Year-end	124,442	120,474

1STDIBS.COM INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	44,680	44,297
Cost & expenses	56,652	56,143
Operating income	(11,972)	(11,846)
Other income (expense), net	788	772
Net before taxes	(9,096)	(7,736)
Income taxes	23	4
Net income	(9,119)	(7,740)
Earnings common share		
Primary	\$(0.26)	\$(0.20)
Fully Diluted	\$(0.26)	\$(0.20)
Common Shares:		
Full Diluted	35,697	39,131
Year-end	36,247	36,693

4D MOLECULAR THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	29	33
Cost & expenses	113,106	80,625
Operating income	(113,077)	(80,592)
Other income (expense), net	6	(55)
Net income	(102,630)	(67,354)
Earnings common share		
Primary	\$(1.84)	\$(1.29)
Fully Diluted	\$(1.84)	\$(1.29)
Common Shares:		
Full Diluted	55,836	52,277
Year-end	46,700	51,914

89BIO INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Cost & expenses	191,733	110,713
Operating income	(191,733)	(110,713)
Net before taxes	(181,889)	(99,421)
Income taxes	890	231
Net income	(182,779)	(99,652)
Earnings common share		
Primary	\$(1.20)	\$(1.02)
Fully Diluted	\$(1.20)	\$(1.02)
Common Shares:		
Full Diluted	152,154	97,839
Year-end	148,305	104,915

908 DEVICES INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	24,813	18,884
Cost & expenses	50,999	35,034
Operating income	(26,186)	(16,150)
Other income (expense), net	1,500	(180)
Net before taxes	(22,674)	(16,330)
Income taxes	71	(13,468)
Net income	(22,674)	(13,468)
Earnings common share		
Primary	\$0.85	\$(0.70)
Fully Diluted	\$0.85	\$(0.70)
Common Shares:		
Full Diluted	35,634	33,386
Year-end	36,058	34,631

AAON, INC.

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	633,621	575,665
Cost & expenses	574,928	461,496
Operating income	58,693	114,169
Other income (expense), net	106	252
Net before taxes	51,988	113,815
Income taxes	44,779	91,244
Net income	\$0.55	\$1.12
Earnings common share		
Primary	\$0.55	\$1.12
Fully Diluted	\$0.54	\$1.09
Common Shares:		
Full Diluted	83,154	83,528
Year-end	81,509	80,951

ACACIA RESEARCH CORP

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	175,659,000	50,158,000
Cost & expenses	139,806,000	50,330,000
Operating income	25,920,000	(6,845,000)
Other income (expense), net	(870,000)	(12,856,000)
Gains or losses	(944,000)	(2,584,000)
Invest. income	3,512,000	
Net before taxes	28,719,000	(17,188,000)
Income taxes	6,628,000	(8,170,000)
Net income	22,091,000	(9,018,000)
Earnings common share		
Primary	\$0.22	\$(0.09)
Fully Diluted	\$0.22	\$(0.09)
Common Shares:		
Full Diluted	96,964,308	99,912,854
Year-end	96,444,993	100,375,459

ACADIA PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	508,882,000	447,794,000
Cost & expenses	457,219,000	402,147,000
Operating income	51,663,000	45,647,000
Other income (expense), net	1,183,000	672,000
Net before taxes	67,990,000	58,184,000
Income taxes	22,337,000	8,240,000
Net income	45,653,000	49,944,000
Earnings common share		
Primary	\$0.27	\$0.30
Fully Diluted	\$0.27	\$0.30
Common Shares:		
Full Diluted	168,219,000	166,391,000
Year-end	168,607,881	165,853,301

ACI WORLDWIDE INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	795,823	689,498
Cost & expenses	654,363	571,042
Operating income	93,374	63,261
Other income (expense), net	(1,093)	(869)
Invest. income	25,927	
Net before taxes	89,509	32,873
Income taxes	18,437	9,737
Net income	71,072	23,136
Earnings common share		
Primary	\$0.68	\$0.22
Fully Diluted	\$0.67	\$0.22
Common Shares:		
Full Diluted	105,960	106,815
Year-end	103,413	104,861

ACLARIS THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	3,232	5,163
Cost & expenses	39,724	36,949
Operating income	(36,492)	(31,786)
Other income (expense), net	1,794	3,859
Net income	(30,514)	(27,927)
Earnings common share		
Primary	\$(0.25)	\$(0.39)
Fully Diluted	\$(0.25)	\$(0.39)
Common Shares:		
Full Diluted	122,486	71,183
Year-end	108,329	71,333

ACM RESEARCH INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	387,719	354,671
Cost & expenses	330,248	291,846
Operating income	57,471	62,825
Other income (expense), net	2,117	3,222
Invest. income	1,702	(1,291)
Net before taxes	65,327	67,196
Income taxes	4,044	13,705
Net income	61,283	53,491
Earnings common share		
Primary	\$0.79	\$0.67
Fully Diluted	\$0.74	\$0.61
Common Shares:		
Full Diluted	67,138	66,521
Year-end	64,119	62,424

ACV AUCTIONS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	376,400	306,313
Cost & expenses	376,588	330,846
Operating income	(21,626)	(41,168)
Net before taxes	(21,781)	(36,949)
Income taxes	334	585
Net income	(22,115)	(37,534)
Earnings common share		
Primary	\$(0.13)	\$(0.23)
Fully Diluted	\$(0.13)	\$(0.23)
Common Shares:		
Full Diluted	169,415	163,637
Year-end	171,559	166,030

ADAPTIVE BIOTECHNOLOGIES CORP

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	111,322	85,063
Cost & expenses	165,120	180,296
Operating income	(54,640)	(96,080)
Net income	(55,423)	(93,781)
Earnings common share		
Primary	\$(0.37)	\$(0.64)
Fully Diluted	\$(0.37)	\$(0.64)
Common Shares:		
Full Diluted	150,647	146,601
Year-end	152,235	147,462

ADDUS HOMECARE CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	687,151	567,668
Cost & expenses	615,894	510,972
Operating income	63,401	49,826
Net before taxes	56,943	45,851
Income taxes	13,663	11,942
Net income	43,280	33,909
Earnings common share		
Primary	\$2.40	\$2.10
Fully Diluted	\$2.36	\$2.06
Common Shares:		
Full Diluted	18,340	16,449
Year-end	18,407	18,100

ADEIA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	173,405	170,755
Cost & expenses	105,913	84,562
Operating income	39,240	43,006
Other income (expense), net	3,146	2,375
Net before taxes	21,521	17,910
Income taxes	(7,015)	8,629
Net income	28,536	9,281
Earnings common share		
Primary	\$0.26	\$0.09
Fully Diluted	\$0.25	\$0.08
Common Shares:		
Full Diluted	112,597	112,757
Year-end	109,325	108,854

ADICET BIO INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	62,277	63,719
Operating income	(62,277)	(63,719)
Other income (expense), net	(235)	(113)
Net income	(59,431)	(57,917)
Earnings common share		
Primary	\$(0.65)	\$(0.68)
Fully Diluted	\$(0.65)	\$(0.68)
Common Shares:		
Full Diluted	91,121	84,848
Year-end	83,253	82,401

ADMA BIOLOGICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	236,786,000	189,066,000
Cost & expenses	159,051,000	127,709,000
Operating income	77,678,000	61,022,000
Other income (expense), net	(1,331,000)	(51,000)
Net before taxes	73,546,000	54,252,000
Income taxes	12,424,000	4,384,000
Net income	61,122,000	49,868,000
Earnings common share		
Primary	\$0.26	\$0.22
Fully Diluted	\$0.25	\$0.21
Common Shares:		
Full Diluted	245,750,155	239,645,940
Year-end	238,567,308	233,026,736

ADTRAN HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	512,812,000	452,164,000
Cost & expenses	530,098,000	836,865,000
Operating income	(17,286,000)	384,701,000
Other income (expense), net	(1,692,000)	409,000
Invest. income	1,389,000	3,125,000

Net before taxes	(26,587,000)	391,908,000
Income taxes	619,000	(16,511,000)
Net income	(27,206,000)	375,397,000
Earnings common share		
Primary	\$(0.38)	\$(4.83)
Fully Diluted	\$(0.38)	\$(4.83)
Common Shares:		
Full Diluted	79,642,000	78,803,000
Year-end	79,779,000	78,855,000

ADVANCED ENERGY INDUSTRIES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	846,100	
Cost & expenses	772,800	665,030
Operating income	62,200	13,645
Other income (expense), net	(8,100)	2,017
Net before taxes	59,200	26,343
Income taxes	8,800	4,952
Income contin. oper.	50,400	21,391
Net income	49,900	20,245
Earnings common share		
Primary	\$1.33	\$0.54
Fully Diluted	\$1.31	\$0.54
Common Shares:		
Full Diluted	38,000	37,733
Year-end	37,700	37,671

AIRBNB INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	5,368,000	4,890,000
Cost & expenses	4,718,000	4,292,000
Operating income	650,000	598,000
Other income (expense), net	(61,000)	(52,000)
Net before taxes	952,000	974,000
Income taxes	156,000	155,000
Net income	796,000	819,000
Earnings common share		
Primary	\$1.29	\$1.29
Fully Diluted	\$1.27	\$1.26
Common Shares:		
Full Diluted	629,000	651,000
Year-end	613,000	634,000

AKAMAI TECHNOLOGIES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,058,633	1,966,550
Cost & expenses	1,697,231	1,609,737
Operating income	306,044	314,714
Other income (expense), net	569	(438)
Net before taxes	325,321	355,098
Income taxes	98,532	47,992
Net income	226,789	307,106
Earnings common share		
Primary	\$1.54	\$2.02
Fully Diluted	\$1.53	\$1.97
Common Shares:		
Full Diluted	148,156	155,527
Year-end	143,200	151,913

AKEBIA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	119,808,000	76,255,000
Cost & expenses	92,205,000	99,915,000
Operating income	27,603,000	(23,660,000)
Other income (expense), net	185,000	(461,000)
Gains or losses	(6,825,000)	2,201,000
Net income	6,359,000	(26,567,000)
Earnings common share		
Primary	\$0.03	\$(0.13)
Fully Diluted	\$0.02	\$(0.13)
Common Shares:		
Full Diluted	256,539,065	207,330,274
Year-end	263,041,832	209,929,145

AKERO THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	161,755	125,695
Operating income	(161,755)	(125,695)
Net income	(141,230)	(109,331)

Earnings common share		
Primary	\$(1.76)	\$(1.70)
Fully Diluted	\$(1.76)	\$(1.70)
Common Shares:		
Full Diluted	80,197	64,234
Year-end	79,919	69,206

ALARM.COM HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	493,130	457,090
Cost & expenses	416,903	398,174
Operating income	61,669	44,499
Other income (expense), net	(2,835)	(1,576)
Equity earnings	(316)	
Net before taxes	74,378	59,555
Income taxes	12,765	3,631
Net income	61,929	55,924
Earnings common share		
Primary	\$1.26	\$1.14
Fully Diluted	\$1.15	\$1.06
Common Shares:		
Full Diluted	60,160	55,868
Year-end	49,835	49,184

ALECTOR INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	11,548	30,976
Cost & expenses	90,381	120,290
Operating income	(78,833)	(89,314)
Other income (expense), net	7,838	14,639
Net before taxes		(74,675)
Income taxes		80
Net income	(70,995)	(74,755)
Earnings common share		
Primary	\$(0.71)	\$(0.78)
Fully Diluted	\$(0.71)	\$(0.78)
Common Shares:		
Full Diluted	99,888	95,243
Year-end	101,212	97,321

ALIGN TECHNOLOGY INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,991,711	
Cost & expenses	1,697,578	1,724,740
Operating income	294,133	301,181
Other income (expense), net	11,650	(6,622)
Net before taxes	313,958	302,252
Income taxes	96,120	100,660
Net income	217,838	201,592
Earnings common share		
Primary	\$2.98	\$2.68
Fully Diluted	\$2.98	\$2.68
Common Shares:		
Full Diluted	73,098	75,315
Year-end	72,486	74,696

ALIGOS THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,276	
Cost & expenses	39,086	50,507
Operating income	(37,810)	(48,460)
Other income (expense), net	848	17,972
Gains or losses	63,176	
Net before taxes	27,453	(29,589)
Income taxes	228	213
Net income	27,225	(29,802)
Earnings common share		
Primary	\$2.90	\$(0.19)
Fully Diluted	\$2.90	\$(0.19)
Common Shares:		
Full Diluted	9,402	156,299
Year-end	6,951	82,878

ALLBIRDS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	71,798	140,908
Cost & expenses	111,155	(49,999)
Operating income	(39,357)	1,749
Other income (expense), net	1,749	(194)
Gains or losses		(37,229)
Net before taxes	(37,229)	147
Income taxes		
Net income	(37,376)	(46,463)
Earnings common share		
Primary	\$(4.64)	\$(6.00)
Fully Diluted	\$(4.64)	\$(6.00)
Common Shares:		
Full Diluted	8,055	7,797
Year-end	8,147	7,883

ALLEGiant TRAVEL COMPANY**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,388,458	1,322,688
Cost & expenses	1,259,115	1,143,139
Operating income	(2,487)	50,344
Other income (expense), net	(941)	(117)
Net before taxes	(46,624)	16,688
Income taxes	(13,560)	3,908
Net income	(33,064)	12,780
Balance for common		12,162
Earnings common share		
Primary	\$(1.84)	\$0.69
Fully Diluted	\$(1.84)	\$0.68
Common Shares:		
Full Diluted	17,989	17,836
Year-end	18,351	18,318

ALLIANCE RESOURCE PARTNERS LP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,087,931	1,245,047
Cost & expenses	759,966	835,329
Operating income	182,996	277,715
Other income (expense), net	(27,914)	(2,269)
Gains or losses	7,282	8,105
Net before taxes	146,115	269,885
Income taxes	9,530	
Net income	136,585	261,076
Balance for common	131,848	253,358
Earnings common share		
Primary	\$1.03	\$1.98
Fully Diluted	\$1.03	\$1.98
Common Shares:		
Full Diluted	128,347	127,866
Year-end	128,428	128,062

ALLIENT INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	272,381	282,745
Cost & expenses	245,707	259,520
Operating income	20,456	16,979
Other income (expense), net	(1,507)	63
Net before taxes	11,762	10,270
Income taxes	2,588	2,218
Net income	9,174	8,052
Earnings common share		
Primary	\$0.55	\$0.49
Fully Diluted	\$0.55	\$0.49
Common Shares:		
Full Diluted	16,671	16,540
Year-end	16,938	16,841

ALPHA TEKNOVA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	20,082	18,904
Cost & expenses	27,858	31,416
Operating income	(8,350)	(13,086)
Other income (expense), net	485	
Net before taxes	(8,174)	(13,503)
Income taxes	41	(42)
Net income	(8,215)	(13,461)
Earnings common share		
Primary	\$(0.15)	\$(0.33)
Fully Diluted	\$(0.15)	\$(0.33)
Common Shares:		

Full Diluted	53,435	40,829
Year-end	53,514	40,915

ALTENERGY ACQUISITION CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	1,321,100	2,188,666
Operating income	(1,294,359)	(1,845,936)
Gains or losses	(483,600)	470,000
Net before taxes	(1,777,959)	(1,375,936)
Income taxes	58	53,131
Net income	(1,778,017)	(1,429,067)
Earnings common share		
Primary	\$(0.28)	\$(0.20)
Fully Diluted	\$(0.28)	\$(0.20)
Common Shares:		
Full Diluted	6,407,214	6,981,599
Year-end	6,266,197	6,488,146

ALTIMMUNE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	10,000	10,000
Cost & expenses	44,747,000	53,549,000
Operating income	(44,737,000)	(53,539,000)
Other income (expense), net	(77,000)	(88,000)
Net before taxes	(42,402,000)	
Income taxes	(681,000)	
Net income	(41,721,000)	(49,034,000)
Earnings common share		
Primary	\$(0.53)	\$(0.69)
Fully Diluted	\$(0.53)	\$(0.69)
Common Shares:		
Full Diluted	78,529,028	70,863,042
Year-end	85,076,300	71,046,267

ALX ONCOLOGY HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	58,468	79,287
Operating income	(58,468)	(79,287)
Other income (expense), net	(13)	(22)
Net income	(56,703)	(74,980)
Earnings common share		
Primary	\$(1.05)	\$(1.47)
Fully Diluted	\$(1.05)	\$(1.47)
Common Shares:		
Full Diluted	54,031	50,969
Year-end	53,507	52,453

AMC NETWORKS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,155,257	1,222,395
Cost & expenses	979,219	1,049,110
Operating income	128,666	120,966
Other income (expense), net	46,452	(3,450)
Net before taxes	105,886	59,636
Income taxes	31,027	34,542
Net income	74,859	25,094
Earnings common share		
Primary	\$1.52	\$0.37
Fully Diluted	\$1.25	\$0.37
Common Shares:		
Full Diluted	56,482	45,443
Year-end	43,383	44,097

AMERICA'S CAR-MART INC**Annual Report****Consolidated Income Statement, Years Ended Apr. 30 (\$):**

	2025	2024	2023 (revised)
Sales	1,146,208,000	1,160,798,000	1,204,194,000
Interest and other income	244,724,000	233,096,000	196,219,000
Total revenues	1,390,932,000	1,393,894,000	1,400,413,000
Selling, general & administrative expenses	188,921,000	179,421,000	176,696,000
Gain (loss) on disposal of property & equipment	(299,000)	(437,000)	(361,000)
Interest Expense	70,650,000	65,348,000	38,312,000

Income (loss) before income taxes	22,801,000	(40,135,000)	25,794,000
Current income tax provision (benefit)	15,531,000	12,765,000	(3,504,000)
Deferred income tax provision (benefit)	(10,662,000)	(21,507,000)	8,866,000
Net income	17,932,000	(31,393,000)	20,432,000
Provision for (benefit from) income taxes	4,869,000	(8,742,000)	5,362,000
Net income (loss)	17,932,000	(31,393,000)	20,432,000
Less: dividends on mandatorily redeemable preferred stock	40,000	40,000	40,000
Net income (loss) attributable to common stockholders	17,892,000	(31,433,000)	20,392,000
Weighted average shares outstanding - basic	7,524,770	6,388,537	6,371,229
Weighted average shares outstanding - diluted	7,681,590	6,388,537	6,566,896
Year end shares outstanding	8,263,280	6,394,675	6,373,404
Earnings (loss) per share-continuing operations-basic	\$2.38	\$(4.92)	\$3.20
Earnings (loss) per share - basic	\$2.38	\$(4.92)	\$3.20
Earnings (loss) per share-continuing operations-diluted	\$2.33	\$(4.92)	\$3.11
Earnings (loss) per share - diluted	\$2.33	\$(4.92)	\$3.11
Number of full time employees	2,300	2,280	...
Number of common stockholders	977	988	...
Cost of sales	726,055,000	758,546,000	800,788,000
Provision for credit losses	374,559,000	423,406,000	352,860,000
Depreciation and Amortization	7,647,000	6,871,000	5,602,000
Total number of employees	2,300	2,280	...

Reclassified to conform 2024 presentation

Consolidated Balance Sheet, Years Ended Apr. 30 (\$):

	2025	2024
Cash and Cash Equivalents	9,808,000	5,522,000
Restricted cash	114,729,000	88,925,000
Accrued interest on finance receivables	7,432,000	6,907,000
Inventory	112,229,000	107,470,000
Income taxes receivable, net	...	2,958,000
Right-of-use asset	63,825,000	61,185,000
Prepaid expenses and other assets	38,082,000	31,276,000
Restricted cash from collections on auto finance receivables	48,571,000	43,956,000
Restricted Cash on Deposit in Reserve		
Accounts	66,158,000	44,969,000
Goodwill	22,802,000	14,449,000
Land	11,998,000	11,998,000
Buildings & improvements	23,575,000	23,435,000
Furniture, fixtures & equipment	26,139,000	21,752,000
Construction in progress	1,028,000	2,393,000
Leasehold improvements	51,466,000	50,689,000
Accumulated depreciation and amortization	57,312,000	49,906,000
Property and equipment, net	56,894,000	60,361,000
Total assets	1,606,474,000	1,477,644,000
Accounts payable	34,980,000	21,379,000
Income taxes payable, net	1,451,000	...
Deferred payment protection plan revenue	51,458,000	51,836,000

Deferred service contract revenue	61,787,000	68,945,000
Accrued employee compensation & benefits	7,983,000	10,774,000
Deferred sales tax	...	6,234,000
Subsidiary redeemable preferred stock	7,898,000	7,627,000
Accrued interest	2,155,000	...
Fair value of contingent consideration	10,326,000	3,193,000
Other accrued liabilities	35,949,000	27,828,000
Notes payable	572,010,000	553,629,000
Cash overdraft	1,289,000	...
Fair Value of contingent consideration	6,298,000	...
Deferred income tax liabilities, net	7,146,000	17,808,000
Lease liability	67,002,000	64,250,000
Revolving line of credit	204,769,000	200,819,000
Total liabilities	1,036,552,000	1,006,494,000
Common stock	156,000	137,000
Additional paid-in capital	195,225,000	113,930,000
Retained earnings	672,261,000	654,369,000
Treasury stock	298,220,000	297,786,000
Mandatorily redeemable preferred stock	400,000	400,000
Total stockholders' equity	569,822,000	471,050,000
Non-controlling interest	100,000	100,000
Total equity	569,922,000	471,150,000

Recent Dividends:

1. America's Car-Mart Inc 8% cumulative mandatorily redeemable preferred.

No dividends paid.

2. America's Car-Mart Inc common.

No dividends paid.

Annual Dividends:

1. America's Car-Mart Inc 8% cumulative mandatorily redeemable preferred.

No dividends paid.

2. America's Car-Mart Inc common.

No dividends paid.

AMERICAN PUBLIC EDUCATION INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	327,317	307,327
Cost & expenses	299,966	289,565
Operating income	19,271	7,402
Equity earnings	4,407	4,407
Net before taxes	17,276	6,491
Income taxes	3,887	1,197
Net income	13,389	887
Balance for common	7,137	(2,179)
Earnings common share		
Primary	\$0.40	\$(0.12)
Fully Diluted	\$0.39	\$(0.12)
Common Shares:		
Full Diluted	18,496	17,568
Year-end	18,062	17,670

AMGEN INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	17,328,000	15,835,000
Cost & expenses	13,494,000	12,935,000
Operating income	3,834,000	2,900,000
Other income (expense), net	1,124,000	(542,000)
Net before taxes	3,541,000	726,000
Income taxes	379,000	93,000
Net income	3,162,000	633,000
Earnings common share		
Primary	\$5.88	\$1.18
Fully Diluted	\$5.84	\$1.17
Common Shares:		
Full Diluted	541,000	541,000
Year-end	538,300	537,200

AMPHASTAR PHARMACEUTICALS INC (DE)

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	344,942	354,230
Cost & expenses	265,465	251,003
Operating income	79,477	103,227
Other income (expense), net	(723)	6,219
Equity earnings	573	573
Net before taxes	70,197	98,119
Income taxes	13,882	16,420
Net income	56,315	81,126
Earnings common share		
Primary	\$1.19	\$1.67
Fully Diluted	\$1.15	\$1.54
Common Shares:		
Full Diluted	49,009	52,530
Year-end	46,491	48,962

AMLYX PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	87,620	87,620
Cost & expenses	80,660	286,036
Operating income	(80,660)	(198,416)
Other income (expense), net	(881)	(1,230)
Net before taxes	(191,251)	(191,251)
Income taxes	242	242
Net income	(77,350)	(191,493)
Earnings common share		
Primary	\$(0.88)	\$(2.82)
Fully Diluted	\$(0.88)	\$(2.82)
Common Shares:		
Full Diluted	87,427	67,940
Year-end	89,156	68,079

AN2 THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2025	2024
Cost & expenses	18,753,000	34,176,000
Operating income	(18,753,000)	(34,176,000)
Net income	(17,111,000)	(31,052,000)
Earnings common share		
Primary	\$(0.57)	\$(1.04)
Fully Diluted	\$(0.57)	\$(1.04)
Common Shares:		
Full Diluted	30,113,321	29,794,001
Year-end	27,376,461	29,829,040

ANAPTYSBIO INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	50,034	18,150
Cost & expenses	103,743	100,672
Operating income	(53,709)	(82,522)
Other income (expense), net	5,433	(2)
Net before taxes	(77,876)	(90,587)
Income taxes	83	9
Net income	(77,959)	(90,596)
Earnings common share		
Primary	\$(2.62)	\$(3.35)
Fully Diluted	\$(2.62)	\$(3.35)
Common Shares:		
Full Diluted	29,722	27,079
Year-end	27,973	27,434

ANDERSONS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	5,794,967	5,513,422
Cost & expenses	5,764,022	5,445,703
Operating income	28,048	71,314
Other income (expense), net	17,093	5,217
Gains or losses	3,117	3,117
Net before taxes	28,048	71,314
Income taxes	5,910	6,179
Net income	22,138	65,135
Earnings common share		
Primary	\$0.24	\$1.22
Fully Diluted	\$0.24	\$1.21
Common Shares:		
Full Diluted	34,298	34,302
Year-end	34,207	34,069

APA CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	5,224,000	4,695,000
Cost & expenses	2,327,000	2,226,000
Operating income	1,791,000	1,375,000
Other income (expense), net	67,000	(76,000)
Net before taxes	1,791,000	1,375,000
Net income	1,083,000	832,000
Earnings common share		
Primary	\$2.62	\$2.00
Fully Diluted	\$2.62	\$2.00
Common Shares:		
Full Diluted	362,000	337,000
Year-end	358,773	369,826

APPIAN CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	337,066	296,285
Cost & expenses	348,884	355,014
Operating income	(11,818)	(58,729)
Other income (expense), net	23,280	(6,662)
Net before taxes	825	(77,144)
Income taxes	2,314	(629)
Net income	(1,489)	(76,515)
Earnings common share		
Primary	\$(0.02)	\$(1.05)
Fully Diluted	\$(0.02)	\$(1.05)
Common Shares:		
Full Diluted	74,148	72,800
Year-end	74,021	72,343

APPLIED OPTOELECTRONICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	202,811	83,943
Cost & expenses	227,725	131,832
Operating income	(24,914)	(47,889)
Other income (expense), net	1,540	1,581
Gains or losses	(9)	(5)
Net income	(18,270)	(49,285)
Earnings common share		
Primary	\$(0.34)	\$(1.27)
Fully Diluted	\$(0.34)	\$(1.27)
Common Shares:		
Full Diluted	53,426	38,864
Year-end	61,890	40,645

APPROVIN CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2025	2024
Total Revenues	2,417,728,000	1,389,385,000
Cost & expenses	620,064,000	641,062,000
Operating income	1,797,664,000	748,323,000
Other income (expense), net	(14,757,000)	9,506,000
Net before taxes	1,678,610,000	609,486,000
Income taxes	183,216,000	49,147,000
Income contin. oper.	1,495,394,000	560,339,000
Net income	1,395,950,000	546,152,000
Balance for common	1,395,600,000	544,400,000
Earnings common share		
Primary	\$4.11	\$1.62
Fully Diluted	\$4.06	\$1.56
Common Shares:		
Full Diluted	343,528,576	348,327,848
Year-end	338,782,503	334,168,646

APREA THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2025	2024
Total Revenues	280,574	942,143
Cost & expenses	7,753,929	7,938,737
Operating income	(7,473,355)	(6,996,594)
Net income	(7,171,529)	(6,280,143)
Earnings common share		
Primary	\$(1.19)	\$(1.24)
Fully Diluted	\$(1.19)	\$(1.24)
Common Shares:		
Full Diluted	6,038,845	5,067,809
Year-end	5,752,175	5,430,215

APYX MEDICAL CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	20,803	22,393
Cost & expenses	26,428	34,555
Operating income	(5,625)	(12,162)
Other income (expense), net	(22)	(14,073)
Net before taxes	(7,812)	(14,073)
Income taxes	98	103
Net income	(7,910)	(14,176)
Earnings common share		
Primary	\$(0.19)	\$(0.41)
Fully Diluted	\$(0.19)	\$(0.41)
Common Shares:		
Full Diluted	40,729	34,644
Year-end	37,794	34,644

AQUESTIVE THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	18,723	32,152
Cost & expenses	49,456	41,054
Operating income	(30,733)	(8,902)
Other income (expense), net	(2,871)	(2,716)
Net income	(36,478)	(15,573)
Earnings common share		
Primary	\$(0.37)	\$(0.19)
Fully Diluted	\$(0.37)	\$(0.19)
Common Shares:		
Full Diluted	97,422	82,263
Year-end	99,353	91,060

ARCELLX INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	15,683	143,307
Cost & expenses	143,307	117,443
Operating income	(127,624)	(50,803)
Net before taxes	(115,012)	(34,059)
Income taxes	29	341
Net income	(115,041)	(34,400)
Earnings common share		
Primary	\$(2.06)	\$(0.65)
Fully Diluted	\$(2.06)	\$(0.65)
Common Shares:		
Full Diluted	55,742	53,137
Year-end	55,371	53,631

ARCTURUS THERAPEUTICS HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	57,683	87,871
Cost & expenses	86,125	139,409
Operating income	(28,442)	(51,538)
Net before taxes	(23,252)	(43,815)
Income taxes	4	218
Net income	(23,256)	(44,033)
Earnings common share		
Primary	\$(0.86)	\$(1.64)
Fully Diluted	\$(0.86)	\$(1.64)
Common Shares:		
Full Diluted	27,118	26,923
Year-end	27,148	27,042

ARCUTIS BIOTHERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	147,350	80,427
Cost & expenses	186,490	162,126
Operating income	(39,140)	(81,699)
Other income (expense), net	4,826	9,273
Net before taxes	(40,325)	(87,390)
Income taxes	621	324
Net income	(40,946)	(87,714)
Earnings common share		
Primary	\$(0.32)	\$(0.75)
Fully Diluted	\$(0.32)	\$(0.75)
Common Shares:		
Full Diluted	126,519	117,265
Year-end	119,798	116,480

ARHAUS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	669,807	604,963
Cost & expenses	617,621	557,221

Operating income	52,186	47,742
Other income (expense), net	236	197
Net before taxes	53,739	49,977
Income taxes	13,791	12,644
Net income	39,948	37,333
Earnings common share		
Primary	\$0.28	\$0.27
Fully Diluted	\$0.28	\$0.27
Common Shares:		
Full Diluted	141,127	140,736
Year-end	140,975	140,461

ARRAY TECHNOLOGIES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	664,606	409,169
Cost & expenses	579,953	342,649
Operating income	73,660	48,016
Other income (expense), net	14,151	(980)
Net before taxes	80,159	36,977
Income taxes	20,151	9,114
Net income	60,008	27,863
Balance for common	30,777	612
Earnings common share		
Primary	\$0.20	\$0.20
Fully Diluted	\$0.20	\$0.20
Common Shares:		
Full Diluted	152,958	152,170
Year-end	152,661	151,875

ARROWHEAD PHARMACEUTICALS INC**Earnings, 9 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	572,976,000	3,551,000
Cost & expenses	518,736,000	442,428,000
Operating income	54,240,000	438,877,000
Other income (expense), net	603,000	1,370,000
Net before taxes	15,412,000	439,662,000
Income taxes	1,419,000	(3,313,000)
Net income	13,993,000	436,349,000
Earnings common share		
Primary	\$0.17	\$(3.63)
Fully Diluted	\$0.17	\$(3.63)
Common Shares:		
Full Diluted	133,352,000	118,260,000
Year-end	138,144,000	124,227,000

ARVINAS INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	211,200,000	101,800,000
Cost & expenses	211,300,000	233,600,000
Operating income	(100,000)	131,800,000
Other income (expense), net	(400,000)	(100,000)
Net before taxes	21,500,000	104,300,000
Income taxes	(200,000)	300,000
Net income	21,700,000	104,600,000
Earnings common share		
Primary	\$0.30	\$(1.46)
Fully Diluted	\$0.30	\$(1.46)
Common Shares:		
Full Diluted	73,000,000	71,700,000
Year-end	73,200,000	68,600,000

ASSEMBLY BIOSCIENCES INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	19,045,000	
Cost & expenses	40,079,000	37,250,000
Operating income	(21,034,000)	(22,932,000)
Net before taxes		(19,823,000)
Income taxes		406,000
Net income	(19,016,000)	(20,229,000)
Earnings common share		
Primary	\$(2.51)	\$(3.64)
Fully Diluted	\$(2.51)	\$(3.64)
Common Shares:		
Full Diluted	7,581,501	5,563,033
Year-end	7,672,249	6,345,561

AST SPACEMOBILE INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	1,874,000	1,400,000
Cost & expenses	114,956,000	79,556,000
Operating income	(130,383,000)	122,702,000
Other income (expense), net	(443,000)	250,000
Gains or losses	(68,238,000)	(47,926,000)
Net before taxes	(198,621,000)	170,628,000
Income taxes	910,000	526,000
Net income	(199,531,000)	171,154,000
Earnings common share		
Primary	\$(0.62)	\$(0.70)
Fully Diluted	\$(0.62)	\$(0.70)
Common Shares:		
Full Diluted	233,101,209	131,316,319
Year-end	250,511,819	148,751,110

ASTEC INDUSTRIES, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	659,700	654,700
Cost & expenses	617,800	659,100
Operating income	41,900	(4,400)
Other income (expense), net	2,300	200
Net before taxes	42,300	(9,000)
Income taxes	11,200	1,700
Net income	31,100	(10,700)
Earnings common share		
Primary	\$1.36	\$(0.47)
Fully Diluted	\$1.35	\$(0.47)
Common Shares:		
Full Diluted	23,026	22,779
Year-end	22,875	22,801

ATARA BIOTHERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	115,724	55,997
Cost & expenses	73,725	105,475
Operating income	41,999	(49,478)
Other income (expense), net	11	62
Net before taxes	40,400	(50,777)
Income taxes	3	24
Net income	40,397	(50,801)
Earnings common share		
Primary	\$3.52	\$(8.64)
Fully Diluted	\$3.49	\$(8.64)
Common Shares:		
Full Diluted	11,576	5,883
Year-end	6,978	4,904

ATEA PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	80,386	116,722
Operating income	(80,386)	(116,722)
Net before taxes	(71,023)	(103,217)
Income taxes	410	474
Net income	(71,433)	(103,691)
Earnings common share		
Primary	\$(0.85)	\$(1.23)
Fully Diluted	\$(0.85)	\$(1.23)
Common Shares:		
Full Diluted	84,449	84,070
Year-end	81,137	84,422

ATHIRA PHARMA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	16,827	55,715
Operating income	(16,827)	(55,715)
Other income (expense), net	718	2,519
Net income	(16,109)	(53,196)
Earnings common share		
Primary	\$(0.41)	\$(1.39)
Fully Diluted	\$(0.41)	\$(1.39)
Common Shares:		
Full Diluted	39,068	38,351
Year-end	39,439	38,439

AUTOMATIC DATA PROCESSING INC.**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$000):**

[illegible]

securities	(338,900)	(1,178,000)
Adoption of SFAS No. 158, net	(883,400)	(1,808,300)
Pension liability	(227,000)	(231,500)
Hedging Reserves	(27,700)	(20,000)
Total stockholders' equity	6,188,000	4,547,600
Total Equity	6,188,000	4,547,600

Recent Dividends:**1. Automatic Data Processing Inc. common.**

ExDate	Amt	Declared	Record	Payable
12/09/2021	1.04	11/10/2021	12/10/2021	01/01/2022
03/10/2022	1.04	01/12/2022	03/11/2022	04/01/2022
06/09/2022	1.04	04/06/2022	06/10/2022	07/01/2022
09/08/2022	1.04	08/03/2022	09/09/2022	10/01/2022
12/08/2022	1.25	11/09/2022	12/09/2022	01/01/2023
03/09/2023	1.25	01/11/2023	03/10/2023	04/01/2023
06/08/2023	1.25	04/12/2023	06/09/2023	07/01/2023
09/07/2023	1.25	08/03/2023	09/08/2023	10/01/2023
12/07/2023	1.40	11/08/2023	12/08/2023	01/01/2024
03/07/2024	1.40	01/10/2024	03/08/2024	04/01/2024
06/14/2024	1.40	04/03/2024	06/14/2024	07/01/2024
09/13/2024	1.40	08/07/2024	09/13/2024	10/01/2024
12/13/2024	1.54	11/06/2024	12/13/2024	01/01/2025
03/14/2025	1.54	01/17/2025	03/14/2025	04/01/2025
06/13/2025	1.54	04/08/2025	06/13/2025	07/01/2025

Annual Dividends:**1. Automatic Data Processing Inc. common.**

2022	4.16	2023	5.00	2024	5.60
2025	4.62				

AVEANNA HEALTHCARE HOLDINGS INC**Earnings, 6 mos. to (Consol. - \$000):**

	06/28/25	06/29/24
Total Revenues	1,148,777	995,611
Cost & expenses	1,011,731	929,874
Operating income	131,835	59,992
Other income (expense), net	51	182
Gains or losses	(5,523)	24,358
Net before taxes	54,286	5,469
Income taxes	22,068	2,735
Net income	32,218	2,734
Earnings common share		
Primary	\$0.16	\$0.01
Fully Diluted	\$0.16	\$0.01
Common Shares:		
Full Diluted	206,763	196,274
Year-end	208,259	192,484

AVEPOINT INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	195,082,000	152,495,000
Cost & expenses	184,701,000	157,834,000
Operating income	10,381,000	(5,339,000)
Other income (expense), net	1,346,000	(3,566,000)
Net before taxes	11,727,000	(8,905,000)
Income taxes	5,268,000	5,987,000
Net income	6,459,000	(14,892,000)
Earnings common share		
Primary	\$0.03	\$(0.08)
Fully Diluted	\$0.03	\$(0.08)
Common Shares:		
Full Diluted	226,951,000	182,150,000
Year-end	211,139,000	186,657,000

AVIDITY BIOSCIENCES INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	5,420	5,588
Cost & expenses	308,079	165,401
Operating income	(302,659)	(159,813)
Other income (expense), net	(1,086)	(217)
Net income	(273,088)	(139,648)
Earnings common share		
Primary	\$(2.11)	\$(1.44)
Fully Diluted	\$(2.11)	\$(1.44)
Common Shares:		
Full Diluted	129,428	97,070
Year-end	120,778	109,266

AVIDXCHANGE HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	218,512,000	210,730,000
Cost & expenses	222,132,000	198,425,000
Operating income	(20,768,000)	(6,210,000)
Net before taxes	(16,163,000)	(329,000)
Income taxes	612,000	244,000
Net income	(16,775,000)	(573,000)
Earnings common share		
Primary	\$(0.08)	\$
Fully Diluted	\$(0.08)	\$
Common Shares:		
Full Diluted	205,982,206	205,961,720
Year-end	207,695,309	207,819,898

AZENTA INC**Earnings, 9 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	434,870	422,372
Cost & expenses	463,088	469,936
Operating income	(28,218)	(47,564)
Other income (expense), net	1,539	(127)
Net before taxes	(12,919)	(20,332)
Income taxes	14,007	3,220
Income contin. oper.	(26,926)	(23,552)
Net income	(106,602)	(159,186)
Earnings common share		
Primary	\$(2.33)	\$(2.90)
Fully Diluted	\$(2.33)	\$(2.90)
Common Shares:		
Full Diluted	45,712	54,914
Year-end	45,785	50,395

BACKBLAZE INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	70,911	61,253
Cost & expenses	86,548	81,572
Operating income	(15,637)	(20,319)
Net before taxes	(16,337)	(21,395)
Income taxes	84	6
Net income	(16,421)	(21,401)
Earnings common share		
Primary	\$(0.30)	\$(0.52)
Fully Diluted	\$(0.30)	\$(0.52)
Common Shares:		
Full Diluted	54,836	41,189
Year-end	56,463	42,886

BARRETT BUSINESS SERVICES, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	600,223	545,433
Cost & expenses	577,366	525,960
Operating income	18,861	15,709
Other income (expense), net	5,019	6,436
Net before taxes	23,792	22,057
Income taxes	6,359	5,492
Net income	17,433	16,565
Earnings common share		
Primary	\$0.68	\$0.63
Fully Diluted	\$0.66	\$0.62
Common Shares:		
Full Diluted	26,309	26,794
Year-end	25,497	25,949

BENTLEY SYSTEMS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	734,648	668,100
Cost & expenses	518,625	478,636
Operating income	199,614	172,108
Other income (expense), net	3,519	6,930
Gains or losses	(7,711)	2,361
Equity earnings	(62)	(28)
Net before taxes	191,140	169,905
Income taxes	29,364	27,577
Net income	161,838	142,356
Balance for common	161,821	142,314
Earnings common share		
Primary	\$0.51	\$0.45
Fully Diluted	\$0.50	\$0.44
Common Shares:		

Full Diluted	333,150	333,725
Year-end	303,438	299,747

BERRY CORP (BRY)**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	392,729	328,930
Cost & expenses	375,132	290,009
Operating income	(88,561)	(66,079)
Other income (expense), net	213	(136)
Net before taxes	(88,561)	(66,079)
Income taxes	(25,485)	(17,226)
Net income	(63,076)	(48,853)
Earnings common share		
Primary	\$(0.81)	\$(0.64)
Fully Diluted	\$(0.81)	\$(0.64)
Common Shares:		
Full Diluted	77,397	76,597
Year-end	77,596	76,939

BEYOND MEAT INC**Earnings, 6 mos. to (Consol. - \$000):**

	06/28/25	06/29/24
Total Revenues	143,689	168,788
Cost & expenses	234,800	256,193
Operating income	(91,111)	(87,405)
Other income (expense), net	12,049	600
Equity earnings	70	23
Net before taxes	(88,849)	(88,849)
Income taxes	(32)	(32)
Net income	(82,158)	(88,840)
Earnings common share		
Primary	\$(1.08)	\$(1.37)
Fully Diluted	\$(1.08)	\$(1.37)
Common Shares:		
Full Diluted	76,349	64,797
Year-end	76,598	64,993

BGC GROUP INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Cost & expenses	1,239,753,000	1,006,536,000
Operating income	155,256,000	126,262,000
Other income (expense), net		40,576,000
Net before taxes	155,256,000	126,262,000
Income taxes	45,612,000	40,046,000
Net income	109,644,000	86,216,000
Balance for common	107,905,000	82,502,000
Earnings common share		
Primary	\$0.22	\$0.17
Fully Diluted	\$0.22	\$0.17
Common Shares:		
Full Diluted	485,090,000	479,417,000
Year-end	475,646,058	489,041,207

BIOATLA INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Cost & expenses	36,261	46,429
Operating income	(36,261)	(46,429)
Gains or losses	1,583	
Net income	(34,045)	(44,306)
Earnings common share		
Primary	\$(0.58)	\$(0.92)
Fully Diluted	\$(0.58)	\$(0.92)
Common Shares:		
Full Diluted	58,378	48,151
Year-end	58,722	48,326

BIODESIX INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	37,976	32,743
Cost & expenses	56,831	52,001
Operating income	(18,855)	(19,258)
Other income (expense), net	149	(699)
Gains or losses	(280)	
Net income	(22,560)	(24,422)
Earnings common share		
Primary	\$(0.15)	\$(0.22)
Fully Diluted	\$(0.15)	\$(0.22)
Common Shares:		
Full Diluted	146,328	112,167
Year-end	146,584	145,150

BIOVENTUS INC**Earnings, 6 mos. to (Consol. – \$000):**

	06/28/25	06/29/24
Total Revenues	271,536	280,674
Cost & expenses	245,267	303,400
Operating income	23,237	(26,545)
Other income (expense), net	(1,338)	(222)
Net before taxes	6,896	(47,030)
Income taxes	946	(6,432)
Net income	5,950	(40,598)
Earnings common share		
Primary	\$0.07	\$(0.48)
Fully Diluted	\$0.07	\$(0.48)
Common Shares:		
Full Diluted	68,766	63,720
Year-end	66,885	65,172

BLACK DIAMOND THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	70,000	
Cost & expenses	28,890	42,376
Operating income	41,110	(42,376)
Other income (expense), net	3,158	3,141
Net income	45,981	(38,134)
Earnings common share		
Primary	\$0.81	\$(0.71)
Fully Diluted	\$0.80	\$(0.71)
Common Shares:		
Full Diluted	57,474	53,482
Year-end	56,887	56,408

BLACKLINE INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	338,956	317,967
Cost & expenses	327,836	314,011
Operating income	11,120	3,956
Other income (expense), net		65,112
Net before taxes	23,512	94,935
Income taxes	10,847	5,206
Net income	12,665	89,729
Earnings common share		
Primary	\$0.23	\$1.42
Fully Diluted	\$0.23	\$0.39
Common Shares:		
Full Diluted	64,420	72,708
Year-end	61,881	62,171

BLACKROCK TCP CAPITAL CORP**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	127,255,534	
Cost & expenses	47,556,568	63,168,729
Operating income	4,988,004	64,086,805
Other income (expense), net	52,405,373	(74,624,174)
Invest. income	(107,214,713)	(35,682,007)
Net income	4,988,004	(46,219,376)
Earnings common share		
Primary	\$0.06	\$(0.63)
Fully Diluted	\$0.06	\$(0.63)
Common Shares:		
Full Diluted	85,060,179	73,819,497
Year-end	85,036,467	85,591,134

BLOOMIN' BRANDS INC**Earnings, 6 mos. to (Consol. – \$000):**

	06/29/25	06/30/24
Total Revenues	2,051,960	2,068,442
Cost & expenses	1,876,534	1,867,383
Operating income	86,881	114,969
Other income (expense), net		(135,797)
Equity earnings	3,097	
Net before taxes	64,995	(49,800)
Income taxes	(7,845)	9,422
Income contin. oper.	69,743	(59,222)
Net income	70,268	(52,659)
Earnings common share		
Primary	\$0.80	\$(0.64)
Fully Diluted	\$0.79	\$(0.64)
Common Shares:		
Full Diluted	85,135	86,856
Year-end	85,062	85,776

BLUE BIRD CORP**Earnings, 9 mos. to (Consol. – \$):**

	06/28/25	06/29/24
Total Revenues	1,070,734,000	996,942,000
Cost & expenses	953,912,000	883,190,000
Operating income	116,822,000	113,752,000
Other income (expense), net	2,780,000	(7,476,000)
Equity earnings	(2,975,000)	(6,671,000)
Net before taxes	118,445,000	100,858,000
Income taxes	30,197,000	26,645,000
Net income	91,223,000	80,884,000
Earnings common share		
Primary	\$2.86	\$2.51
Fully Diluted	\$2.76	\$2.43
Common Shares:		
Full Diluted	33,023,743	33,222,354
Year-end	31,480,251	32,331,161

BOWMAN CONSULTING GROUP LTD**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	235,021,000	199,409,000
Cost & expenses	211,776,000	190,077,000
Operating income	10,180,000	(3,845,000)
Other income (expense), net	(3,746,000)	(4,428,000)
Net before taxes	6,434,000	(8,273,000)
Income taxes	2,169,000	(4,633,000)
Net income	4,265,000	(3,640,000)
Balance for common	4,047,000	(3,640,000)
Earnings common share		
Primary	\$0.25	\$(0.24)
Fully Diluted	\$0.24	\$(0.24)
Common Shares:		
Full Diluted	16,589,787	15,064,827
Year-end	17,240,980	17,599,049

BRILLIANT EARTH GROUP INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	202,820	202,763
Cost & expenses	207,556	200,754
Operating income	(4,736)	2,009
Other income (expense), net	2,378	2,951
Net before taxes	(4,368)	2,453
Income taxes	12	11
Net income	(4,380)	2,442
Earnings common share		
Primary	\$(0.04)	\$0.03
Fully Diluted	\$(0.04)	\$0.02
Common Shares:		
Full Diluted	14,333	98,037
Year-end	63,974	62,555

BRUKER CORP**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	1,598,800,000	1,522,400,000
Cost & expenses	1,555,100,000	1,409,500,000
Operating income	43,700,000	112,900,000
Other income (expense), net	(800,000)	(19,600,000)
Equity earnings	(1,000,000)	
Net before taxes	25,600,000	95,500,000
Income taxes	5,600,000	35,900,000
Net income	21,000,000	59,600,000
Earnings common share		
Primary	\$0.16	\$0.40
Fully Diluted	\$0.16	\$0.40
Common Shares:		
Full Diluted	151,800,000	147,000,000
Year-end	151,715,927	151,391,821

BUMBLE INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	495,330	536,390
Net Sales		536,390
Cost & expenses	772,807	401,416
Operating income	(293,693)	100,744
Other income (expense), net	(18,674)	917
Net before taxes	(334,675)	83,661
Income taxes	12,477	12,102
Net income	(347,152)	71,559
Balance for common	(240,300)	52,000
Earnings common share		

Primary	\$(2.31)	\$0.41
Fully Diluted	\$(2.31)	\$0.41
Common Shares:		
Full Diluted	104,319	127,490
Year-end	103,952	126,469

C4 THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	13,701	15,045
Cost & expenses	71,366	68,706
Operating income	(57,665)	(53,661)
Net income	(52,342)	(46,077)
Earnings common share		
Primary	\$(0.74)	\$(0.67)
Fully Diluted	\$(0.74)	\$(0.67)
Common Shares:		
Full Diluted	70,920	68,621
Year-end	71,007	68,816

CABALETTA BIO INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	83,042	58,310
Operating income	(83,042)	(58,310)
Other income (expense), net	(61)	
Net income	(81,071)	(52,649)
Earnings common share		
Primary	\$(1.44)	\$(1.07)
Fully Diluted	\$(1.44)	\$(1.07)
Common Shares:		
Full Diluted	56,341	48,398
Year-end	91,452	48,291

CARDLYTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	125,147	
Cost & expenses	139,449	163,103
Operating income	(26,868)	(38,638)
Other income (expense), net		13,017
Net income	(22,565)	(28,532)
Earnings common share		
Primary	\$(0.43)	\$(0.62)
Fully Diluted	\$(0.43)	\$(0.62)
Common Shares:		
Full Diluted	52,309	46,168
Year-end	51,257	49,402

CARECLOUD INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	55,009,000	54,052,000
Cost & expenses	43,275,000	44,008,000
Operating income	5,015,000	2,400,000
Other income (expense), net	(49,000)	(287,000)
Net before taxes	4,933,000	1,511,000
Income taxes	83,000	78,000
Net income	4,850,000	1,433,000
Balance for common	674,000	(3,802,000)
Earnings common share		
Primary	\$0.02	\$(0.24)
Fully Diluted	\$0.02	\$(0.24)
Common Shares:		
Full Diluted	33,118,912	16,073,364
Year-end	42,322,039	16,145,187

CAREDx INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	171,364	164,323
Cost & expenses	195,859	194,216
Operating income	(24,495)	(29,893)
Other income (expense), net	367	(390)
Net before taxes	(18,980)	(24,572)
Income taxes	(59)	(61)
Net income	(18,921)	(24,511)
Earnings common share		
Primary	\$(0.35)	\$(0.47)
Fully Diluted	\$(0.35)	\$(0.47)
Common Shares:		
Full Diluted	54,782	51,944
Year-end	53,220	52,617

CARGURUS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	459,191	434,488
Cost & expenses	380,250	496,763
Operating income	70,599	(67,300)
Other income (expense), net	128	216
Net before taxes	75,959	(60,738)
Income taxes	14,571	(13,318)
Net income	61,388	(47,420)
Earnings common share		
Primary	\$0.61	\$(0.45)
Fully Diluted	\$0.60	\$(0.45)
Common Shares:		
Full Diluted	102,614	105,501
Year-end	98,955	103,005

CARLYLE GROUP INC (THE)**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,758,100	1,406,500
Cost & expenses	1,987,400	1,406,500
Operating income	611,600	339,500
Other income (expense), net	100	
Gains or losses	(12,100)	
Invest. income	52,900	
Net before taxes	611,600	339,500
Income taxes	124,900	91,400
Net income	486,700	248,100
Earnings common share		
Primary	\$1.25	\$0.59
Fully Diluted	\$1.23	\$0.58
Common Shares:		
Full Diluted	366,655	368,120
Year-end	358,962	356,375

CARLYLE SECURED LENDING INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	72,266	64,949
Operating income	49,879	55,322
Other income (expense), net	745	6,993
Gains or losses	(54)	683
Invest. income	(21,886)	(14,988)
Net before taxes	28,684	48,010
Income taxes	27,858	46,260
Net income	826	1,750
Earnings common share		
Primary	\$0.45	\$0.91
Fully Diluted	\$0.44	\$0.85
Common Shares:		
Full Diluted	65,169	56,366
Year-end	72,903	50,795

CARTESIAN THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,398	39,285
Cost & expenses	45,098	38,876
Operating income	(43,700)	409
Other income (expense), net	3,758	3,159
Gains or losses	38,118	(46,556)
Net before taxes	(1,824)	(42,988)
Income taxes	(1,824)	(42,988)
Net income	0	0
Earnings common share		
Primary	\$(0.07)	\$(3.88)
Fully Diluted	\$(0.07)	\$(3.88)
Common Shares:		
Full Diluted	25,942	11,069
Year-end	26,000	17,816

CASS INFORMATION SYSTEMS INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	73,993	74,766
Operating income	17,155	14,465
Net before taxes	17,155	14,465
Income taxes	3,445	3,093
Income contin. oper.	13,710	11,372
Net income	17,821	11,636
Earnings common share		
Primary	\$1.34	\$0.86
Fully Diluted	\$1.31	\$0.84
Common Shares:		
Full Diluted	13,580	13,804
Year-end	13,280	13,645

CDW CORP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	11,175,700	10,394,100
Cost & expenses	10,394,100	9,535,000
Operating income	781,600	761,100
Other income (expense), net	1,200	(1,200)
Net before taxes	668,900	656,300
Income taxes	172,800	159,100
Net income	496,100	497,200
Earnings common share		
Primary	\$3.76	\$3.70
Fully Diluted	\$3.73	\$3.66
Common Shares:		
Full Diluted	132,900	135,800
Year-end	131,100	133,600

CELSIUS HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	1,068,535,000	757,685,000
Cost & expenses	873,539,000	580,247,000
Operating income	194,996,000	177,438,000
Other income (expense), net	1,658,000	
Net before taxes	190,458,000	197,092,000
Income taxes	46,184,000	39,498,000
Net income	144,274,000	157,594,000
Balance for common	119,939,000	131,502,000
Earnings common share		
Primary	\$0.49	\$0.56
Fully Diluted	\$0.48	\$0.55
Common Shares:		
Full Diluted	248,757,000	237,569,000
Year-end	257,769,000	233,344,377

CENTRAL GARDEN & PET CO**Earnings, 9 mos. to (Consol. – \$000):**

	06/28/25	06/29/24
Total Revenues	2,450,886	2,530,971
Cost & expenses	2,194,444	2,313,176
Operating income	256,442	217,795
Other income (expense), net	96	1,047
Net before taxes	230,607	187,446
Income taxes	56,208	43,733
Net income	174,399	143,713
Earnings common share		
Primary	\$2.72	\$2.17
Fully Diluted	\$2.69	\$2.13
Common Shares:		
Full Diluted	64,283	66,848
Year-end	62,810	67,400

CENTURY ALUMINUM CO.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,262,000	1,050,300
Cost & expenses	1,195,200	1,042,000
Operating income	66,800	8,300
Other income (expense), net	(9,100)	245,500
Gains or losses	(21,000)	3,400
Net before taxes	16,900	239,000
Income taxes	300	1,000
Net income	16,600	238,000
Balance for common	23,800	231,300
Earnings common share		
Primary	\$0.26	\$2.50
Fully Diluted	\$0.25	\$2.24
Common Shares:		
Full Diluted	94,600	98,800
Year-end	93,339	92,739

CERENCE INC**Earnings, 9 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	191,142	276,699
Cost & expenses	190,003	835,757
Operating income	(529)	(560,708)
Other income (expense), net	2,444	2,023
Net before taxes	(3,353)	(564,227)
Income taxes		3,435
Net income	(5,353)	(567,662)
Earnings common share		
Primary	\$(0.12)	\$(13.66)
Fully Diluted	\$(0.12)	\$(13.66)

Common Shares:

Full Diluted	43,127	41,566
Year-end	43,264	41,804

CERTARA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	210,574	189,967
Cost & expenses	165,277	174,076
Operating income	17,175	(10,328)
Net before taxes	10,793	(17,703)
Income taxes	8,018	(446)
Net income	2,775	(17,257)
Earnings common share		
Primary	\$0.02	\$(0.11)
Fully Diluted	\$0.02	\$(0.11)
Common Shares:		
Full Diluted	161,601	160,015
Year-end	160,615	160,881

CERUS CORP.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	118,258	105,729
Operating income	(9,276)	(11,815)
Other income (expense), net	1,451	864
Net before taxes	(13,283)	(15,447)
Income taxes	150	18
Net income	(13,433)	(15,465)
Earnings common share		
Primary	\$(0.07)	\$(0.08)
Fully Diluted	\$(0.07)	\$(0.08)
Common Shares:		
Full Diluted	189,195	183,536
Year-end	191,588	185,201

CEVA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	49,923	50,509
Cost & expenses	58,488	55,205
Operating income	(8,864)	(4,995)
Other income (expense), net	(262)	(118)
Net before taxes	(4,905)	(2,450)
Income taxes	2,126	3,289
Net income	(7,031)	(5,739)
Earnings common share		
Primary	\$(0.30)	\$(0.24)
Fully Diluted	\$(0.30)	\$(0.24)
Common Shares:		
Full Diluted	23,832	23,568
Year-end	23,847	23,660

CHORD ENERGY CORP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	2,395,606	2,345,940
Cost & expenses	1,734,022	1,387,158
Operating income	(65,222)	561,960
Other income (expense), net	(4,810)	29,065
Gains or losses	61,950	(22,969)
Net before taxes	(42,688)	548,256
Income taxes	127,380	135,541
Net income	(170,068)	412,715
Balance for common	(168,643)	410,891
Earnings common share		
Primary	\$(2.89)	\$9.12
Fully Diluted	\$(2.89)	\$8.87
Common Shares:		
Full Diluted	58,420	46,313
Year-end	57,649	62,231

CIDARA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues		1,275
Cost & expenses	52,653	105,801
Operating income	(52,653)	(104,526)
Other income (expense), net	(110)	
Income contin. oper.		(102,387)
Income discount. oper.		852
Net income	(49,198)	(101,535)
Earnings common share		
Primary	\$(3.31)	\$(22.31)

Fully Diluted	\$(3.31)	\$(22.31)
Common Shares:		
Full Diluted	14,866	4,551
Year-end	23,235	4,569

CIPHER MINING INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	92,524,000	84,945,000
Cost & expenses	88,302,000	16,835,000
Operating income	(83,331,000)	30,615,000
Other income (expense), net	1,064,000	(1,231,000)
Gains or losses		250,000
Net before taxes	(83,695,000)	30,701,000
Net income	(84,756,000)	24,609,000
Earnings common share		
Primary	\$(0.23)	\$0.08
Fully Diluted	\$(0.23)	\$0.08
Common Shares:		
Full Diluted	367,823,593	316,652,300
Year-end	386,758,546	328,616,426

CLEAN ENERGY FUELS CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	206,377,000	201,663,000
Cost & expenses	269,678,000	194,120,000
Operating income	(135,530,000)	(14,903,000)
Other income (expense), net	(13,493,000)	(11,135,000)
Net before taxes	(158,299,000)	(34,503,000)
Income taxes	(2,860,000)	580,000
Net income	(155,439,000)	(35,083,000)
Earnings common share		
Primary	\$(0.70)	\$(0.16)
Fully Diluted	\$(0.70)	\$(0.16)
Common Shares:		
Full Diluted	222,024,912	223,250,123
Year-end	219,187,208	223,332,502

CLEARFIELD INC**Earnings, 9 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	132,547,000	119,933,000
Cost & expenses	134,763,000	140,142,000
Operating income	(2,216,000)	(20,209,000)
Net before taxes	2,429,000	(14,937,000)
Income taxes	1,401,000	(3,311,000)
Net income	1,028,000	(11,626,000)
Earnings common share		
Primary	\$0.07	\$(0.79)
Fully Diluted	\$0.07	\$(0.79)
Common Shares:		
Full Diluted	14,047,802	14,699,278
Year-end	13,805,717	14,238,693

CLEARSIDE BIOMEDICAL INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	2,822	320
Cost & expenses	11,595	16,119
Operating income	(8,773)	(15,799)
Other income (expense), net	(3,230)	(3,558)
Net before taxes	(12,003)	
Income taxes	715	
Net income	(12,718)	(19,357)
Earnings common share		
Primary	\$(0.16)	\$(0.27)
Fully Diluted	\$(0.16)	\$(0.27)
Common Shares:		
Full Diluted	77,385	72,292
Year-end	78,496	74,731

CLOVER HEALTH INVESTMENTS CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	939,951,000	703,182,000
Cost & expenses	950,924,000	718,050,000
Operating income	(11,833,000)	(15,516,000)
Gains or losses	(19,000)	(484,000)
Income contin. oper.		(16,000,000)
Net income	(11,852,000)	(11,762,000)
Earnings common share		
Primary	\$(0.02)	\$(0.03)
Fully Diluted	\$(0.02)	\$(0.03)

Common Shares:		
Full Diluted	508,893,753	487,575,520
Year-end	510,761,778	481,561,408

COGENT COMMUNICATIONS HOLDINGS, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	493,298	526,613
Cost & expenses	413,717	488,219
Operating income	(71,747)	(106,536)
Other income (expense), net	(5,606)	
Gains or losses		22,202
Net before taxes	(144,788)	(124,625)
Income taxes	(34,939)	(26,980)
Net income	(109,849)	(97,645)
Earnings common share		
Primary	\$(2.30)	\$(2.06)
Fully Diluted	\$(2.30)	\$(2.06)
Common Shares:		
Full Diluted	47,804	47,409
Year-end	49,246	48,991

COGNITION THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Cost & expenses	27,753	28,780
Operating income	(27,753)	(28,780)
Other income (expense), net	12,547	12,800
Net income	(15,214)	(16,192)
Earnings common share		
Primary	\$(0.24)	\$(0.44)
Fully Diluted	\$(0.24)	\$(0.44)
Common Shares:		
Full Diluted	62,170	36,899
Year-end	64,963	40,112

COHERUS ONCOLOGY INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	17,853	12,604
Cost & expenses	108,774	120,017
Operating income	(90,921)	(107,413)
Other income (expense), net	3,088	(8,294)
Income contin. oper.	(92,260)	(122,887)
Net income	241,198	89,954
Earnings common share		
Primary	\$2.08	\$0.79
Fully Diluted	\$2.08	\$0.79
Common Shares:		
Full Diluted	115,968	113,785
Year-end	116,223	115,199

COLLEGIUM PHARMACEUTICAL INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	365,757	290,199
Cost & expenses	308,965	193,254
Operating income	56,792	96,945
Other income (expense), net		(7,184)
Net before taxes	20,147	65,719
Income taxes	5,747	18,400
Net income	14,400	47,319
Earnings common share		
Primary	\$0.45	\$1.46
Fully Diluted	\$0.44	\$1.24
Common Shares:		
Full Diluted	39,283	40,511
Year-end	31,549	32,320

COLUMBIA SPORTSWEAR CO.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	1,383,698	1,340,226
Cost & expenses	1,360,781	1,319,347
Operating income	22,917	20,879
Other income (expense), net	3,715	747
Net before taxes	38,287	39,167
Income taxes	6,235	8,608
Net income	32,052	30,559
Earnings common share		
Primary	\$0.58	\$0.51
Fully Diluted	\$0.58	\$0.51
Common Shares:		
Full Diluted	55,395	59,603
Year-end	54,769	58,752

COMSCORE INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	175,098	172,632
Cost & expenses	177,581	174,836
Operating income	(3,747)	(3,805)
Other income (expense), net		(18)
Gains or losses		669
Net before taxes	(12,604)	(3,455)
Income taxes	881	(693)
Net income	(13,485)	(2,762)
Balance for common	(22,418)	(11,246)
Earnings common share		
Primary	\$(4.41)	\$(2.28)
Fully Diluted	\$(4.41)	\$(2.28)
Common Shares:		
Full Diluted	5,078	4,938
Year-end	5,015	4,890

CONDUENT INC**Earnings, 6 mos. to Jun 30(Consol. - \$Millions):**

	2025	2024
Total Revenues	1,505	1,749
Cost & expenses	1,479	1,163
Operating income	(94)	427
Net before taxes	(94)	427
Income taxes	(3)	112
Net income	(91)	315
Balance for common	(96)	310
Earnings common share		
Primary	\$(0.59)	\$1.54
Fully Diluted	\$(0.59)	\$1.51
Common Shares:		
Full Diluted	161	208
Year-end	159	164

CONNECTONE BANCORP INC (NEW)**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Cost & expenses	275,928	218,392
Operating income	2,121	48,827
Net before taxes	2,121	48,827
Income taxes	2,172	12,566
Net income	(51)	36,261
Balance for common	(3,061)	33,154
Earnings common share		
Primary	\$(0.08)	\$0.87
Fully Diluted	\$(0.08)	\$0.86
Common Shares:		
Full Diluted	40,150	38,453
Year-end	50,270	38,365

CONSENSUS CLOUD SOLUTIONS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	174,859	175,646
Cost & expenses	98,313	98,098
Operating income	76,546	77,548
Other income (expense), net	(3,413)	4,565
Net before taxes	56,419	68,773
Income taxes	14,486	18,529
Net income	41,933	50,244
Earnings common share		
Primary	\$2.15	\$2.61
Fully Diluted	\$2.14	\$2.61
Common Shares:		
Full Diluted	19,594	19,261
Year-end	19,092	19,297

CONSTELLATION ENERGY CORP**Earnings, 6 mos. to Jun 30(Consol. - \$Millions):**

	2025	2024
Total Revenues		11,637
Cost & expenses	10,985	9,122
Operating income	1,402	1,913
Other income (expense), net	286	368
Equity earnings		2
Net before taxes	1,424	2,012
Income taxes	462	318
Net income	962	1,692
Earnings common share		
Primary	\$3.05	\$5.37
Fully Diluted	\$3.05	\$5.35
Common Shares:		

Full Diluted.....	314	317
Year-end	312	313

CONSTRUCTION PARTNERS INC**Earnings, 9 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,912,507	1,285,726
Cost & expenses	1,788,467	1,220,254
Operating income	124,040	65,472
Other income (expense), net	508	47
Equity earnings	12	
Net before taxes	59,587	52,532
Income taxes	14,364	12,905
Net income	45,211	39,627
Earnings common share		
Primary	\$0.82	\$0.76
Fully Diluted	\$0.82	\$0.75
Common Shares:		
Full Diluted	55,303	52,572
Year-end	55,972	52,762

CORMEDIX INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	78,818,447	806,119
Cost & expenses	39,149,661	32,811,180
Operating income	39,668,786	(32,005,061)
Other income (expense), net		500,000
Net before taxes	40,993,386	(30,012,382)
Income taxes	521,507	(1,394,770)
Net income	40,471,879	(28,617,612)
Earnings common share		
Primary	\$0.60	\$(0.50)
Fully Diluted	\$0.58	\$(0.50)
Common Shares:		
Full Diluted	70,354,212	57,562,064
Year-end	74,620,742	55,274,791

CORSAIR GAMING INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	689,862	598,557
Cost & expenses	709,048	633,490
Operating income	(19,186)	(34,933)
Other income (expense), net	(5,803)	(1,128)
Net before taxes	(28,931)	(40,314)
Income taxes	1,692	(5,778)
Net income	(30,623)	(34,536)
Earnings common share		
Primary	\$(0.26)	\$(0.41)
Fully Diluted	\$(0.26)	\$(0.41)
Common Shares:		
Full Diluted	105,554	103,760
Year-end	106,000	104,073

CORVEL CORP**Earnings, 3 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	234,711,000	211,722,000
Cost & expenses	199,428,000	183,687,000
Operating income	35,283,000	28,035,000
Net before taxes	35,283,000	28,035,000
Income taxes	8,048,000	6,458,000
Net income	27,235,000	21,577,000
Earnings common share		
Primary	\$0.53	\$1.26
Fully Diluted	\$0.52	\$1.25
Common Shares:		
Full Diluted	51,912,000	17,313,000
Year-end	51,325,363	17,123,561

Consolidated Balance Sheet Items, as of (\$):

	2025	
Assets:		
Cash & equivalents	202,025,000	
Current assets	421,624,000	
Net property & equip.	108,440,000	
Total assets	597,448,000	
Liabilities:		
Current liabilities	235,221,000	
Stockholders' equity	342,532,000	
Net current assets	186,403,000	

CORVUS PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	20,182	12,188
Operating income	(20,182)	(12,188)
Other income (expense), net	(928)	(341)
Gains or losses	27,141	1,816
Net income	7,195	(9,963)
Earnings common share		
Primary	\$0.10	\$(0.18)
Fully Diluted	\$(0.26)	\$(0.18)
Common Shares:		
Full Diluted	76,522	54,374
Year-end	74,514	62,551

COVENANT LOGISTICS GROUP INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	572,209,000	566,260,000
Cost & expenses	508,103,000	503,110,000
Operating income	19,190,000	19,912,000
Other income (expense), net	8,044,000	7,770,000
Net before taxes	21,907,000	20,545,000
Income taxes	5,504,000	4,677,000
Income contin. oper.		15,868,000
Net income	16,403,000	16,168,000
Earnings common share		
Primary	\$0.62	\$0.61
Fully Diluted	\$0.60	\$0.58
Common Shares:		
Full Diluted	27,564,000	27,604,000
Year-end	25,046,273	26,341,736

CREDITRISKMONITOR.COM, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	9,930,955	9,742,474
Cost & expenses	9,581,553	9,609,897
Operating income	146,638	(61,486)
Other income (expense), net	360,516	397,495
Net before taxes	507,154	336,009
Income taxes	118,565	79,416
Net income	388,589	256,593
Earnings common share		
Primary	\$0.04	\$0.02
Fully Diluted	\$0.04	\$0.02
Common Shares:		
Full Diluted	10,843,170	10,761,722
Year-end	10,767,501	10,722,401

CRICUT INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	334,746	335,339
Cost & expenses	275,300	283,702
Operating income	59,446	51,637
Other income (expense), net	243	1,135
Net before taxes	66,464	58,082
Income taxes	18,062	18,666
Net income	48,402	39,416
Earnings common share		
Primary	\$0.23	\$0.18
Fully Diluted	\$0.23	\$0.18
Common Shares:		
Full Diluted	214,650	217,391
Year-end	212,466	216,086

CRINETICS PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,392	1,039
Cost & expenses	241,909	157,351
Operating income	(240,517)	(156,312)
Other income (expense), net	(183)	(264)
Equity earnings		470
Net income	(212,411)	(140,985)
Earnings common share		
Primary	\$(2.27)	\$(1.86)
Fully Diluted	\$(2.27)	\$(1.86)
Common Shares:		
Full Diluted	93,448	75,690
Year-end	94,126	79,322

CROCS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,086,706	2,050,135
Cost & expenses	2,291,248	1,497,968
Operating income	(204,542)	552,167
Other income (expense), net	152	65
Net before taxes	(243,668)	490,454
Income taxes	88,511	109,093
Net income	(332,179)	381,361
Earnings common share		
Primary	\$(5.94)	\$6.31
Fully Diluted	\$(5.94)	\$6.26
Common Shares:		
Full Diluted	55,946	60,910
Year-end	54,800	59,500

CROSS COUNTRY HEALTHCARE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	567,480	718,945
Cost & expenses	565,443	725,869
Operating income	(6,836)	(16,285)
Other income (expense), net	(83)	1,442
Net before taxes	(6,628)	(15,873)
Income taxes	521	(2,515)
Net income	(7,149)	(13,358)
Earnings common share		
Primary	\$(0.22)	\$(0.39)
Fully Diluted	\$(0.22)	\$(0.39)
Common Shares:		
Full Diluted	32,388	34,088
Year-end	32,523	33,388

CSG SYSTEMS INTERNATIONAL INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	596,581	585,453
Cost & expenses	527,743	517,263
Operating income	59,240	57,217
Other income (expense), net	(6,204)	732
Net before taxes	41,421	47,464
Income taxes	13,024	14,168
Net income	28,397	33,296
Earnings common share		
Primary	\$1.02	\$1.17
Fully Diluted	\$1.01	\$1.16
Common Shares:		
Full Diluted	28,199	28,698
Year-end	28,877	29,591

CULLINAN THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	130,794	93,016
Operating income	(130,794)	(93,016)
Other income (expense), net	(266)	(116)
Net income	(118,556)	(79,368)
Earnings common share		
Primary	\$(1.81)	\$(1.61)
Fully Diluted	\$(1.81)	\$(1.61)
Common Shares:		
Full Diluted	58,960	49,031
Year-end	59,074	57,872

CUMBERLAND PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	22,550,418	18,346,550
Cost & expenses	19,994,135	19,031,970
Operating income	544,469	(2,895,938)
Net before taxes	524,318	(2,982,224)
Income taxes	11,341	22,885
Net income	512,977	(3,005,109)
Earnings common share		
Primary	\$0.03	\$(0.21)
Fully Diluted	\$0.03	\$(0.21)
Common Shares:		
Full Diluted	15,274,134	14,107,852
Year-end	14,959,937	14,083,183

CUMULUS MEDIA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	373,366	404,902
Cost & expenses	355,550	395,410
Operating income	(11,096)	(20,057)
Other income (expense), net	(32)	14,976
Net before taxes	(43,169)	(39,575)
Income taxes	2,019	2,278
Net income	(45,188)	(41,853)
Earnings common share		
Primary	\$(2.61)	\$(2.49)
Fully Diluted	\$(2.61)	\$(2.49)
Common Shares:		
Full Diluted	17,323	16,786
Year-end	17,440	16,936

CYTEK BIOSCIENCES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	87,059	91,477
Cost & expenses	112,657	110,737
Operating income	(25,598)	(19,260)
Other income (expense), net	7,199	881
Net before taxes	(18,041)	(16,179)
Income taxes	(1,056)	424
Net income	(16,985)	(16,603)
Earnings common share		
Primary	\$(0.13)	\$(0.13)
Fully Diluted	\$(0.13)	\$(0.13)
Common Shares:		
Full Diluted	127,633	131,181
Year-end	127,185	131,505

CYTOKINETICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	68,348	1,084
Cost & expenses	335,485	257,491
Operating income	(267,137)	(256,407)
Gains or losses	(8,100)	(400)
Net income	(295,746)	(278,961)
Earnings common share		
Primary	\$(2.49)	\$(2.63)
Fully Diluted	\$(2.49)	\$(2.63)
Common Shares:		
Full Diluted	118,979	106,013
Year-end	119,604	117,525

CYTMX THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	69,575	66,578
Cost & expenses	48,239	63,373
Operating income	21,336	3,205
Other income (expense), net	28	(12)
Net before taxes	23,497	7,358
Income taxes	126	101
Net income	23,371	7,257
Earnings common share		
Primary	\$0.22	\$0.09
Fully Diluted	\$0.21	\$0.09
Common Shares:		
Full Diluted	108,928	84,116
Year-end	164,911	78,118

DATADOG INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,588,313	1,231,918
Cost & expenses	1,636,233	1,231,918
Operating income	(47,920)	24,614
Other income (expense), net	(9,638)	(461)
Net before taxes	37,884	93,978
Income taxes	10,595	7,523
Net income	27,289	86,455
Earnings common share		
Primary	\$0.08	\$0.26
Fully Diluted	\$0.08	\$0.23
Common Shares:		
Full Diluted	361,289	382,641
Year-end	348,609	336,770

DEFINITIVE HEALTHCARE CORP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	119,941	127,217
Cost & expenses	291,369	494,376
Operating income	(188,956)	(385,890)
Other income (expense), net	15,790	44,240
Net before taxes	(174,788)	(341,585)
Income taxes	(10,430)	(22,680)
Net income	(164,358)	(318,905)
Earnings common share		
Primary	\$(1.05)	\$(1.90)
Fully Diluted	\$(1.05)	\$(1.90)
Common Shares:		
Full Diluted	109,783	117,592
Year-end	104,747	117,053

DENALI THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	280,543	248,845
Operating income	(280,543)	(200,828)
Gains or losses	14,537	
Net income	(257,089)	(200,828)
Earnings common share		
Primary	\$(1.50)	\$(1.26)
Fully Diluted	\$(1.50)	\$(1.26)
Common Shares:		
Full Diluted	171,337	159,118
Year-end	145,685	143,124

DENTSPLY SIRONA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,815,000	1,937,000
Cost & expenses	1,880,000	1,845,000
Operating income	(65,000)	92,000
Other income (expense), net	(1,000)	8,000
Net before taxes	(109,000)	65,000
Income taxes	(84,000)	52,000
Net income	(25,000)	13,000
Earnings common share		
Primary	\$(0.13)	\$0.07
Fully Diluted	\$(0.13)	\$0.07
Common Shares:		
Full Diluted	199,200	207,300
Year-end	199,300	202,600

DESIGN THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Cost & expenses	41,987,000	29,443,000
Operating income	(41,987,000)	(29,443,000)
Other income (expense), net	5,189,000	6,545,000
Net income	(36,798,000)	(22,898,000)
Earnings common share		
Primary	\$(0.65)	\$(0.41)
Fully Diluted	\$(0.65)	\$(0.41)
Common Shares:		
Full Diluted	56,808,888	56,522,244
Year-end	56,948,126	56,620,014

DIAMONDBACK ENERGY, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	7,726,000,000	4,710,000,000
Cost & expenses	2,551,000,000	1,484,000,000
Operating income	2,812,000,000	2,274,000,000
Other income (expense), net	92,000,000	17,000,000
Gains or losses	29,000,000	(30,000,000)
Net before taxes	2,837,000,000	2,178,000,000
Income taxes	607,000,000	475,000,000
Net income	2,230,000,000	1,703,000,000
Balance for common	2,094,000,000	1,594,000,000
Earnings common share		
Primary	\$7.20	\$8.93
Fully Diluted	\$7.20	\$8.93
Common Shares:		
Full Diluted	290,880,000	178,418,000
Year-end	291,155,296	178,394,239

DIGI INTERNATIONAL INC**Earnings, 9 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	315,883,000	318,994,000
Cost & expenses	273,874,000	285,802,000

Operating income	42,009,000	33,192,000
Other income (expense), net	(43,000)	(9,794,000)
Net before taxes	37,404,000	10,806,000
Income taxes	6,581,000	164,000
Net income	30,823,000	10,642,000
Earnings common share		
Primary	\$0.84	\$0.29
Fully Diluted	\$0.82	\$0.29
Common Shares:		
Full Diluted	37,623,000	36,921,000
Year-end	37,112,993	36,407,314

DIODES, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	698,325,000	621,743,000
Cost & expenses	675,977,000	597,424,000
Operating income	10,685,000	16,656,000
Other income (expense), net	(4,821,000)	996,000
Gains or losses	39,343,000	4,720,000
Net before taxes	50,456,000	31,610,000
Income taxes	9,083,000	6,180,000
Net income	41,373,000	25,430,000
Earnings common share		
Primary	\$0.90	\$0.48
Fully Diluted	\$0.90	\$0.48
Common Shares:		
Full Diluted	46,452,000	46,320,000
Year-end	46,211,196	46,146,009

DIRECT DIGITAL HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	18,301,000	44,130,000
Cost & expenses	24,651,000	49,003,000
Operating income	(6,350,000)	(4,873,000)
Other income (expense), net	(151,000)	92,000
Net before taxes	(6,501,000)	(4,781,000)
Income taxes	(475,000)	
Net income	(6,976,000)	(4,781,000)
Earnings common share		
Primary	\$(0.20)	\$(0.09)
Fully Diluted	\$(0.20)	\$(0.09)
Common Shares:		
Full Diluted	22,517,388	14,656,446
Year-end	22,517,388	14,656,446

DISH NETWORK CORP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	6,905,902	7,208,159
Cost & expenses	6,371,789	6,455,767
Operating income	(238,353)	(5,792)
Other income (expense), net	(275)	(65,009)
Gains or losses	25,493	127,874
Net before taxes	(615,441)	(254,956)
Income taxes	(152,845)	(32,901)
Net income	(462,596)	(222,055)
Earnings common share		
Primary	\$(462,654.00)	\$(225,728.00)
Fully Diluted	\$(462,654.00)	\$(225,728.00)
Common Shares:		
Full Diluted	1	1
Year-end	1	1

DORCHESTER MINERALS LP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	75,559	68,339
Cost & expenses	14,102	11,958
Operating income	29,989	41,795
Net income	29,989	41,795
Earnings common share		
Primary	\$0.61	\$1.01
Fully Diluted	\$0.61	\$1.01
Common Shares:		
Full Diluted	47,340	39,847
Year-end	47,340	40,088

DRAFTKINGS INC (NEW)**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	2,921,313,000	2,279,437,000
Cost & expenses	2,817,000,000	2,450,663,000
Operating income	104,313,000	171,226,000
Other income (expense), net	24,481,000	(1,181,000)
Gains or losses	(3,356,000)	(8,303,000)
Equity earnings	236,000	(91,000)
Net before taxes	130,498,000	152,758,000
Income taxes	6,190,000	(73,921,000)
Net income	124,072,000	(78,746,000)
Earnings common share		
Primary	\$0.25	\$(0.17)
Fully Diluted	\$0.23	\$(0.17)
Common Shares:		
Full Diluted	529,551,000	476,788,000
Year-end	496,051,000	485,426,000

DRIVEN BRANDS HOLDINGS INC**Earnings, 6 mos. to (Consol. – \$000):**

	06/28/25	06/29/24
Total Revenues	1,067,151	1,000,788
Cost & expenses	899,719	778,692
Operating income	99,377	158,156
Net before taxes	43,471	77,587
Income taxes	14,172	28,818
Income contin. oper.	29,299	48,769
Net income	53,070	34,420
Earnings common share		
Primary	\$0.33	\$0.21
Fully Diluted	\$0.33	\$0.21
Common Shares:		
Full Diluted	162,984	160,683
Year-end	164,275	164,082

DROPBOX INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,250,400	1,265,800
Cost & expenses	898,200	995,300
Operating income	352,200	270,500
Other income (expense), net	(1,700)	2,200
Net before taxes	317,300	284,700
Income taxes	41,400	41,900
Net income	275,900	242,800
Earnings common share		
Primary	\$0.98	\$0.74
Fully Diluted	\$0.96	\$0.73
Common Shares:		
Full Diluted	286,100	412,600
Year-end	267,400	318,700

DUOLINGO INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	483,008	345,880
Cost & expenses	426,051	310,741
Operating income	56,957	35,139
Other income (expense), net	2,661	(1,328)
Net before taxes	81,460	54,565
Income taxes	1,544	3,258
Net income	79,916	51,307
Earnings common share		
Primary	\$1.76	\$1.19
Fully Diluted	\$1.64	\$1.08
Common Shares:		
Full Diluted	48,770	47,530
Year-end	45,787	43,500

DXP ENTERPRISES, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	975,251	858,191
Cost & expenses	888,750	791,708
Operating income	86,501	66,483
Other income (expense), net	603	3,004
Gains or losses	(728)	
Net before taxes	58,769	38,559
Income taxes	14,568	10,534
Net income	44,201	28,025
Balance for common	44,156	27,980
Earnings common share		
Primary	\$2.81	\$1.75
Fully Diluted	\$2.67	\$1.66
Common Shares:		

Full Diluted	16,536	16,838
Year-end	15,694	15,789

EASTERN CO.**Earnings, 6 mos. to (Consol. – \$):**

	06/28/25	06/29/24
Total Revenues	136,101,298	139,798,820
Cost & expenses	129,318,044	130,026,199
Operating income	6,783,254	9,772,621
Other income (expense), net	(124,495)	(9,712)
Net before taxes	5,327,818	8,255,437
Income taxes	1,124,703	1,844,265
Income contin. oper.	4,203,115	6,411,172
Net income	5,383,854	5,455,445
Earnings common share		
Primary	\$0.88	\$0.88
Fully Diluted	\$0.88	\$0.87
Common Shares:		
Full Diluted	6,134,023	6,250,222
Year-end	6,098,163	6,228,432

EDGEWISE THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	88,569	72,860
Operating income	(88,569)	(72,860)
Net income	(76,913)	(60,022)
Earnings common share		
Primary	\$(0.77)	\$(0.66)
Fully Diluted	\$(0.77)	\$(0.66)
Common Shares:		
Full Diluted	100,062	90,541
Year-end	105,341	93,643

EHEALTH INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	173,901	158,820
Cost & expenses	192,147	204,690
Operating income	(18,246)	(45,870)
Other income (expense), net	2,916	4,726
Net before taxes	(20,326)	(46,802)
Income taxes	(4,878)	(1,850)
Net income	(15,448)	(44,952)
Balance for common	(39,755)	(66,699)
Earnings common share		
Primary	\$(1.32)	\$(2.29)
Fully Diluted	\$(1.32)	\$(2.29)
Common Shares:		
Full Diluted	30,202	29,072
Year-end	30,487	29,300

ELECTROCORE INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	14,100,000	11,582,000
Cost & expenses	21,428,000	18,022,000
Operating income	(7,328,000)	(6,440,000)
Other income (expense), net	(397,000)	(123,000)
Net before taxes	(7,574,000)	(6,283,000)
Income taxes	(48,000)	(122,000)
Net income	(7,526,000)	(6,161,000)
Earnings common share		
Primary	\$(0.91)	\$(0.90)
Fully Diluted	\$(0.91)	\$(0.90)
Common Shares:		
Full Diluted	8,302,000	6,831,000
Year-end	7,466,425	6,446,866

EMBECTA CORP**Earnings, 9 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	816,400	837,000
Cost & expenses	623,000	696,400
Operating income	185,600	140,600
Other income (expense), net	2,900	(6,100)
Net before taxes	107,300	51,200
Income taxes	38,300	(12,500)
Net income	69,000	63,700
Earnings common share		
Primary	\$1.18	\$1.11
Fully Diluted	\$1.18	\$1.10
Common Shares:		
Full Diluted	58,721	58,143
Year-end	58,473	57,676

ENERGY RECOVERY INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	36,116	39,289
Cost & expenses	47,204	52,237
Operating income	(11,088)	(12,948)
Other income (expense), net	(20)	(102)
Net before taxes	(9,095)	(9,945)
Income taxes	(1,269)	(1,043)
Net income	(7,826)	(8,902)
Earnings common share		
Primary	\$(0.14)	\$(0.16)
Fully Diluted	\$(0.14)	\$(0.16)
Common Shares:		
Full Diluted	54,578	57,234
Year-end	53,684	57,423

EPLUS INC**Earnings, 3 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	637,315,000	535,652,000
Cost & expenses	594,046,000	499,374,000
Operating income	36,200,000	31,459,000
Other income (expense), net	612,000	1,711,000
Net before taxes	36,812,000	33,170,000
Income taxes	9,684,000	8,977,000
Income contin. oper.	27,128,000	24,193,000
Net income	37,697,000	27,339,000
Earnings common share		
Primary	\$1.43	\$1.03
Fully Diluted	\$1.43	\$1.02
Common Shares:		
Full Diluted	26,381,000	26,801,000
Year-end	26,627,000	26,940,000

Consolidated Balance Sheet Items, as of (\$):

	2025
Assets:	
Cash & equivalents	480,178,000
Inventories	101,053,000
Current assets	1,402,316,000
Net property & equip.	107,538,000
Total assets	1,799,135,000
Liabilities:	
Current liabilities	687,750,000
Stockholders' equity	1,020,431,000
Net current assets	714,566,000

ETON PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	36,210	17,040
Cost & expenses	38,155	20,775
Operating income	(1,945)	(3,735)
Net before taxes	(4,017)	(3,798)
Income taxes	140	54
Net income	(4,157)	(3,852)
Earnings common share		
Primary	\$(0.15)	\$(0.15)
Fully Diluted	\$(0.15)	\$(0.15)
Common Shares:		
Full Diluted	26,889	25,771
Year-end	26,818	25,746

EURONET WORLDWIDE INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,989,800	1,843,200
Cost & expenses	1,690,000	1,578,500
Operating income	233,800	198,300
Other income (expense), net		700
Gains or losses	2,900	
Net before taxes	176,800	164,600
Income taxes	40,700	55,200
Net income	136,100	109,400
Earnings common share		
Primary	\$3.16	\$2.40
Fully Diluted	\$3.08	\$2.28
Common Shares:		
Full Diluted	44,518	48,829
Year-end	40,996	44,907

EVERCOMMERCE INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,989,800	1,843,200
Cost & expenses	1,690,000	1,578,500
Operating income	233,800	198,300
Other income (expense), net		700
Gains or losses	2,900	
Net before taxes	176,800	164,600
Income taxes	40,700	55,200
Net income	136,100	109,400
Earnings common share		
Primary	\$3.16	\$2.40
Fully Diluted	\$3.08	\$2.28
Common Shares:		
Full Diluted	44,518	48,829
Year-end	40,996	44,907

	2025	2024
Total Revenues	290,288	278,375
Cost & expenses	226,924	234,163
Operating income	30,007	3,407
Net before taxes	8,450	(11,936)
Income taxes	1,755	6,626
Income contin. oper.	6,695	(18,562)
Net income	440	(19,700)
Earnings common share		
Primary	\$(0.11)	\$(0.11)
Fully Diluted	\$(0.11)	\$(0.11)
Common Shares:		
Full Diluted	184,838	185,908
Year-end	182,189	184,581

EVERSPIN TECHNOLOGIES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	26,339	25,066
Cost & expenses	30,232	28,485
Operating income	(3,893)	(3,419)
Other income (expense), net	1,230	791
Net before taxes	(1,832)	(2,628)
Income taxes	4	76
Net income	(1,836)	(2,704)
Earnings common share		
Primary	\$(0.08)	\$(0.13)
Fully Diluted	\$(0.08)	\$(0.13)
Common Shares:		
Full Diluted	22,347	21,410
Year-end	22,571	21,657

EVGO INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	173,317,000	121,777,000
Cost & expenses	229,310,000	176,591,000
Operating income	(64,212,000)	(64,757,000)
Gains or losses	6,272,000	2,704,000
Net before taxes	(55,954,000)	(57,733,000)
Income taxes	94,000	70,000
Net income	(56,048,000)	(57,803,000)
Balance for common	(24,229,000)	(20,073,000)
Earnings common share		
Primary	\$(0.18)	\$(0.19)
Fully Diluted	\$(0.18)	\$(0.19)
Common Shares:		
Full Diluted	132,644,000	105,130,000
Year-end	133,526,365	105,744,772

EVOLUS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	137,909	126,242
Cost & expenses	160,521	140,030
Operating income	(25,382)	(16,624)
Other income (expense), net	(94)	107
Net before taxes	(35,909)	(24,369)
Income taxes	125	90
Net income	(36,034)	(24,459)
Earnings common share		
Primary	\$(0.56)	\$(0.40)
Fully Diluted	\$(0.56)	\$(0.40)
Common Shares:		
Full Diluted	64,120	60,761
Year-end	64,639	63,053

EXPEDIA GROUP INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	6,774,000	6,447,000
Cost & expenses	5,917,000	5,691,000
Operating income	415,000	341,000
Other income (expense), net	(3,000)	8,000
Gains or losses	(258,000)	50,000
Net before taxes	206,000	333,000
Income taxes	81,000	94,000
Net income	125,000	239,000
Earnings common share		
Primary	\$1.02	\$1.88
Fully Diluted	\$0.96	\$1.79
Common Shares:		
Full Diluted	134,296	140,131
Year-end	124,492	130,804

EXPENSIFY INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	71,838	66,823
Cost & expenses	83,663	68,397
Operating income	(11,825)	(1,574)
Net before taxes	(10,612)	(2,788)
Income taxes	1,345	3,757
Net income	(11,957)	(6,545)
Earnings common share		
Primary	\$(0.13)	\$(0.08)
Fully Diluted	\$(0.13)	\$(0.08)
Common Shares:		
Full Diluted	91,889	85,868
Year-end	92,647	88,195

EXPONENT INC.**Earnings, 6 mos. to (Consol. – \$000):**

	07/04/25	06/28/24
Total Revenues	287,469	285,469
Cost & expenses	225,860	219,012
Operating income	61,609	66,457
Other income (expense), net	7,908	8,791
Net before taxes	74,575	80,105
Income taxes	21,372	20,736
Net income	53,203	59,369
Earnings common share		
Primary	\$1.04	\$1.16
Fully Diluted	\$1.03	\$1.15
Common Shares:		
Full Diluted	51,587	51,475
Year-end	50,502	50,731

EYEPOINT PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	29,786	21,161
Cost & expenses	140,850	89,028
Operating income	(111,064)	(67,867)
Net before taxes	(104,528)	93
Income taxes	93	93
Net income	(104,621)	(60,110)
Earnings common share		
Primary	\$(1.50)	\$(1.13)
Fully Diluted	\$(1.50)	\$(1.13)
Common Shares:		
Full Diluted	69,847	53,059
Year-end	68,890	52,160

F5 INC**Earnings, 9 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	2,277,982	2,069,446
Cost & expenses	1,717,686	1,601,880
Operating income	560,296	467,566
Other income (expense), net	32,971	24,385
Net before taxes	593,267	491,951
Income taxes	91,380	90,469
Net income	501,887	401,482
Earnings common share		
Primary	\$8.65	\$6.82
Fully Diluted	\$8.54	\$6.75
Common Shares:		
Full Diluted	58,773	59,461
Year-end	57,867	58,284

FIDUS INVESTMENT CORP**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Cost & expenses	39,547,000	35,624,000
Operating income	46,940,000	45,859,000
Other income (expense), net	4,259,000	(1,359,000)
Invest. income	5,762,000	12,527,000
Net before taxes	46,940,000	45,859,000
Income taxes	1,998,000	1,637,000
Net income	44,942,000	44,222,000
Earnings common share		
Primary	\$1.06	\$1.10
Fully Diluted	\$1.06	\$1.10
Common Shares:		
Full Diluted	34,620,172	31,511,236
Year-end	35,379,900	33,161,240

FIRST ADVANTAGE CORP (NEW)**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	745,221	353,962
Cost & expenses	576,295	284,985
Operating income	45,354	9,177
Other income (expense), net	(254)	
Net before taxes	(46,265)	(1,746)
Income taxes	(5,379)	(699)
Net income	(40,886)	(1,047)
Earnings common share		
Primary	\$(0.24)	\$(0.01)
Fully Diluted	\$(0.24)	\$(0.01)
Common Shares:		
Full Diluted	172,931	143,728
Year-end	173,839	145,325

FIVE STAR BANCORP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	82,346	69,832
Operating income	38,490	30,113
Other income (expense), net	656	
Net before taxes	38,490	30,113
Income taxes	10,871	8,700
Net income	27,619	21,413
Earnings common share		
Primary	\$1.30	\$1.12
Fully Diluted	\$1.30	\$1.12
Common Shares:		
Full Diluted	21,261	19,166
Year-end	21,361	21,320

FLUENCE ENERGY INC**Earnings, 9 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,220,939	1,470,414
Cost & expenses	1,302,735	1,497,854
Operating income	(91,182)	(36,029)
Net before taxes	(91,182)	(36,029)
Income taxes	869	1,328
Net income	(92,051)	(37,357)
Earnings common share		
Primary	\$(0.51)	\$(0.20)
Fully Diluted	\$(0.51)	\$(0.20)
Common Shares:		
Full Diluted	130,062	125,274
Year-end	130,860	128,894

FLYWIRE CORP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	265,343	217,779
Cost & expenses	285,336	239,529
Operating income	(19,993)	(21,750)
Invest. income	166	
Net before taxes	(10,070)	(13,805)
Income taxes	6,097	6,292
Net income	(16,167)	(20,097)
Earnings common share		
Primary	\$(0.13)	\$(0.16)
Fully Diluted	\$(0.13)	\$(0.16)
Common Shares:		
Full Diluted	122,540	123,860
Year-end	122,181	125,107

FORTINET INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	3,169,700	2,787,600
Cost & expenses	2,257,900	2,029,200
Operating income	911,800	758,400
Other income (expense), net	45,000	(5,100)
Equity earnings	(10,500)	18,600
Net before taxes	1,036,600	813,700
Income taxes	173,600	116,000
Net income	873,500	679,100
Earnings common share		
Primary	\$1.14	\$0.89
Fully Diluted	\$1.13	\$0.88
Common Shares:		
Full Diluted	774,800	770,200
Year-end	765,600	764,200

FOSTER (L.B.) CO**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	241,350	265,116
Cost & expenses	235,853	254,919
Operating income	3,535	7,857
Net before taxes	3,535	7,857
Income taxes	2,813	635
Net income	722	7,222
Earnings common share		
Primary	\$0.07	\$0.68
Fully Diluted	\$0.07	\$0.66
Common Shares:		
Full Diluted	10,945	11,062
Year-end	10,431	10,783

FOX FACTORY HOLDING CORP

Earnings, 6 mos. to (Consol. – \$000):

	07/04/25	06/28/24
Total Revenues	729,894	681,963
Cost & expenses	940,677	632,178
Operating income	(232,059)	27,465
Other income (expense), net	1,515	2
Net before taxes	(257,866)	273
Income taxes	(837)	(1,638)
Net income	(257,029)	1,911
Earnings common share		
Primary	\$(6.15)	\$0.05
Fully Diluted	\$(6.15)	\$0.05
Common Shares:		
Full Diluted	41,749	41,717
Year-end	41,801	41,682

FUNKO INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	384,208	463,356
Cost & expenses	412,363	436,528
Operating income	(57,945)	(4,170)
Other income (expense), net	(1,055)	(996)
Net before taxes	(67,371)	(16,558)
Income taxes	1,692	1,689
Net income	(69,063)	(18,247)
Earnings common share		
Primary	\$(1.26)	\$(0.34)
Fully Diluted	\$(1.26)	\$(0.34)
Common Shares:		
Full Diluted	53,948	51,406
Year-end	54,530	52,488

GALECTO INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Cost & expenses	6,020	11,318
Operating income	(6,020)	(11,318)
Net before taxes	(5,964)	(10,773)
Income taxes	6	42
Net income	(5,970)	(10,815)
Earnings common share		
Primary	\$(4.51)	\$(10.00)
Fully Diluted	\$(4.51)	\$(10.00)
Common Shares:		
Full Diluted	1,322	1,085
Year-end	1,325	1,085

GCM GROSVENOR INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	245,503,000	225,820,000
Cost & expenses	210,928,000	220,945,000
Operating income	34,575,000	4,875,000
Other income (expense), net	2,028,000	947,000
Gains or losses	10,612,000	(2,324,000)
Invest. income	6,546,000	6,967,000
Net before taxes	42,190,000	(1,592,000)
Income taxes	3,389,000	4,354,000
Net income	38,801,000	(5,946,000)
Earnings common share		
Primary	\$0.33	\$0.16
Fully Diluted	\$0.07	\$(0.08)
Common Shares:		
Full Diluted	195,641,160	188,537,688
Year-end	53,217,309	44,560,068

GENCOR INDUSTRIES INC

Earnings, 9 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	96,606,000	92,245,000
Cost & expenses	82,365,000	79,797,000
Operating income	14,241,000	12,448,000
Invest. income	1,037,000	2,087,000
Net before taxes	18,567,000	17,020,000
Income taxes	4,827,000	3,914,000
Net income	13,740,000	13,106,000
Earnings common share		
Primary	\$0.94	\$0.89
Fully Diluted	\$0.94	\$0.89
Common Shares:		
Full Diluted	14,658,000	14,658,000
Year-end	14,657,702	14,657,702

GENTEX CORP.

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	1,234,631,300	1,163,150,989
Cost & expenses	1,003,124,059	918,920,655
Operating income	231,507,241	244,230,334
Other income (expense), net	(2,409,520)	(15,251,428)
Net before taxes	229,097,721	228,978,906
Income taxes	38,573,226	34,707,753
Net income	190,524,495	194,271,153
Balance for common	187,439,850	191,488,981
Earnings common share		
Primary	\$0.85	\$0.84
Fully Diluted	\$0.85	\$0.84
Common Shares:		
Full Diluted	221,385,600	227,945,120
Year-end	219,520,750	230,229,539

GEOSPACE TECHNOLOGIES CORP

Earnings, 9 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	80,089	100,160
Cost & expenses	82,166	94,222
Operating income	(2,077)	5,938
Other income (expense), net	(109)	(104)
Net before taxes	(607)	6,391
Income taxes	55	109
Net income	(662)	6,282
Earnings common share		
Primary	\$(0.05)	\$0.47
Fully Diluted	\$(0.05)	\$0.47
Common Shares:		
Full Diluted	12,784	13,432
Year-end	12,807	13,071

GERON CORP.

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	88,639	1,186
Cost & expenses	117,797	126,653
Operating income	(29,158)	(125,467)
Other income (expense), net	(144)	(125)
Net income	(36,210)	(122,773)
Earnings common share		
Primary	\$(0.05)	\$(0.19)
Fully Diluted	\$(0.05)	\$(0.19)
Common Shares:		
Full Diluted	666,039	628,699
Year-end	637,850	601,048

GEVO INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	72,522,000	9,250,000
Cost & expenses	74,030,000	47,692,000
Operating income	(14,343,000)	(47,170,000)
Other income (expense), net	(154,000)	212,000
Net income	(19,044,000)	(39,877,000)
Earnings common share		
Primary	\$(0.08)	\$(0.17)
Fully Diluted	\$(0.08)	\$(0.17)
Common Shares:		
Full Diluted	232,490,122	239,929,385
Year-end	241,841,590	240,565,240

GIBRALTAR INDUSTRIES INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	555,874	514,634
Cost & expenses	487,713	443,720
Operating income	68,161	70,914
Other income (expense), net	29	166
Net before taxes	69,473	73,325
Income taxes	16,920	19,387
Income contin. oper.	52,553	53,938
Net income	47,123	57,144
Earnings common share		
Primary	\$1.57	\$1.87
Fully Diluted	\$1.56	\$1.86
Common Shares:		
Full Diluted	30,133	30,801
Year-end	29,506	30,477

GILEAD SCIENCES INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	13,749,000	13,640,000
Cost & expenses	9,039,000	15,318,000
Operating income	4,711,000	(1,678,000)
Other income (expense), net	(120,000)	(265,000)
Net before taxes	4,077,000	(2,433,000)
Income taxes	802,000	123,000
Net income	3,275,000	(2,556,000)
Earnings common share		
Primary	\$2.63	\$(2.05)
Fully Diluted	\$2.61	\$(2.05)
Common Shares:		
Full Diluted	1,257,000	1,247,000
Year-end	1,242,000	1,246,000

GLADSTONE COMMERCIAL CORP

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Cost & expenses	21,509,000	19,949,000
Operating income	9,214,000	5,065,000
Other income (expense), net	936,000	596,000
Net income	9,773,000	5,125,000
Balance for common	3,374,000	(1,313,000)
Earnings common share		
Primary	\$0.07	\$(0.03)
Fully Diluted	\$0.07	\$(0.03)
Common Shares:		
Full Diluted	45,417,792	40,157,479
Year-end	46,895,665	41,433,681

GLADSTONE LAND CORP

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	41,549,000	
Cost & expenses	8,834,000	8,822,000
Operating income	5,011,000	9,819,000
Other income (expense), net	13,922,000	8,709,000
Net income	7,230,000	12,744,000
Balance for common	(4,774,000)	795,000
Earnings common share		
Primary	\$(0.13)	\$0.02
Fully Diluted	\$(0.13)	\$0.02
Common Shares:		
Full Diluted	36,184,658	35,838,442
Year-end	36,184,658	35,838,442

GOGO INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	456,345	206,381
Cost & expenses	355,937	142,298
Operating income	71,148	56,355
Other income (expense), net	(85)	(1,618)
Gains or losses	(3,900)	
Net before taxes	35,966	42,382
Income taxes	11,117	11,053
Net income	24,849	31,329
Earnings common share		
Primary	\$0.19	\$0.24
Fully Diluted	\$0.18	\$0.24
Common Shares:		
Full Diluted	135,971	132,094
Year-end	133,334	126,883

GOLD RESOURCE CORP

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	23,582,000	39,484,000
Cost & expenses	33,258,000	48,801,000
Operating income	(19,291,000)	(17,186,000)
Other income (expense), net	(7,526,000)	(1,615,000)
Invest. income	(821,000)	16,000
Net before taxes	(19,291,000)	(17,186,000)
Income taxes	514,000	14,569,000
Net income	(19,805,000)	(31,755,000)
Earnings common share		
Primary	\$(0.16)	\$(0.35)
Fully Diluted	\$(0.16)	\$(0.35)
Common Shares:		
Full Diluted	122,053,340	89,855,890
Year-end	136,449,731	92,292,848

GOLDEN ENTERTAINMENT INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	324,463,000	341,381,000
Net Sales		341,381,000
Cost & expenses	256,534,000	202,968,000
Operating income	22,985,000	93,677,000
Other income (expense), net		(4,446,000)
Net before taxes	7,759,000	69,935,000
Income taxes	628,000	27,349,000
Net income	7,131,000	42,586,000
Balance for common		42,586,000
Earnings common share		
Primary	\$0.27	\$1.48
Fully Diluted	\$0.26	\$1.40
Common Shares:		
Full Diluted	27,555,000	30,482,000
Year-end	26,158,000	28,315,000

GOODRX HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	406,040	398,490
Cost & expenses	315,210	338,324
Operating income	50,189	27,259
Other income (expense), net	694	
Net before taxes	36,245	11,939
Income taxes	12,350	6,254
Net income	23,895	5,685
Earnings common share		
Primary	\$0.06	\$0.01
Fully Diluted	\$0.06	\$0.01
Common Shares:		
Full Diluted	368,345	393,620
Year-end	352,771	378,607

GOODYEAR TIRE & RUBBER CO.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	8,718,000	9,107,000
Cost & expenses	8,067,000	8,805,000
Operating income	436,000	69,000
Net before taxes	436,000	69,000
Income taxes	37,000	66,000
Net income	399,000	3,000
Earnings common share		
Primary	\$1.28	\$0.04
Fully Diluted	\$1.27	\$0.04
Common Shares:		
Full Diluted	290,000	288,000
Year-end	286,000	284,687

GRAND CANYON EDUCATION INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	536,809	502,138
Cost & expenses	392,787	370,731
Operating income	139,812	127,197
Net before taxes	146,419	135,034
Income taxes	33,255	32,146
Net income	113,164	102,888
Earnings common share		
Primary	\$4.02	\$3.50
Fully Diluted	\$4.00	\$3.48
Common Shares:		
Full Diluted	28,301	29,527
Year-end	28,234	29,549

GRAYSCALE STELLAR LUMENS TRUST (XLM)**Earnings, 9 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	636,000	173,000
Operating income	16,109,000	(2,472,000)
Other income (expense), net	16,544,000	(2,112,000)
Invest. income	201,000	(187,000)
Net income	16,109,000	(2,472,000)
Earnings common share		
Primary	\$11.63	\$(2.22)
Fully Diluted	\$11.63	\$(2.22)
Common Shares:		
Full Diluted	1,384,900	1,111,400
Year-end	1,384,900	1,111,400

GREEN PLAINS INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	1,154,344,000	1,216,039,000
Cost & expenses	1,195,020,000	1,235,568,000
Operating income	(90,623,000)	(62,600,000)
Other income (expense), net	(1,554,000)	794,000
Net before taxes	(113,352,000)	(73,086,000)
Income taxes	2,400,000	56,000
Net income	(115,752,000)	(73,142,000)
Earnings common share		
Primary	\$(2.22)	\$(1.19)
Fully Diluted	\$(2.22)	\$(1.19)
Common Shares:		
Full Diluted	65,287,000	63,637,000
Year-end	65,588,229	64,655,686

GROCERY OUTLET HOLDING CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	06/28/25	06/29/24
Total Revenues	2,305,339	2,165,464
Cost & expenses	2,315,075	2,138,796
Operating income	(9,736)	26,668
Other income (expense), net		(24)
Net before taxes	(22,800)	17,933
Income taxes	(4,444)	4,957
Net income	(18,356)	12,976
Earnings common share		
Primary	\$(0.19)	\$0.13
Fully Diluted	\$(0.19)	\$0.13
Common Shares:		
Full Diluted	97,801	100,753
Year-end	98,103	99,155

GROUPON INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	242,889	247,699
Cost & expenses	227,951	235,971
Operating income	14,938	11,728
Net before taxes	40,975	(5,437)
Income taxes	12,355	15,481
Income contin. oper.	28,620	
Net income	28,149	(20,918)
Earnings common share		
Primary	\$0.69	\$(0.58)
Fully Diluted	\$0.64	\$(0.58)
Common Shares:		
Full Diluted	43,357	38,570
Year-end	40,424	39,704

HACKETT GROUP INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	06/27/25	06/28/24
Total Revenues	156,764,000	154,843,000
Cost & expenses	147,766,000	130,802,000
Operating income	8,998,000	24,041,000
Net before taxes	8,430,000	23,057,000
Income taxes	3,626,000	5,578,000
Net income	4,804,000	17,479,000
Earnings common share		
Primary	\$0.17	\$0.64
Fully Diluted	\$0.17	\$0.63
Common Shares:		
Full Diluted	28,433,000	27,809,000
Year-end	27,508,316	27,641,923

HARVARD BIOSCIENCE INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	42,224	47,609
Cost & expenses	90,389	49,293
Operating income	(50,487)	(4,348)
Other income (expense), net	(968)	(323)
Gains or losses		(1,593)
Net before taxes	(53,048)	(7,764)
Income taxes	(426)	(143)
Net income	(52,622)	(7,621)
Earnings common share		
Primary	\$(1.19)	\$(0.18)
Fully Diluted	\$(1.19)	\$(0.18)
Common Shares:		
Full Diluted	44,200	43,443
Year-end	44,531	43,611

HEALTH CATALYST INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	160,134	150,625
Cost & expenses	192,395	168,062
Operating income	(57,265)	(38,619)
Interest expense		3,663
Other income (expense), net	454	(38)
Net before taxes	(64,424)	(33,920)
Income taxes	296	183
Net income	(64,720)	(34,103)
Earnings common share		
Primary	\$(0.94)	\$(0.58)
Fully Diluted	\$(0.94)	\$(0.58)
Common Shares:		
Full Diluted	69,092	58,948
Year-end	70,267	60,075

HEALTHSTREAM INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	147,881,000	144,316,000
Cost & expenses	115,996,000	113,509,000
Operating income	10,264,000	10,101,000
Other income (expense), net	(39,000)	1,741,000
Net before taxes	12,114,000	11,842,000
Income taxes	2,393,000	2,448,000
Net income	9,721,000	9,394,000
Earnings common share		
Primary	\$0.32	\$0.31
Fully Diluted	\$0.32	\$0.31
Common Shares:		
Full Diluted	30,519,000	30,472,000
Year-end	29,897,000	30,408,000

HENNESSY ADVISORS INC**Earnings, 9 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues		20,868,000
Cost & expenses	16,704,000	14,754,000
Operating income	10,130,000	5,929,000
Net before taxes	10,484,000	6,554,000
Income taxes	2,946,000	1,785,000
Net income	7,538,000	4,769,000
Earnings common share		
Primary	\$0.97	\$0.62
Fully Diluted	\$0.95	\$0.62
Common Shares:		
Full Diluted	7,939,553	7,698,987
Year-end	7,787,494	7,681,007

HERTZ GLOBAL HOLDINGS INC (NEW)**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	3,998,000	4,433,000
Cost & expenses	3,179,000	2,957,000
Operating income	(841,000)	(1,054,000)
Net before taxes	(841,000)	(1,054,000)
Income taxes	(104,000)	(3,000)
Net income	(737,000)	(1,051,000)
Earnings common share		
Primary	\$(2.39)	\$(3.44)
Fully Diluted	\$(2.39)	\$(3.44)
Common Shares:		
Full Diluted	308,000	306,000
Year-end	309,897	306,439

HIGHPEAK ENERGY INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	457,848,000	563,030,000
Cost & expenses	110,985,000	112,206,000
Operating income	64,083,000	110,448,000
Other income (expense), net	(2,489,000)	(2,001,000)
Gains or losses	18,519,000	(55,745,000)
Net before taxes	80,113,000	52,702,000
Income taxes	17,602,000	
Net income	62,511,000	36,155,000
Balance for common	56,425,000	32,689,000
Earnings common share		
Primary	\$0.46	\$0.26
Fully Diluted	\$0.45	\$0.25
Common Shares:		
Full Diluted	126,169,000	129,265,000
Year-end	126,132,288	127,495,868

HILLEVAX INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	14,589	92,760
Operating income	(14,589)	(92,760)
Other income (expense), net	1,740	2,628
Net income	(11,327)	(87,497)
Earnings common share		
Primary	\$(0.23)	\$(1.79)
Fully Diluted	\$(0.23)	\$(1.79)
Common Shares:		
Full Diluted	50,048	48,820
Year-end	50,126	49,290

HOMESTREET INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	205,575	244,907
Operating income	(9,532)	(18,562)
Net before taxes	(9,532)	(18,562)
Income taxes	(655)	(4,827)
Net income	(8,877)	(13,735)
Earnings common share		
Primary	\$(0.47)	\$(0.73)
Fully Diluted	\$(0.47)	\$(0.73)
Common Shares:		
Full Diluted	18,921	18,857
Year-end	18,921	18,858

HONEST CO INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	190,709	179,266
Cost & expenses	185,314	184,625
Operating income	5,395	(5,359)
Net before taxes	7,207	(5,441)
Income taxes	84	38
Net income	7,123	(5,479)
Earnings common share		
Primary	\$0.06	\$(0.06)
Fully Diluted	\$0.06	\$(0.06)
Common Shares:		
Full Diluted	114,310	97,676
Year-end	111,600	100,157

HORIZON BANCORP INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	153,959	159,765
Operating income	52,480	31,178
Net before taxes	52,480	31,178
Income taxes	7,893	3,047
Net income	44,587	28,131
Earnings common share		
Primary	\$1.02	\$0.64
Fully Diluted	\$1.01	\$0.64
Common Shares:		
Full Diluted	43,994	43,918
Year-end	44,099	43,712

HORIZON TECHNOLOGY FINANCE CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	9,235	9,450
Operating income	(41,463)	257
Net before taxes	(41,463)	257
Income taxes	750	736

Net income	(42,213)	(479)
Earnings common share		
Primary	\$(1.04)	\$(0.01)
Fully Diluted	\$(1.04)	\$(0.01)
Common Shares:		
Full Diluted	40,725	34,507
Year-end	42,028	36,044

HUMACYTE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	818,000	
Cost & expenses	53,729,000	56,077,000
Operating income	(52,911,000)	(56,077,000)
Gains or losses	58,443,000	(30,492,000)
Net income	1,481,000	(88,559,000)
Earnings common share		
Primary	\$0.01	\$(0.78)
Fully Diluted	\$0.01	\$(0.78)
Common Shares:		
Full Diluted	143,664,424	113,710,344
Year-end	156,342,893	119,347,688

I3 VERTICALS INC**Earnings, 9 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	158,257	139,909
Cost & expenses	135,108	120,170
Operating income	2,301	945
Other income (expense), net	7,020	2,150
Net before taxes	7,389	(19,212)
Income taxes	3,272	3,153
Income contin. oper.	4,117	(22,365)
Net income	22,302	(3,414)
Earnings common share		
Primary	\$0.62	\$(0.20)
Fully Diluted	\$0.60	\$(0.20)
Common Shares:		
Full Diluted	24,824	23,340
Year-end	23,781	23,443

ICU MEDICAL INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,153,568	1,163,110
Cost & expenses	1,130,093	1,166,073
Operating income	23,475	(2,963)
Other income (expense), net	141	(1,659)
Gains or losses	41,596	77
Equity earnings	(2,837)	
Net before taxes	22,773	(56,301)
Income taxes	5,748	4,576
Net income	19,862	(60,877)
Earnings common share		
Primary	\$0.81	\$(2.51)
Fully Diluted	\$0.80	\$(2.51)
Common Shares:		
Full Diluted	24,746	24,295
Year-end	24,685	24,425

IHEARTMEDIA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,740,754	1,728,130
Cost & expenses	1,548,548	2,462,987
Operating income	9,936	(944,375)
Other income (expense), net	(420)	(833)
Invest. income	(19,495)	91,582
Net before taxes	(211,259)	(1,044,718)
Net income	(364,871)	(1,000,097)
Earnings common share		
Primary	\$(2.38)	\$(6.65)
Fully Diluted	\$(2.38)	\$(6.65)
Common Shares:		
Full Diluted	153,382	150,466
Year-end	152,495	146,732

IMMUNIC INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	53,908	46,695
Operating income	(53,908)	(46,695)
Other income (expense), net	1,191	(1,658)
Gains or losses		(4,796)

Net income	(52,293)	(50,964)
Earnings common share		
Primary	\$(0.45)	\$(0.51)
Fully Diluted	\$(0.45)	\$(0.51)
Common Shares:		
Full Diluted	116,845	99,607
Year-end	98,651	90,079

IMMUNITYBIO INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	42,942	1,087
Cost & expenses	178,656	195,616
Operating income	(135,714)	(194,529)
Other income (expense), net	641	4,020
Gains or losses	(30,467)	(2,647)
Invest. income	(254)	(45)
Net before taxes	(222,205)	
Income taxes	35	
Net income	(222,240)	(268,714)
Earnings common share		
Primary	\$(0.26)	\$(0.40)
Fully Diluted	\$(0.26)	\$(0.40)
Common Shares:		
Full Diluted	870,786	679,885
Year-end	852,904	691,793

IMMUNOVANT INC**Earnings, 3 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	127,224,000	94,281,000
Operating income	(119,700,000)	(87,073,000)
Other income (expense), net	1,187,000	28,000
Net before taxes	(119,700,000)	(87,073,000)
Income taxes	913,000	77,000
Net income	(120,613,000)	(87,150,000)
Earnings common share		
Primary	\$(0.71)	\$(0.60)
Fully Diluted	\$(0.71)	\$(0.60)
Common Shares:		
Full Diluted	170,872,994	146,085,729
Year-end	171,069,176	146,195,673

Consolidated Balance Sheet Items, as of (\$):

	2025
Assets:	
Cash & equivalents	598,912,000
Current assets	651,763,000
Net property & equip.	737,000
Total assets	661,440,000
Liabilities:	
Current liabilities	52,900,000
Stockholders' equity	608,540,000
Net current assets	598,863,000

IN8BIO INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	10,861	17,334
Operating income	(10,644)	(17,191)
Net income	(10,644)	(17,191)
Earnings common share		
Primary	\$(3.65)	\$(11.70)
Fully Diluted	\$(3.65)	\$(11.70)
Common Shares:		
Full Diluted	2,920	1,483
Year-end	4,078	1,548

INFORMATION SERVICES GROUP INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	121,148	128,532
Cost & expenses	110,817	124,125
Operating income	8,061	1,280
Net before taxes	5,958	(1,303)
Income taxes	2,287	48
Net income	3,671	(1,351)
Earnings common share		
Primary	\$0.08	\$(0.03)
Fully Diluted	\$0.07	\$(0.03)
Common Shares:		
Full Diluted	50,190	48,645
Year-end	48,323	48,903

INGLES MARKETS INC**Earnings, 9 mos. to Jun 30**(Consol. – \$):

	06/28/25	06/29/24
Total Revenues	3,965,609,341	4,242,080,604
Cost & expenses	3,883,055,398	4,093,493,272
Operating income	82,553,943	148,587,332
Other income (expense), net	8,909,015	10,541,529
Net before taxes	76,717,310	142,475,826
Income taxes	18,824,000	35,462,000
Net income	57,893,310	107,013,826
Earnings common share		
Primary	\$3.05	\$5.63
Fully Diluted	\$3.05	\$5.63
Common Shares:		
Full Diluted	18,994,376	18,994,376
Year-end	18,994,376	18,994,376

INNOSPEC INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	880,500	935,200
Cost & expenses	803,700	844,000
Operating income	76,800	91,200
Other income (expense), net	(5,600)	3,300
Gains or losses		1,600
Net before taxes	76,300	99,000
Income taxes	20,000	26,400
Net income	56,300	72,600
Earnings common share		
Primary	\$2.26	\$2.91
Fully Diluted	\$2.24	\$2.89
Common Shares:		
Full Diluted	25,097	25,091
Year-end	24,898	24,941

INNOVIVA INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	188,915	177,397
Cost & expenses	98,736	84,026
Operating income	90,179	74,502
Other income (expense), net	(1,773)	(2,209)
Gains or losses	(54,486)	(68,657)
Net before taxes	34,009	5,845
Income taxes	16,905	3,998
Net income	17,104	1,847
Earnings common share		
Primary	\$0.27	\$0.03
Fully Diluted	\$0.24	\$0.03
Common Shares:		
Full Diluted	84,342	63,064
Year-end	63,011	62,562

INOGEN, INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	174,557	166,790
Cost & expenses	188,342	190,128
Operating income	(13,785)	(23,338)
Other income (expense), net	1,057	277
Net before taxes	(10,576)	(20,325)
Income taxes	(250)	(157)
Net income	(10,326)	(20,168)
Earnings common share		
Primary	\$(0.40)	\$(0.86)
Fully Diluted	\$(0.40)	\$(0.86)
Common Shares:		
Full Diluted	26,068	23,508
Year-end	27,040	23,719

INSMED INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	200,238,000	165,840,000
Cost & expenses	758,728,000	597,723,000
Operating income	(561,016,000)	(434,409,000)
Other income (expense), net	27,716,000	17,699,000
Gains or losses		2,746,000
Net before taxes	(576,114,000)	(456,273,000)
Income taxes	2,155,000	1,427,000
Net income	(578,269,000)	(457,700,000)
Earnings common share		
Primary	\$(3.12)	\$(3.02)
Fully Diluted	\$(3.12)	\$(3.02)
Common Shares:		
Full Diluted	185,104,000	151,579,000
Year-end	211,110,658	166,666,599

INSULET CORP

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	1,218,100	930,200
Cost & expenses	1,008,200	818,700
Operating income	209,900	111,500
Other income (expense), net	(124,800)	(2,500)
Net before taxes	76,500	106,000
Income taxes	18,600	(134,100)
Net income	57,900	240,100
Earnings common share		
Primary	\$0.82	\$3.43
Fully Diluted	\$0.82	\$3.32
Common Shares:		
Full Diluted	70,641	73,771
Year-end	70,391	70,112

INTEGRAL AD SCIENCE HOLDING CORP

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	283,270	243,535
Cost & expenses	217,162	198,060
Operating income	32,403	14,686
Interest expense		3,462
Net before taxes	32,488	11,224
Income taxes	8,087	4,789
Net income	24,401	6,435
Earnings common share		
Primary	\$0.15	\$0.04
Fully Diluted	\$0.15	\$0.04
Common Shares:		
Full Diluted	167,502	164,198
Year-end	165,274	160,787

INTELLIA THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	30,872	35,892
Cost & expenses	261,675	288,938
Operating income	(230,803)	(253,046)
Gains or losses	(786)	(26,419)
Net income	(215,584)	(254,411)
Earnings common share		
Primary	\$(2.08)	\$(2.64)
Fully Diluted	\$(2.08)	\$(2.64)
Common Shares:		
Full Diluted	103,617	96,238
Year-end	105,331	98,289

INTERFACE INC.

Earnings, 6 mos. to (Consol. – \$000):

	06/29/25	06/30/24
Total Revenues	672,935	636,378
Cost & expenses	597,661	573,781
Operating income	75,274	62,597
Other income (expense), net	(5,114)	144
Net before taxes	61,302	50,145
Income taxes	15,739	13,408
Net income	45,563	36,737
Balance for common	45,663	36,455
Earnings common share		
Primary	\$0.78	\$0.63
Fully Diluted	\$0.77	\$0.63
Common Shares:		
Full Diluted	59,123	58,703
Year-end	58,393	58,303

INTERPARFUMS INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	672,755,000	666,192,000
Cost & expenses	538,502,000	533,391,000
Operating income	134,253,000	132,801,000
Other income (expense), net	324,000	37,000
Net before taxes	127,536,000	131,304,000
Income taxes	30,936,000	31,403,000
Net income	96,600,000	99,901,000
Earnings common share		
Primary	\$2.32	\$2.43
Fully Diluted	\$2.32	\$2.41
Common Shares:		
Full Diluted	32,162,000	32,266,000
Year-end	32,117,600	32,024,280

IOVANCE BIOTHERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	109,276,000	31,821,000
Cost & expenses	344,271,000	251,457,000
Operating income	(234,995,000)	(219,636,000)
Net before taxes	(227,671,000)	(212,943,000)
Income taxes	150,000	(2,866,000)
Net income	(227,821,000)	(210,077,000)
Earnings common share		
Primary	\$(0.69)	\$(0.76)
Fully Diluted	\$(0.69)	\$(0.76)
Common Shares:		
Full Diluted	328,721,000	275,518,000
Year-end	341,919,364	297,305,999

IROBOT CORP

Earnings, 6 mos. to (Consol. – \$000):

	06/28/25	06/29/24
Total Revenues	229,127	
Cost & expenses	311,313	365,204
Operating income	(82,466)	(49,168)
Other income (expense), net	1,885	(392)
Gains or losses	(2,687)	(5,121)
Net before taxes	(110,146)	(61,202)
Income taxes	(65)	837
Net income	(110,081)	(62,039)
Earnings common share		
Primary	\$(3.41)	\$(2.16)
Fully Diluted	\$(3.41)	\$(2.16)
Common Shares:		
Full Diluted	32,259	28,740
Year-end	31,308	30,077

ITEOS THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues		35,000
Cost & expenses	123,811	96,398
Operating income	(123,811)	(61,398)
Other income (expense), net	(91)	5,326
Net before taxes	(110,569)	(40,869)
Income taxes	2,772	4,475
Net income	(113,341)	(45,344)
Earnings common share		
Primary	\$(2.61)	\$(1.20)
Fully Diluted	\$(2.61)	\$(1.20)
Common Shares:		
Full Diluted	43,404	37,771
Year-end	38,272	36,520

J&J SNACK FOODS CORP.

Earnings, 9 mos. to (Consol. – \$000):

	06/28/25	06/29/24
Total Revenues	1,172,990	1,147,999
Cost & expenses	1,100,131	1,070,296
Operating income	72,859	77,703
Other income (expense), net	2,348	2,265
Net before taxes	74,469	78,436
Income taxes	20,255	21,526
Net income	54,214	56,910
Earnings common share		
Primary	\$2.78	\$2.94
Fully Diluted	\$2.77	\$2.93
Common Shares:		
Full Diluted	19,554	19,423
Year-end	19,455	19,408

JACK IN THE BOX, INC.

Earnings, 9 mos. to (Consol. – \$000):

	07/06/25	07/07/24
Total Revenues	1,139,121	1,222,016
Cost & expenses	1,137,869	1,144,376
Operating income	(42,079)	31,434
Other income (expense), net	(4,472)	(5,264)
Net before taxes	(107,269)	(35,321)
Income taxes	(20,754)	23,316
Net income	(86,515)	(58,637)
Earnings common share		
Primary	\$(4.54)	\$(2.98)
Fully Diluted	\$(4.54)	\$(2.98)
Common Shares:		
Full Diluted	19,051	19,690
Year-end	18,882	19,125

JAMF HOLDING CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	344,122	305,139
Cost & expenses	348,046	332,423
Operating income	(19,136)	(41,077)
Other income (expense), net	(850)	...
Net before taxes	(16,905)	(37,377)
Income taxes	3,441	2,409
Net income	(20,346)	(39,786)
Earnings common share		
Primary	\$(0.16)	\$(0.31)
Fully Diluted	\$(0.16)	\$(0.31)
Common Shares:		
Full Diluted	131,048	127,603
Year-end	132,726	127,467

JANUX THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	10,149	...
Cost & expenses	80,015	44,132
Operating income	(80,015)	(33,983)
Net income	(57,366)	(20,719)
Earnings common share		
Primary	\$(0.93)	\$(0.40)
Fully Diluted	\$(0.93)	\$(0.40)
Common Shares:		
Full Diluted	61,847	51,751
Year-end	59,298	52,162

KALTURA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	91,446	88,813
Cost & expenses	95,780	104,653
Operating income	(4,334)	(15,840)
Other income (expense), net	(296)	(193)
Net before taxes	(7,100)	(16,328)
Income taxes	1,769	4,772
Net income	(8,869)	(21,100)
Earnings common share		
Primary	\$(0.06)	\$(0.14)
Fully Diluted	\$(0.06)	\$(0.14)
Common Shares:		
Full Diluted	153,772	145,940
Year-end	153,602	149,205

KARAT PACKAGING INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	227,610	208,213
Cost & expenses	203,240	189,022
Operating income	24,370	19,191
Other income (expense), net	1,493	997
Net before taxes	23,447	20,519
Income taxes	5,580	4,816
Net income	17,867	15,703
Earnings common share		
Primary	\$0.87	\$0.76
Fully Diluted	\$0.86	\$0.76
Common Shares:		
Full Diluted	20,195	20,095
Year-end	20,083	20,015

KARYOPHARM THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	67,944	75,912
Cost & expenses	125,587	137,791
Operating income	(57,643)	(61,879)
Other income (expense), net	17,614	59,194
Net before taxes	(60,638)	(13,432)
Income taxes	76	138
Net income	(60,714)	(13,570)
Earnings common share		
Primary	\$(7.11)	\$(1.65)
Fully Diluted	\$(7.11)	\$(1.65)
Common Shares:		
Full Diluted	8,545	7,883
Year-end	8,647	8,309

KELLY SERVICES, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	06/29/25	06/30/24
Total Revenues	2,266,700	2,102,600
Cost & expenses	2,233,700	2,063,600
Operating income	33,000	39,000
Interest income	5,100	5,100
Other income (expense), net	300	(7,900)
Gains or losses	1,200	...
Net before taxes	27,500	35,500
Income taxes	2,700	5,100
Net income	24,800	30,400
Balance for common	24,000	29,700
Earnings common share		
Primary	\$0.68	\$0.84
Fully Diluted	\$0.67	\$0.83
Common Shares:		
Full Diluted	35,600	35,900
Year-end	35,200	35,600

KEROS THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	229,414,000	120,000
Cost & expenses	117,191,000	99,042,000
Operating income	112,223,000	(98,922,000)
Other income (expense), net	13,353,000	10,551,000
Net before taxes	125,576,000	...
Income taxes	7,821,000	...
Net income	117,755,000	(88,371,000)
Earnings common share		
Primary	\$2.90	\$(2.46)
Fully Diluted	\$2.86	\$(2.46)
Common Shares:		
Full Diluted	41,153,758	35,894,305
Year-end	40,615,414	36,169,558

KINETIK HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	870,001,000	700,851,000
Cost & expenses	586,830,000	469,495,000
Operating income	96,735,000	82,689,000
Other income (expense), net	115,548,000	115,899,000
Invest. income	59,884,000	...
Net before taxes	103,572,000	157,356,000
Income taxes	9,894,000	13,001,000
Net income	93,678,000	144,355,000
Balance for common	23,342,000	40,011,000
Earnings common share		
Primary	\$0.38	\$0.68
Fully Diluted	\$0.38	\$0.67
Common Shares:		
Full Diluted	61,693,000	59,503,000
Year-end	63,545,388	59,735,864

KINGSWAY FINANCIAL SERVICES INC (DE)**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	52,606	51,713
Cost & expenses	61,108	51,713
Operating income	(1,840)	893
Other income (expense), net	(3,342)	(3,979)
Gains or losses	178	78
Invest. income	847	1,035
Net before taxes	(6,652)	(4,280)
Income taxes	(395)	188
Income contin. oper.	...	(4,468)
Net income	(6,257)	(4,514)
Balance for common	(7,067)	(4,848)
Earnings common share		
Primary	\$(0.26)	\$(0.18)
Fully Diluted	\$(0.26)	\$(0.18)
Common Shares:		
Full Diluted	27,150	27,223
Year-end	28,430	27,262

KLA CORP**Annual Report****Consolidated Income Statement, Years Ended Jun. 30**

	2025	2024	2023
Product	9,472,854	7,482,679	...
Service	2,683,308	2,329,568	...
Product revenues	...	...	8,379,025

Service revenues	...	...	2,117,031
Total revenues	12,156,162	9,812,247	10,496,056
Costs of revenues	4,751,867	3,928,073	...
Costs of revenues	...	...	4,218,307
Research & development	1,360,334	1,278,981	1,296,727
Selling, general and administrative	1,029,734	969,509	...
Selling, general & administrative	...	...	986,326
Goodwill impairment	239,100	289,474	...
Interest expense	...	...	296,940
Gain (loss) on extinguishment of debt	...	...	(13,286)
Interest Income	180,276	160,688	...
Interest income	...	...	74,095
Interest expense	302,166	311,253	...
Foreign exchange (gains) losses, net	(2,964)	7,268	...
Foreign exchange gains (losses), net	...	...	(233)
Net realized gains (losses) on sale of investments	59	(103)	(986)
Other income (expense)	(5,884)	(12,778)	31,844
Other expense (income), net	171,487	155,075	...
Domestic income (loss) before income taxes	...	...	2,017,338
Foreign income (loss) before income taxes	...	...	1,771,852
Income (loss) before income taxes	4,644,448	3,190,032	3,789,190
Current provision (benefit) for income taxes - federal	624,002	395,876	553,197
Current provision (benefit) for income taxes - state	21,161	10,737	14,804
Current provision (benefit) for income taxes - foreign	182,448	160,401	188,991
Total current income taxes provision (benefit)	827,611	567,014	756,992
Deferred provision (benefit) for income taxes - federal	(222,907)	(110,686)	(228,414)
Deferred provision (benefit) for income taxes - state	(5,433)	(2,770)	(4,295)
Deferred provision (benefit) for income taxes - foreign	(16,466)	(25,422)	(122,444)
Total deferred income taxes provision (benefit)	(244,806)	(138,878)	(355,153)
Provision for (benefit from) income taxes	582,805	428,136	401,839
Income (loss) before minority interest	4,061,643	2,761,896	...
Net income (loss)	4,061,643	2,761,896	3,387,351
Less: net income (loss) attributable to non-controlling interest	...	...	(74)
Net income attributable to KLA Corporation	4,061,643	2,761,896	3,387,277
Weighted average shares outstanding - basic	133,030	135,345	139,483

Weighted average shares outstanding - diluted	133,750	136,187	140,235	Other non-current assets	154,370	692,723	Other income (expense), net	1,800	(100)
Year end shares outstanding	132,023	134,425	136,750	Total assets	16,067,926	15,433,566	Net before taxes	10,000	16,700
Income (loss) per share - continuing operations - basic	\$30.53	\$20.41	...	Current portion of long-term debt	...	749,936	Income taxes	2,600	7,500
Net income (loss) per share - basic	\$30.53	\$20.41	\$24.28	Accounts Payable	458,509	359,487	Net income	7,400	9,200
Income (loss) per share - continuing operations - diluted	\$30.37	\$20.28	...	Deferred system revenue	816,834	985,856	Earnings common share		
Net income (loss) per share - diluted	\$30.37	\$20.28	\$24.15	Deferred service revenue	548,011	501,926	Primary	\$0.05	\$0.06
Common DPS - by Period End Date - Gross	\$6.75	...	...	Executive Deferred Savings Plan	350,426	303,088	Fully Diluted	\$0.05	\$0.06
Cash dividends declared per share	...	\$5.65	\$5.20	Compensation and benefits	418,515	371,713	Common Shares:		
Total number of employees	15,200	15,230	...	Other accrued expenses	534,621	431,017	Full Diluted	156,900	147,500
Number of full time employees	15,000	15,000	15,000	Income taxes payable	167,262	146,740	Year-end	168,556	150,729
Number of part time employees	200	230	210	Interest payable	110,056	128,727	KRISPY KREME INC		
Number of common stockholders	405	413	408	Operating lease liabilities	45,192	36,391	Earnings, 6 mos. to (Consol. - \$000):		
Foreign currency translation adjustments	...	(11,219)	(20,741)	Customer deposits	636,369	645,893	06/29/25	06/30/24	
As is; ² Approximately; ³ As of July 17, 2023				Total current liabilities	4,085,795	4,660,774	Total Revenues	754,951	881,507
Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):				Deferred tax liabilities	446,945	486,690	Cost & expenses	1,140,088	794,554
	2025	2024		Long-term debt	5,884,257	5,880,199	Operating income	(454,820)	18,767
Cash and cash equivalents	2,078,908	1,977,129		Deferred service revenue	348,844	294,460	Other income (expense), net	1,570	(1,522)
Short-term investments	2,415,715	2,526,866		Pension liabilities	...	51,778	Gains or losses	(11,501)	...
Accounts receivable, gross	2,297,930	1,865,823		Customer credits & advances	6,823	99,794	Net before taxes	(497,643)	(10,943)
Allowance for doubtful accounts	34,015	32,782		Income taxes payable	221,808	291,106	Income taxes	(23,120)	651
Accounts receivable, net	2,263,915	1,833,041		Operating lease liabilities	158,833	153,117	Net income	(474,523)	(11,594)
Customer service parts	...	589,751		Other non-current liabilities	170,418	743,115	Earnings common share		
Raw materials	600,769	1,485,400		Other non-current liabilities	609,632	147,320	Primary	\$(2.75)	\$(0.08)
Work-in-process	833,933	700,895		Pension liabilities	51,750	...	Fully Diluted	\$(2.75)	\$(0.08)
Finished goods	285,661	258,735		Total liabilities	11,375,473	12,065,238	Common Shares:		
Discontinued PCB business	3,212,149	3,034,781		Common stock and capital in excess of par value	132	134	Full Diluted	170,546	168,890
Raw materials	1,491,786	...		Capital in excess of par value	2,511,790	2,279,999	Year-end	170,964	169,357
Contract assets	105,081	69,259		Retained earnings	2,179,330	1,137,270	KULICKE & SOFFA INDUSTRIES, INC.		
Deferred costs of revenue	223,829	279,879		Currency translation adjustments	(57,277)	(75,846)	Earnings, 9 mos. to (Consol. - \$000):		
Prepaid expenses	201,053	124,969		Unrealized gains (losses) on available-for-sale securities	5,792	(3,654)	06/28/25	06/29/24	
Income tax related receivables	64,704	102,398		Unrealized gains (losses) on defined benefit plans	(12,112)	46,243	Total Revenues	476,523	524,913
Other current assets	728,102	82,822		Unrealized gains (losses) on derivatives	64,798	(15,818)	Cost & expenses	480,635	620,098
Total current assets	10,698,789	10,031,144		Accumulated other comprehensive loss	1,201	(49,075)	Operating income	(4,112)	(95,185)
Land	86,677	78,260		Total KLA Corporation stockholders' equity	4,692,453	3,368,328	Net before taxes	13,775	(68,438)
Buildings & leasehold improvements	73,993	64,480		Total stockholders' equity	4,692,453	3,368,328	Income taxes	19,941	12,685
Machinery & equipment	1,238,599	1,116,793		Recent Dividends:			Net income	(6,166)	(81,123)
Construction in process	207,807	215,006		I. KLA Corp common.			Earnings common share		
Buildings and leasehold improvements	1,132,176	919,919		ExDate	Amt	Declared	Record	Payable	
Land, property & equipment, gross	2,739,252	2,394,458		02/11/2022	1.05	02/02/2022	02/14/2022	03/01/2022	
Accumulated depreciation	1,486,477	...		05/13/2022	1.05	05/05/2022	05/16/2022	06/01/2022	
Less: accumulated depreciation	...	1,284,490		08/12/2022	1.30	08/04/2022	08/15/2022	09/01/2022	
Land, property and equipment, net	1,252,775	...		11/14/2022	1.30	11/03/2022	11/15/2022	12/01/2022	
Land, property & equipment, net	...	1,109,968		02/10/2023	1.30	02/02/2023	02/13/2023	03/01/2023	
Goodwill	1,792,193	2,015,726		05/12/2023	1.30	05/04/2023	05/15/2023	06/01/2023	
Deferred income taxes	1,105,770	915,241		08/14/2023	1.30	08/03/2023	08/15/2023	09/01/2023	
Purchased intangibles, net	444,785	...		11/14/2023	1.45	11/02/2023	11/15/2023	12/01/2023	
Purchased intangible assets, net	...	668,764		02/15/2024	1.45	02/08/2024	02/19/2024	03/01/2024	
Executive deferred savings plan	349,530	303,365		05/14/2024	1.45	05/02/2024	05/15/2024	05/31/2024	
Operating lease right of use assets	269,714	231,812		08/15/2024	1.45	08/01/2024	08/15/2024	09/03/2024	
				11/18/2024	1.70	11/07/2024	11/18/2024	12/03/2024	
				02/24/2025	1.70	02/13/2025	02/24/2025	03/04/2025	
				05/19/2025	1.90	05/08/2025	05/19/2025	06/03/2025	
				Annual Dividends:					
				I. KLA Corp common.					
				2022	4.70	2023	5.35	2024	6.05
				2025	3.60				
				KRATOS DEFENSE & SECURITY SOLUTIONS, INC.					
				Earnings, 6 mos. to (Consol. - \$000):					
				06/29/25	06/30/24				
				Total Revenues	654,100	577,300			
				Cost & expenses	643,800	557,800			
				Operating income	10,300	19,500			
				LAM RESEARCH CORP					
				Annual Report					
				Consolidated Income Statement, Years Ended (\$000):					
				06/29/25	06/30/24	06/25/23			
				Revenue	18,435,591	14,905,386			
				Net sales	...	...			17,428,516
				Revenue	18,435,591	14,905,386			17,428,516
				Cost of goods sold	9,456,532	7,809,220			9,573,425

Cost of goods sold				adjustments	(29,080)	6,858	Total liabilities	11,483,641	10,205,274
- restructuring charges (recoveries)	...	...	78,166	Restructuring charges, net - cost of goods sold	...	43,375	Common Stock	1,268	130
Total cost of goods sold	...	...	9,651,591	Total cost of goods sold	9,456,532	7,852,595	Additional paid-in capital	8,697,290	8,225,303
Gross margin	8,979,059	7,052,791	7,776,925				Treasury Stock	27,763,430	24,366,866
Research & development expenses	2,096,387	1,902,444	1,727,162	Adjusted for 10-for-1 stock split, October 3, 2024			Accumulated other comprehensive loss	(62,423)	(130,428)
Selling, general & administrative expenses	981,704	868,247	832,753	Consolidated Balance Sheet, Years Ended (\$000):			Total stockholders' equity	9,861,619	8,539,454
Restructuring Charges	...	18,187	...		06/29/25	06/30/24	Rep Total Equity & Minority Interest	9,861,619	8,539,454
Restructuring charges (recoveries), net	...	...	42,150	Cash & cash equivalents	6,390,659	5,847,856	Recent Dividends:		
Total operating expenses	3,078,091	2,788,878	2,602,065	Accounts receivable, gross	3,384,567	2,524,527	1. Lam Research Corp common.		
Operating income (loss)	5,900,968	4,263,913	5,174,860	Less allowance for doubtful accounts	6,496	5,277	ExDate	Amt	Declared
Interest income	231,331	251,938	138,984	Accounts receivable, net	3,378,071	2,519,250	12/14/2021	1.50	11/1/2021
Interest expense	178,203	185,236	186,462	Raw materials	2,662,248	2,921,139	03/15/2022	1.50	02/10/2022
Gains (losses) on deferred compensation plan related assets, net	...	...	20,186	Work-in-process	282,885	284,078	06/14/2022	1.50	05/11/2022
Foreign exchange gains (losses), net	(26,412)	(4,837)	(7,078)	Finished goods	1,362,858	1,012,707	09/13/2022	1.73	08/25/2022
Other income (expense), net	...	58,767	...	Inventories	4,307,991	4,217,924	06/14/2022	1.50	05/11/2022
Other income (expense), net	57,161	(24,323)	...	Prepaid expenses and other current assets	440,274	298,190	08/25/2022	1.73	09/14/2022
Gains (losses) on deferred compensation plan related assets, net	39,121	...	...	Total current assets	14,516,995	12,883,220	12/13/2022	1.73	11/10/2022
Other, net	(8,676)	...	...	Manufacturing & engineering equipment	2,219,207	1,956,478	03/14/2023	1.73	02/09/2023
Income (loss) before income taxes	5,958,129	4,360,222	5,109,210	Computer equipment & software	...	178,941	06/13/2023	1.73	05/11/2023
Current	701,819	566,106	541,416	Computer & computer-related equipment	...	85,629	09/12/2023	2.00	08/24/2023
Current	22,979	20,081	32,082	Land	166,207	163,796	12/12/2023	2.00	11/09/2023
Current	238,363	143,595	196,842	Buildings	1,914,570	1,605,802	02/08/2024	2.00	02/08/2024
Deferred	(372,783)	(186,238)	(136,178)	Furniture & fixtures	92,740	...	06/18/2024	2.00	05/16/2024
Deferred	12,448	(15,118)	(2,813)	Comp Software&Equip-NBV	182,439	...	09/17/2024	2.30	08/29/2024
Deferred	(2,914)	4,024	(33,070)	Property & equipment, gross	4,575,163	3,990,646	Annual Dividends:		
Reported Net Income After Tax	5,358,217	3,827,772	...	accumulated depreciation and amortization	2,169,641	1,860,664	1. Lam Research Corp common.		
Income tax expense (benefit)	599,912	532,450	598,279	Finance leases - property plant & equipment	2,428,744	2,154,518	2022	6.23	2023
Net income (loss)	5,358,217	3,827,772	4,510,931	Property and equipment net - Balancing value	23,222	...	2023	7.18	2024
Weighted average shares outstanding - basic	1,286,101	1,314,100	1,354,720	Restricted cash	...	24,536	2024	8.30	...
Weighted average shares outstanding - diluted	1,290,142	1,319,950	1,358,340	Goodwill	...	1,626,528	LAMAR ADVERTISING CO (NEW)		
Year end shares outstanding	1,268,740	1,303,770	1,332,970	Intangible assets, net	...	138,545	Earnings, 6 mos. to Jun 30(Consol. - \$000):		
Income (loss) per share-continuing operations - basic	\$4.17	\$2.91	...	Other assets	2,590,836	1,941,917	2025	...	2024
Net income (loss) per share - basic	\$4.17	\$2.91	\$3.33	Goodwill and intangible assets	1,808,685	...	Total Revenues	1,084,741	1,063,401
Income (loss) per share-continuing operations - diluted	\$4.15	\$2.90	\$3.32	Total assets	21,345,260	18,744,728	Cost & expenses	539,896	602,155
Common DPS - by Period End Date	\$0.89	\$0.77	...	Trade accounts payable	854,208	613,966	Operating income	388,914	308,827
Gross	\$0.89	\$0.77	...	Accrued compensation	618,370	516,717	Other income (expense), net	206	(555)
Dividends per common share	...	...	\$0.69	Warranty reserves	...	228,060	Net before taxes	311,177	220,487
Total number of full time employees	...	...	17,200	Income & other taxes payable	541,426	186,700	Income taxes	16,932	4,394
Number of common stockholders	325	416	439	Dividend payable	291,981	260,905	Net income	294,245	216,093
Foreign currency translation				Other accrued expenses & other current liabilities	...	608,888	Balance for common	292,928	215,408
				Deferred profit	2,565,540	1,417,781	Earnings common share		
				Current portion of long-term debt & finance lease obligations	754,311	504,814	Primary	\$2.88	\$2.11
				Restructuring	...	607	Fully Diluted	\$2.87	\$2.10
				Operating leases	78,707	64,443	Common Shares:		
				Other Current Liabilities - Balancing value	615,099	544,445	Full Diluted	102,234	102,523
				Accrued expenses and other current liabilities	2,394,366	1,801,877	Year-end	101,219	102,295
				Other	693,806	...	LATHAM GROUP INC		
				Accrued expenses and other current liabilities			Earnings, 6 mos. to (Consol. - \$000):		
				- Balancing value	248,783	...	Total Revenues	284,059	270,751
				Total current liabilities	6,568,425	4,338,438	Cost & expenses	249,775	239,978
				Long-term portion of capital leases	...	12,475	Operating income	19,793	17,933
				Long-term debt and capital leases - Balancing value	...	4,466,045	Other income (expense), net	4,796	(549)
				Long-term debt & finance lease obligations, less current portion	3,730,194	4,478,520	Net before taxes	11,069	6,389
				Income taxes payable	603,412	813,304	Income taxes	1,051	974
				Other long-term liabilities	581,610	575,012	Net income	10,018	5,415
							Earnings common share		
							Primary	\$0.09	\$0.05
							Fully Diluted	\$0.08	\$0.05
							Common Shares:		
							Full Diluted	119,625	116,472
							Year-end	116,536	115,577
							LEGACY HOUSING CORP		
							Earnings, 6 mos. to Jun 30(Consol. - \$000):		
							2025	2024	
							Total Revenues	85,831	85,738
							Cost & expenses	57,423	52,958
							Operating income	28,408	32,780
							Other income (expense), net	1,164	3,752
							Net before taxes	30,504	38,309
							Income taxes	5,533	6,980
							Net income	24,971	31,329
							Earnings common share		
							Primary	\$1.04	\$1.29
							Fully Diluted	\$1.01	\$1.26
							Common Shares:		

Full Diluted	24,649	24,900
Year-end	23,869	24,153

LEGALZOOM.COM INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	375,619	351,576
Cost & expenses	369,753	345,375
Operating income	10,070	11,334
Other income (expense), net	999	104
Net before taxes	10,070	11,334
Income taxes	5,209	5,276
Net income	4,861	6,058
Earnings common share		
Primary	\$0.03	\$0.03
Fully Diluted	\$0.03	\$0.03
Common Shares:		
Full Diluted	182,694	189,926
Year-end	180,081	176,108

LEMAITRE VASCULAR INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	124,103	109,327
Cost & expenses	95,335	83,073
Operating income	28,768	26,254
Net before taxes	32,311	28,303
Income taxes	7,521	6,590
Net income	24,790	21,713
Earnings common share		
Primary	\$1.10	\$0.97
Fully Diluted	\$1.08	\$0.96
Common Shares:		
Full Diluted	22,896	22,657
Year-end	22,637	22,469

LESLIE'S INC**Earnings, 9 mos. to** (Consol. – \$000):

	06/28/25	06/29/24
Total Revenues	852,709	932,262
Cost & expenses	872,469	901,565
Operating income	(19,760)	30,697
Net before taxes	(67,185)	(22,683)
Income taxes	6,969	(9,227)
Net income	(74,154)	(13,456)
Earnings common share		
Primary	\$(0.40)	\$(0.07)
Fully Diluted	\$(0.40)	\$(0.07)
Common Shares:		
Full Diluted	185,256	184,614
Year-end	185,578	184,913

LEXICON PHARMACEUTICALS, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	30,128,000	2,777,000
Cost & expenses	52,071,000	103,464,000
Operating income	(21,943,000)	100,687,000
Other income (expense), net	4,053,000	6,020,000
Net income	(22,043,000)	101,826,000
Earnings common share		
Primary	\$(0.06)	\$(0.37)
Fully Diluted	\$(0.06)	\$(0.37)
Common Shares:		
Full Diluted	362,687,000	278,113,000
Year-end	363,398,860	361,492,295

LGI HOMES, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	834,905,000	993,348,000
Cost & expenses	795,128,000	907,094,000
Operating income	39,777,000	86,254,000
Other income (expense), net	7,987,000	13,723,000
Net before taxes	47,764,000	99,977,000
Income taxes	12,237,000	24,351,000
Net income	35,527,000	75,626,000
Earnings common share		
Primary	\$1.52	\$3.21
Fully Diluted	\$1.52	\$3.20
Common Shares:		
Full Diluted	23,364,957	23,635,116
Year-end	23,056,635	23,500,280

LIBERTY BROADBAND CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	527,000	491,000
Cost & expenses	338,000	340,000
Operating income	84,000	49,000
Other income (expense), net	668,000	589,000
Gains or losses	6,000	27,000
Net before taxes	678,000	562,000
Income taxes	27,000	126,000
Net income	651,000	436,000
Earnings common share		
Primary	\$4.55	\$3.05
Fully Diluted	\$4.55	\$3.05
Common Shares:		
Full Diluted	143,000	143,000
Year-end	143,489	142,848

LIBERTY MEDIA CORP (DE) - FORMULA ONE GROUP**Earnings, 6 mos. to Jun 30**(Consol. – \$Millions):

	2025	2024
Total Revenues	1,788	5,915
Cost & expenses	1,429	4,400
Operating income	202	1,030
Other income (expense), net	178	120
Gains or losses	(64)	166
Net before taxes	204	939
Income taxes	(5)	187
Net income	209	752
Earnings common share		
Primary	\$1.62	\$0.43
Fully Diluted	\$1.55	\$0.42
Common Shares:		
Full Diluted	255	255
Year-end	250	236

LIFEMD INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	127,915,941	94,806,109
Cost & expenses	126,279,789	107,282,920
Operating income	1,636,152	(12,476,811)
Net income	346,850	(13,485,957)
Balance for common	(2,243,195)	(15,197,120)
Earnings common share		
Primary	\$(0.05)	\$(0.38)
Fully Diluted	\$(0.05)	\$(0.38)
Common Shares:		
Full Diluted	43,772,151	40,269,139
Year-end	45,038,186	41,656,532

LIFESTANCE HEALTH GROUP INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	678,281	612,768
Cost & expenses	651,865	604,323
Operating income	(1,346)	(32,719)
Other income (expense), net	(93)	(870)
Gains or losses	1,960	
Net before taxes	(7,412)	(43,355)
Income taxes	(4,330)	1,019
Net income	(3,082)	(44,374)
Earnings common share		
Primary	\$(0.01)	\$(0.12)
Fully Diluted	\$(0.01)	\$(0.12)
Common Shares:		
Full Diluted	385,015	377,880
Year-end	389,077	383,314

LIFETIME BRANDS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	271,947	283,908
Cost & expenses	308,055	280,911
Operating income	(36,108)	2,997
Other income (expense), net	(14,152)	(256)
Gains or losses	(747)	(2092)
Equity earnings		
Net before taxes	(46,824)	(22,182)
Income taxes	(2,924)	153
Net income	(43,900)	(24,427)
Earnings common share		
Primary	\$(2.03)	\$(1.14)
Fully Diluted	\$(2.03)	\$(1.14)

Common Shares:

Full Diluted	21,639	21,399
Year-end	22,657	22,158

LIGAND PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	92,960,000	72,509,000
Cost & expenses	104,217,000	72,178,000
Operating income	(27,772,000)	(16,112,000)
Other income (expense), net	(1,129,000)	(35,713,000)
Invest. income	(11,428,000)	96,516,000
Net before taxes	(38,957,000)	48,057,000
Income taxes	(1,353,000)	13,829,000
Net income	(37,604,000)	34,228,000
Earnings common share		
Primary	\$(1.95)	\$1.91
Fully Diluted	\$(1.95)	\$1.87
Common Shares:		
Full Diluted	19,259,000	18,282,000
Year-end	19,411,000	18,103,000

LIGHT & WONDER INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,582,000	1,575,000
Cost & expenses	1,021,000	1,062,000
Operating income	371,000	340,000
Other income (expense), net	3,000	18,000
Net before taxes	228,000	208,000
Income taxes	51,000	44,000
Net income	177,000	164,000
Earnings common share		
Primary	\$2.09	\$1.83
Fully Diluted	\$2.05	\$1.78
Common Shares:		
Full Diluted	86,000	92,000
Year-end	84,000	89,000

LINCOLN EDUCATIONAL SERVICES CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	233,980	206,281
Cost & expenses	227,688	207,856
Operating income	6,292	(1,575)
Net before taxes	4,903	(1,473)
Income taxes	1,404	(577)
Net income	3,499	(896)
Earnings common share		
Primary	\$0.11	\$(0.03)
Fully Diluted	\$0.11	\$(0.03)
Common Shares:		
Full Diluted	31,172	30,481
Year-end	31,625	31,491

LIQUIDITY SERVICES INC**Earnings, 9 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	358,581	256,391
Cost & expenses	326,732	230,956
Operating income	24,108	16,138
Net before taxes	27,191	18,687
Income taxes	6,920	5,071
Net income	20,271	13,616
Earnings common share		
Primary	\$0.66	\$0.45
Fully Diluted	\$0.63	\$0.43
Common Shares:		
Full Diluted	32,404	31,618
Year-end	31,231	30,528

LYFT INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	3,038,355,000	2,713,047,000
Cost & expenses	3,064,774,000	2,803,224,000
Operating income	(26,419,000)	(90,177,000)
Other income (expense), net	87,906,000	7,602,000
Gains or losses		(47,000)
Net before taxes	50,305,000	(22,077,000)
Income taxes	7,424,000	4,444,000
Net income	42,881,000	(26,521,000)
Earnings common share		
Primary	\$0.10	\$(0.07)

Fully Diluted	\$0.10	\$(0.07)
Common Shares:		
Full Diluted	424,137,000	404,033,000
Year-end	411,106,000	410,151,107

MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC

Earnings, 9 mos. to (Consol. – \$000):

	07/04/25	06/28/24
Total Revenues	706,088	528,868
Cost & expenses	616,031	482,736
Operating income	90,057	46,132
Other income (expense), net	(193,098)	
Net before taxes	(84,927)	59,012
Income taxes	14,403	11,567
Net income	(99,330)	47,445
Earnings common share		
Primary	\$(1.35)	\$0.66
Fully Diluted	\$(1.35)	\$0.65
Common Shares:		
Full Diluted	73,828	73,258
Year-end	74,465	72,185

MADDEN (STEVEN) LTD.

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	1,112,534,000	1,075,934,000
Cost & expenses	1,099,293,000	972,318,000
Operating income	13,241,000	103,616,000
Gains or losses	9,252,000	
Net before taxes	19,527,000	106,525,000
Income taxes	16,979,000	25,015,000
Net income	2,548,000	81,510,000
Earnings common share		
Primary	\$0.01	\$1.10
Fully Diluted	\$0.01	\$1.09
Common Shares:		
Full Diluted	70,970,000	72,430,000
Year-end	72,651,000	72,606,000

MAGNITE INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	329,103	312,199
Cost & expenses	308,508	316,453
Operating income	20,595	(4,254)
Other income (expense), net	(1,576)	(4,811)
Net before taxes	1,610	(22,017)
Income taxes	105	(3,182)
Net income	1,505	(18,835)
Earnings common share		
Primary	\$0.01	\$(0.13)
Fully Diluted	\$0.01	\$(0.13)
Common Shares:		
Full Diluted	149,184	139,924
Year-end	142,383	141,141

MAMMOTH ENERGY SERVICES INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	32,001,000	31,366,000
Cost & expenses	64,610,000	130,395,000
Operating income	(36,918,000)	104,830,000
Other income (expense), net	(961,000)	(63,516,000)
Net before taxes	(37,367,000)	175,993,000
Income taxes	(97,000)	(13,270,000)
Income contin. oper.	(37,270,000)	162,723,000
Net income	8,311,000	167,804,000
Earnings common share		
Primary	\$0.18	\$(3.50)
Fully Diluted	\$0.18	\$(3.50)
Common Shares:		
Full Diluted	48,188,000	48,002,000
Year-end	48,194,035	48,127,369

MANNKIND CORP

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	154,881	138,649
Cost & expenses	127,289	105,317
Operating income	27,592	33,332
Other income (expense), net	(7,050)	
Gains or losses	(1,550)	
Net before taxes	14,557	9,203
Income taxes	731	587

Net income	13,826	8,616
Earnings common share		
Primary	\$0.05	\$0.03
Fully Diluted	\$0.04	\$0.03
Common Shares:		
Full Diluted	312,381	279,358
Year-end	306,332	274,467

MARAVAI LIFESCIENCES HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	94,247	133,602
Cost & expenses	209,687	165,903
Operating income	(115,440)	(32,301)
Other income (expense), net	(4,038)	(2,456)
Net before taxes	(126,816)	(43,264)
Income taxes	(4,126)	(2,164)
Net income	(122,690)	(41,100)
Earnings common share		
Primary	\$(0.48)	\$(0.16)
Fully Diluted	\$(0.48)	\$(0.16)
Common Shares:		
Full Diluted	143,833	134,088
Year-end	144,615	141,489

MARKETAXESS HOLDINGS INC.

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Cost & expenses	210,361	197,583
Operating income	180,246	173,839
Other income (expense), net	577	(2,222)
Net before taxes	193,570	183,054
Income taxes	107,325	45,501
Net income	86,245	137,553
Earnings common share		
Primary	\$2.31	\$3.65
Fully Diluted	\$2.31	\$3.64
Common Shares:		
Full Diluted	37,377	37,740
Year-end	37,416	37,784

MARQETA INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	289,465	243,237
Cost & expenses	305,247	180,555
Operating income	(27,766)	55,189
Other income (expense), net	19,300	28,143
Net before taxes	(8,466)	83,332
Income taxes	441	284
Net income	(8,907)	83,048
Earnings common share		
Primary	\$(0.02)	\$0.16
Fully Diluted	\$(0.02)	\$0.16
Common Shares:		
Full Diluted	481,260	525,415
Year-end	449,459	510,748

MASIMO CORP.

Earnings, 6 mos. to (Consol. – \$000):

	06/28/25	06/29/24
Total Revenues	742,900	683,500
Cost & expenses	600,400	588,400
Operating income	142,500	95,100
Net before taxes	123,700	72,400
Income taxes	31,600	15,500
Income contin. oper.	92,100	56,900
Net income	(119,400)	34,900
Earnings common share		
Primary	\$(2.21)	\$0.66
Fully Diluted	\$(2.21)	\$0.64
Common Shares:		
Full Diluted	54,100	54,300
Year-end	54,300	53,200

MATTHEWS INTERNATIONAL CORP

Earnings, 9 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	1,178,848,000	1,349,042,000
Cost & expenses	1,075,673,000	1,283,794,000
Operating income	86,813,000	37,457,000
Other income (expense), net	1,954,000	(2,732,000)
Net before taxes	41,390,000	(2,176,000)
Income taxes	38,391,000	(10,677,000)

Net income	2,999,000	8,501,000
Earnings common share		
Primary	\$0.10	\$0.28
Fully Diluted	\$0.10	\$0.27
Common Shares:		
Full Diluted	31,408,000	31,223,000
Year-end	30,790,906	30,597,624

MERCURY SYSTEMS INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	06/27/25	06/28/24	06/30/23
Cost of Revenues	657,526	639,374	...
Net revenues	912,020	835,275	...
Net revenues	...	...	973,882
Net revenues	912,020	835,275	973,882
Cost of revenues	...	...	657,154
Gross margin	254,494	195,901	316,728
Selling, general & administrative	154,412	166,786	160,637
Research & development	67,647	101,328	108,799
Amortization of intangible assets	42,849	47,661	...
Amortization of intangible assets	...	...	53,552
Restructuring and other charges	7,216	26,170	...
Restructuring expense	...	...	6,981
Acquisition costs & other related expenses	...	...	8,444
Acquisition costs and other related expenses	1,997	1,710	...
Total operating expenses	274,121	343,655	338,413
Income (loss) from operations	(19,627)	(147,754)	(21,685)
Interest Income	3,607	1,199	...
Interest income	...	...	1,053
Interest Expense	33,430	35,015	...
Interest expense	...	...	25,159
Other income (expense), net	(974)	(7,705)	(2,751)
Income (loss) before income taxes	(50,424)	(189,275)	(48,542)
Current	(609)	(19,791)	33,898
Current	392	(3,016)	10,054
Current	175	95	104
Deferred	(10,212)	(21,274)	(54,010)
Deferred	40	288	(53)
Deferred	(2,306)	(7,937)	(10,200)
Net Income After Taxes	(37,904)	(137,640)	...
Income tax provision	(12,520)	(51,635)	(20,207)
Net income (loss)	(37,904)	(137,640)	(28,335)
Weighted average shares outstanding			
- basic	58,746	57,738	56,554
Weighted average shares outstanding			
- diluted	58,746	57,738	56,554
Year end shares outstanding	59,003	58,094	56,962
Income (loss) per share - continuing operations - basic	\$(0.65)	\$(2.38)	...
Net earnings (loss) per share - basic	\$(0.65)	\$(2.38)	\$(0.50)
Income (loss) per share - continuing operations - diluted	\$(0.65)	\$(2.38)	...
Net earnings (loss) per share - diluted	\$(0.65)	\$(2.38)	\$(0.50)
Full-Time Employees (Period End)	2,162	2,364	...
Total number of employees	2,162	2,364	2,596
Number of common stockholders	45,709	32,036	710

Number of nominee stockholders	...	24,235
Foreign currency translation adjustments	380	300
Net (loss) income	...	(28,335)

Consolidated Balance Sheet, Years Ended (\$000):

	06/27/25	06/28/24
Cash and cash equivalents	309,099	180,521
Accounts receivable, gross	111,355	113,461
Less: allowance for doubtful accounts	1,767	2,020
Accounts receivable, net	109,588	111,441
Raw materials	195,496	200,501
Work in process	118,376	118,060
Finished goods	19,048	16,739
Inventory	332,920	335,300
Prepaid income taxes	457	...
Prepaid expenses & other current assets	278,475	304,029
Prepaid expenses and other current assets	27,639	22,493
Total current assets	1,058,178	953,784
Computer equipment & software	23,176	21,694
Leasehold improvements	74,278	72,420
Machinery & equipment	168,412	150,991
Computer equipment and software	149,342	138,366
Property & equipment, gross	415,208	383,471
accumulated depreciation	313,768	273,118
Property and equipment, net	101,440	110,353
Goodwill	938,093	938,093
Intangible assets, net	210,611	250,512
Operating lease right-of-use assets	52,264	60,860
Deferred income taxes	69,016	58,612
Other non-current assets	5,162	6,691
Total assets	2,434,764	2,378,905
Accounts Payable	79,116	81,068
Accrued expenses	43,143	42,926
Accrued compensation	51,321	36,398
Accrued expenses	11,810	11,614
Accrued expenses - Balancing value	31,333	31,312
Deferred revenues and customer advances	126,797	73,915
Income Taxes	...	109
Total current liabilities	300,377	234,416
Notes payable	591,500	591,500
Income taxes payable	4,046	7,713
Operating lease liabilities	52,738	62,584
Other non-current liabilities	12,642	9,917
Total liabilities	961,303	906,130
Common stock	590	581
Additional paid-in capital	1,287,478	1,242,402
Retained earnings	181,895	219,799
Accumulated foreign currency translation adjustments	1,711	...
pension benefit plan adjustments	1,430	...
Accumulated other comprehensive income	3,498	9,993
Total shareholders equity	...	...
Accumulated Gain Loss	...	...
Net Cash Flow Hedge	...	...
Parent	357	...
Total shareholders' equity	1,473,461	1,472,775
Total Equity	1,473,461	1,472,775

Recent Dividends:**1. Mercury Systems Inc common.**

No dividends paid.

Annual Dividends:**1. Mercury Systems Inc common.**

No dividends paid.

MGE ENERGY INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	378,422	337,049
Cost & expenses	235,302	213,037
Operating income	87,088	70,480
Other income (expense), net	6,311	7,737
Net before taxes	77,361	61,888
Income taxes	9,271	4,280
Net income	68,090	57,608
Earnings common share		
Primary	\$1.86	\$1.59
Fully Diluted	\$1.86	\$1.59
Common Shares:		
Full Diluted	36,557	36,196
Year-end	36,542	36,176

MICROCHIP TECHNOLOGY INC**Earnings, 3 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	1,075,500	1,241,300
Cost & expenses	935,800	899,200
Operating income	32,100	219,100
Other income (expense), net	4,600	1,700
Net before taxes	(15,800)	161,800
Income taxes	2,800	32,500
Net income	(18,600)	129,300
Balance for common	(46,400)	...
Earnings common share		
Primary	\$(0.09)	\$0.24
Fully Diluted	\$(0.09)	\$0.24
Common Shares:		
Full Diluted	539,200	542,800
Year-end	539,677	536,505

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025
Cash & equivalents	566,500
Inventories	1,169,100
Current assets	2,753,800
Net property & equip	1,153,900
Total assets	14,979,500
Liabilities:	
Current liabilities	1,190,400
Long-term debt	5,458,100
Stockholders' equity	6,857,100
Net current assets	1,563,400

MICROVISION INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	744,000	2,856,000
Cost & expenses	29,440,000	54,197,000
Operating income	(28,696,000)	(51,341,000)
Other income (expense), net	(4,431,000)	1,416,000
Gains or losses	2,794,000	...
Invest. income	2,564,000	...
Net before taxes	(42,842,000)	(49,925,000)
Income taxes	166,000	318,000
Net income	(43,008,000)	(50,243,000)
Earnings common share		
Primary	\$(0.18)	\$(0.25)
Fully Diluted	\$(0.18)	\$(0.25)
Common Shares:		
Full Diluted	245,347,000	202,706,000
Year-end	278,018,000	211,961,000

MIDDLEBY CORP**Earnings, 6 mos. to (Consol. - \$000):**

	06/28/25	06/29/24
Total Revenues	1,884,486	1,918,472
Cost & expenses	1,588,496	1,605,631
Operating income	295,990	312,841
Other income (expense), net	(3,331)	7,612
Net before taxes	254,451	269,613
Income taxes	56,143	67,650
Net income	198,308	201,963
Earnings common share		
Primary	\$3.73	\$3.76
Fully Diluted	\$3.68	\$3.72
Common Shares:		
Full Diluted	53,888	54,233
Year-end	51,397	53,769

MKS INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	1,910,000,000	1,755,000,000
Cost & expenses	1,542,000,000	1,399,000,000
Operating income	246,000,000	233,000,000
Other income (expense), net	(14,000,000)	(37,000,000)
Net before taxes	131,000,000	41,000,000
Income taxes	17,000,000	4,000,000
Net income	114,000,000	37,000,000
Earnings common share		
Primary	\$1.69	\$0.56
Fully Diluted	\$1.69	\$0.55
Common Shares:		
Full Diluted	67,500,000	67,500,000
Year-end	67,200,000	67,300,000

MONSTER BEVERAGE CORP (NEW)**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	3,966,150,000	3,799,695,000
Cost & expenses	2,764,783,000	2,730,541,000
Operating income	1,201,367,000	1,069,154,000
Net before taxes	1,224,704,000	1,129,285,000
Income taxes	292,917,000	261,867,000
Net income	931,787,000	867,418,000
Earnings common share		
Primary	\$0.96	\$0.84
Fully Diluted	\$0.95	\$0.83
Common Shares:		
Full Diluted	982,748,000	1,044,363,000
Year-end	976,398,000	983,380,000

MONTE ROSA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	108,123	5,759
Cost & expenses	79,641	73,348
Operating income	28,482	(67,589)
Gains or losses	59	...
Net before taxes	36,611	(61,943)
Income taxes	2,021	335
Net income	34,590	(62,278)
Earnings common share		
Primary	\$0.42	\$(0.95)
Fully Diluted	\$0.42	\$(0.95)
Common Shares:		
Full Diluted	82,890	65,695
Year-end	61,717	61,328

MONTEREY CAPITAL ACQUISITION CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2024	2023	2022
			(revised)
General & administrative expenses	...	...	2,098,401
Income (loss) from operations	(11,602,349)	(7,464,871)	(2,098,401)
Dividend & interest income	1,453,891	...	1,289,804
Loss on change in fair value of forward purchase agreement liability ...	...	...	(2,770,000)
Other income	117,573	67,691	55,466
Income (loss) before income taxes ..	(22,508,208)	(9,198,854)	(3,523,131)
Current federal income taxes	...	...	240,507
Deferred federal income taxes	...	...	(398,526)
Change in valuation allowance	...	...	398,526
Income tax provision	...	...	240,507
Net loss attributable to noncontrolling interests	(57,540)	49,188	...
Net income attributable to company	(22,565,748)	(9,149,666)	...

Net income (loss)	(22,508,208)	(9,198,854)	(3,763,638)	Interest expense	2,714,048	1,431,354	...	Non-current portion of finance lease liability	91,726	203,081
Weighted average class A shares subject to possible redemption				Gain on extinguishment of debt	2,257,638	...	...	Noncurrent portion of debt, net of debt discount	1,303,665	1,150,481
outstanding - basic	...	...	5,872,877	Change in fair value of convertible debt	(1,707,747)	...	...	Total liabilities	36,543,049	22,639,037
Weighted average class A shares outstanding - basic	...	...	88,093	Change in fair value of contingent consideration	(59,723)	...	...	Class A common stock	2,910	1,334
Weighted average class B shares outstanding - basic	...	...	2,191,507	Change in fair value of derivative liabilities	(187,428)	...	...	Additional paid-in-capital	20,152,919	13,288,174
Weighted average shares outstanding - basic	19,071,591	21,124,056	...	Other expense	134,886	...	...	Accumulated deficit	(45,426,099)	(22,860,351)
Weighted average class A shares subject to possible redemption				Loss on forward purchase agreement modification	(266,655)	...	...	Accumulated other comprehensive income	166,007	114,624
outstanding - diluted	...	...	5,872,877	Other expense	(34,413)	...	...	Total stockholder's equity	(25,104,263)	(9,456,219)
Weighted average class A shares outstanding - diluted	...	...	88,093	Non-Operating Income/Expense - Total	(10,905,859)	(1,733,983)	...	Noncontrolling interest	1,317,756	(26,345)
Weighted average class B shares outstanding - diluted	...	...	2,191,507	□ Shares increased due to the effect of class A common stock subject to possible redemption; □ As of March 31, 2023				Total Equity	(23,786,507)	(9,482,564)
Weighted average class B shares outstanding - diluted	...	...	2,191,507	Consolidated Balance Sheet, Years Ended Dec. 31 (\$):				Recent Dividends:		
Year end shares outstanding	29,093,289	13,338,437	□ 11,638,000					1. Monterey Capital Acquisition Corp class A common sub-		
Net earnings (loss) per class A shares subject to possible redemption - basic	...	...	\$(0.46)					ject to possible redemption.		
Net earnings (loss) per class A share - basic	...	...	\$(0.46)					No dividends paid.		
Net earnings (loss) per class B share - basic	...	...	\$(0.46)					2. Monterey Capital Acquisition Corp class A common.		
Net earnings (loss) per share - basic	\$(1.18)	\$(0.43)	...					No dividends paid.		
Net earnings (loss) per class A shares subject to possible redemption - diluted	...	...	\$(0.46)					3. Monterey Capital Acquisition Corp class B common.		
Net earnings (loss) per class A share - diluted	...	...	\$(0.46)					No dividends paid.		
Net earnings (loss) per class B share - diluted	...	...	\$(0.46)					Annual Dividends:		
Net earnings (loss) per share - diluted	\$(1.18)	\$(0.43)	...					1. Monterey Capital Acquisition Corp class A common sub-		
Full-Time Employees (Period End)	85	...	...					ject to possible redemption.		
Total number of employees	85	...	3					No dividends paid.		
Number of class A common stockholders	...	...	□ 1					2. Monterey Capital Acquisition Corp class A common.		
Number of class B common stockholders	...	...	□ 2					No dividends paid.		
General and administrative expenses	15,145,429	12,320,295	...					3. Monterey Capital Acquisition Corp class B common.		
Gain (Loss) on change in fair value of Forward Purchase Agreement liability	(8,254,390)	...	...					No dividends paid.		
Revenues	22,652,885	19,972,239	...					MUSTANG BIO INC		
Total Revenue	22,652,885	...	...					Earnings, 6 mos. to Jun 30(Consol. - \$000):		
Cost of revenues	16,706,177	14,934,962	...							
Loss on extinguishment of debt	(1,645,443)	(370,320)	...							
Loss on impairment of intangible assets	2,403,628	181,853	...							

	06/29/25	06/30/24
Total Revenues	46,998	44,767
Cost & expenses	33,979	30,773
Operating income	12,791	13,745
Other income (expense), net	21	21
Net before taxes	12,257	12,784
Income taxes	3,329	3,507
Net income	8,928	9,277
Earnings common share		
Primary	\$2.18	\$2.27
Fully Diluted	\$2.16	\$2.27
Common Shares:		
Full Diluted	4,124	4,089
Year-end	4,090	4,085

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025	2024
Cash & equivalents	26,867	900
Inventories	55,513	2,097
Current assets	63,436	
Net property & equip.		
Total assets		
Liabilities:		
Current liabilities	20,574	47,492
Long-term debt		(9,342)
Stockholders' equity		34,939
Net current assets		

NATIONAL RESEARCH CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	67,588,000	70,334,000
Cost & expenses	54,120,000	49,749,000
Operating income	10,184,000	17,625,000
Other income (expense), net	11,000	(16,000)
Net before taxes	8,304,000	16,518,000
Income taxes	2,623,000	3,984,000
Net income	5,681,000	12,534,000
Balance for common		12,532,000
Earnings common share		
Primary	\$0.25	\$0.53
Fully Diluted	\$0.25	\$0.52
Common Shares:		
Full Diluted	22,820,000	23,934,000
Year-end	23,103,685	23,871,257

NATIONAL VISION HOLDINGS INC**Earnings, 6 mos. to (Consol. - \$000):**

	06/28/25	06/29/24
Total Revenues	996,747	934,527
Cost & expenses	908,662	864,581
Operating income	42,586	24,033
Net before taxes	33,804	16,581
Income taxes	10,893	5,869
Income contin. oper.	10,712	
Net income	22,911	8,560
Earnings common share		
Primary	\$0.29	\$0.11
Fully Diluted	\$0.29	\$0.11
Common Shares:		
Full Diluted	79,658	78,774
Year-end	79,175	78,628

NEKTAR THERAPEUTICS**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	21,635	45,128
Cost & expenses	102,400	130,329
Operating income	(80,765)	(85,201)
Other income (expense), net	526	(135)
Equity earnings	6,847	
Net before taxes	(85,764)	(89,154)
Income taxes	(136)	11
Net income	(92,475)	(89,165)
Earnings common share		
Primary	\$(6.57)	\$(6.60)
Fully Diluted	\$(6.57)	\$(6.60)
Common Shares:		
Full Diluted	14,075	13,452
Year-end	12,457	12,271

NERDWALLET INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	396,100	312,500
Cost & expenses	384,700	318,400
Operating income	11,400	(5,900)
Gains or losses	200	(100)
Net before taxes	12,800	(3,500)
Income taxes	4,400	4,800
Net income	8,400	(8,300)
Earnings common share		
Primary	\$0.11	\$(0.11)
Fully Diluted	\$0.11	\$(0.11)
Common Shares:		
Full Diluted	76,300	77,500
Year-end	76,000	78,707

NETGEAR INC**Earnings, 6 mos. to (Consol. - \$000):**

	06/29/25	06/30/24
Total Revenues	332,592	308,486
Cost & expenses	354,931	376,993
Operating income	(22,339)	(68,507)
Other income (expense), net	12,147	5,563
Net before taxes	(10,192)	(62,944)
Income taxes	2,270	881
Net income	(12,462)	(63,825)
Earnings common share		
Primary	\$(0.43)	\$(2.19)
Fully Diluted	\$(0.43)	\$(2.19)
Common Shares:		
Full Diluted	28,815	29,136
Year-end	28,993	28,679

NETSCOUT SYSTEMS INC**Earnings, 3 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	186,747	174,565
Cost & expenses	182,192	626,275
Operating income	(6,564)	(463,324)
Other income (expense), net	940	8,475
Net before taxes	(2,828)	(453,696)
Income taxes	851	(10,320)
Net income	(3,679)	(443,376)
Earnings common share		
Primary	\$(0.05)	\$(6.20)
Fully Diluted	\$(0.05)	\$(6.20)
Common Shares:		
Full Diluted	71,729	71,467
Year-end	72,521	71,311

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025	2024
Cash & equivalents	489,572	
Inventories	13,047	
Current assets	683,915	
Net property & equip.	21,494	
Total assets	2,157,426	
Liabilities:		
Current liabilities	386,982	
Stockholders' equity	1,547,551	
Net current assets	296,933	

NEUMORA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Cost & expenses	124,976	123,896
Operating income	(124,976)	(123,896)
Other income (expense), net	(505)	(36)
Net before taxes	(120,593)	(112,296)
Income taxes	130	125
Net income	(120,723)	(112,421)
Earnings common share		
Primary	\$(0.75)	\$(0.71)
Fully Diluted	\$(0.75)	\$(0.71)
Common Shares:		
Full Diluted	161,572	158,464
Year-end	161,748	159,950

NEURONETICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	70,083	33,867
Cost & expenses	89,155	49,233
Operating income	(19,072)	(15,366)
Other income (expense), net	435	1,465
Net income	(22,528)	(17,705)

Earnings common share		
Primary	\$(0.36)	\$(0.59)
Fully Diluted	\$(0.36)	\$(0.59)
Common Shares:		
Full Diluted	63,835	29,762
Year-end	66,113	30,136

NEWMARK GROUP INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues		1,179,874
Cost & expenses	1,310,413	1,076,912
Operating income	25,224	18,108
Net before taxes	7,718	2,630
Income taxes	(5,844)	5,530
Net income	13,562	(2,900)
Earnings common share		
Primary	\$0.07	\$(0.01)
Fully Diluted	\$0.06	\$(0.01)
Common Shares:		
Full Diluted	253,670	174,121
Year-end	175,638	171,670

NEWS CORP (NEW)**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$000):**

	2025	2024	2023
Revenues:	1,367,000	1,400,000	1,473,000
Circulation and Subscription	3,009,000	2,909,000	2,818,000
Consumer	2,047,000	2,000,000	1,899,000
Real estate	1,410,000	1,284,000	1,189,000
Other	619,000	659,000	633,000
Total revenues	8,452,000	8,252,000	8,012,000
Operating expenses	3,736,000	3,814,000	3,911,000
Selling, general & administrative expense	3,301,000	3,197,000	3,012,000
Depreciation and amortization	459,000	440,000	415,000
Depreciation	361,000	341,000	309,000
Amortization of Intangibles			
excluding Goodwill	98,000	99,000	106,000
Gain on sale of cost method investments	87,000	...	...
Income (loss) before income tax expense	923,000	585,000	380,000
Current U.S. federal income tax expense (benefit)	...	1,000	1,000
Current U.S. state & local income tax expense (benefit)	12,000	10,000	15,000
Current foreign income tax expense (benefit)	180,000	165,000	125,000
Total current income tax expense (benefit)	192,000	176,000	141,000
Deferred U.S. federal income tax expense (benefit)	29,000	22,000	(10,000)
Deferred U.S. state & local income tax expense (benefit)	9,000	3,000	...
Deferred foreign income tax expense (benefit)	45,000	5,000	21,000
Total deferred income tax expense (benefit)	83,000	30,000	11,000
Income tax expense (benefit)	275,000	206,000	152,000
Net income (loss)	648,000	379,000	228,000
Income (loss) from continuing operations	648,000	379,000	228,000
Income (loss) from discontinued			

operations, net of tax.....	692,000	(25,000)	(41,000)	Intangibles excluding Goodwill ..	...	...	2,000	Share of other comprehensive income from equity affiliates, net	(1,543,000)	(1,251,000)
Net loss attributable to noncontrolling interests from discontinued operations	8,000	22,000	27,000	⌚ Restated to reflect discontinued operations				Total News Corporation stockholders' equity	8,774,000	8,120,000
Net income (loss)	1,340,000	354,000	187,000	Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):	2025	2024	(revised)	Noncontrolling interests	615,000	891,000
Less: net income (loss) attributable to noncontrolling interests	(168,000)	(110,000)	(65,000)	Cash & cash equivalents	2,403,000	1,960,000		Total equity	9,389,000	9,011,000
Net income (loss) attributable to New Corporation stockholders	1,180,000	266,000	149,000	allowances	56,000	65,000		Recent Dividends:		
Weighted average shares outstanding - basic	567,700	571,200	576,400	Receivables, net	1,562,000	1,503,000		1. News Corp (New) class A common.		
Weighted average shares outstanding - diluted	569,900	573,500	578,800	Inventory, net	327,000	296,000		No dividends paid.		
Year end shares outstanding	565,386	569,094	571,960	Total current assets	4,811,000	4,372,000		2. News Corp (New) class B common.		
Income (loss) from continuing operations per share - basic	\$0.85	\$0.47	\$0.28	Investments	1,016,000	430,000		No dividends paid.		
Earnings per share-inc from discontinued oper	\$1.22	\$(0.04)	\$(0.07)	Land	123,000	121,000		Annual Dividends:		
Income (loss) from discontinued operations per share - basic	\$1.22	\$(0.04)	\$(0.07)	Buildings & leaseholds	1,511,000	1,527,000		1. News Corp (New) class A common.		
Net income (loss) per share - basic	\$2.08	\$0.47	\$0.26	Digital set top units & installations	...	1,171,000		No dividends paid.		
Income (loss) from continuing operations per share - diluted	\$2.07	\$0.46	\$0.26	Machinery & equipment	752,000	945,000		2. News Corp (New) class B common.		
Earn per share-inc from discount ops - diluted	\$1.21	\$(0.04)	\$(0.07)	Capitalized software	1,753,000	2,206,000		No dividends paid.		
Income (loss) from discontinued operations per share - diluted	\$1.21	\$(0.04)	\$(0.07)	Finance lease right-of-use assets	789,000	958,000		NEXSTAR MEDIA GROUP INC		
Net income (loss) per share - diluted	\$2.07	\$0.46	\$0.26	Finance lease right-of-use assets	...	125,000		Earnings, 6 mos. to Jun 30(Consol. - \$000):	2025	2024
Common DPS - by Period End Date - Gross	\$0.10	\$0.20	\$0.20	accumulated depreciation and amortization	2,921,000	4,396,000		Total Revenues	2,462,000	...
Common DPS - by Period End Date - Gross	\$0.10	\$0.20	\$0.20	Property plant & equipment, before construction in progress	1,331,000	1,914,000		Cost & expenses	1,628,000	1,639,000
Full-Time Employees (Period End)	22,300	23,900	...	Construction in progress	113,000	215,000		Operating income	432,000	516,000
Total number of employees	22,300	...	...	Intangible assets, net	1,930,000	2,322,000		Other income (expense), net	30,000	89,000
Impairment and restructuring charges	132,000	133,000	121,000	Goodwill	4,373,000	5,186,000		Net before taxes	268,000	378,000
Equity losses of affiliates	(15,000)	(6,000)	(127,000)	Deferred income tax assets	254,000	332,000		Income taxes	80,000	105,000
Interest expense, net	3,000	(18,000)	(49,000)	Royalty advances to authors	377,000	375,000		Net income	188,000	273,000
Other	(3,000)	46,000	(12,000)	Inventory	...	226,000		Balance for common	197,000	...
Gain on remeasurement of previously-held interest in Elara	21,000	(13,000)	(9,000)	Other non-current assets	1,000,000	1,170,000		Earnings common share		
Restructuring charges	...	...	119,000	Other	138,000	422,000		Primary	\$6.50	\$8.85
Number of Common Shareholders	13,000	...	...	Equity method investments	85,000	216,000		Fully Diluted	\$6.43	\$8.71
Net (income) loss attributable to noncontrolling interests from discontinued operations	(111,000)	59,000	(3,000)	Equity securities	931,000	214,000		Common Shares:		
Impairment -				Retirement benefit assets	165,000	147,000		Full Diluted	30,719	33,656
				Non-current receivables	320,000	...		Year-end	30,315	32,486
				Total assets	15,504,000	16,684,000		NEXTCURE INC		
				Accounts payable	335,000	314,000		Earnings, 6 mos. to Jun 30(Consol. - \$000):	2025	2024
				Accrued expenses	1,036,000	1,231,000		Total Revenues	2,741,000	2,151,000
				Deferred revenue	498,000	551,000		Cost & expenses	38,914	34,798
				Royalties & commissions payable	...	215,000		Operating income	(38,914)	(34,798)
				Allowance for sales returns	138,000	141,000		Other income (expense), net	1,130	2,287
				Current borrowings	...	54,000		Net income	(37,784)	(32,511)
				Current borrowings - Balancing value	25,000	33,000		Earnings common share		
				Other current liabilities	714,000	905,000		Primary	\$(16.05)	\$(13.92)
				Programming rights payable	202,000	98,000		Fully Diluted	\$(16.05)	\$(13.92)
				Other	300,000	334,000		Common Shares:		
				Current operating lease liabilities	74,000	117,000		Full Diluted	2,354	2,328
				Capitalized Leases - Current Portion	...	21,000		Year-end	2,338	2,331
				Total current liabilities	2,608,000	3,055,000		NEXTRAV INC		
				Telstra facility	...	2,851,000		Earnings, 6 mos. to Jun 30(Consol. - \$):	2025	2024
				Finance lease liability	1,937,000	2,855,000		Total Revenues	113,403	95,038
				Capitalized Lease Obligations - Long-Term	...	4,000		Cost & expenses	127,249	122,446
				Deferred income tax liabilities	57,000	119,000		Operating income	(13,846)	(27,408)
				Operating lease liabilities	904,000	1,027,000		Other income (expense), net	(44)	1,263
				Other non-current liabilities	492,000	492,000		Net before taxes	(11,530)	(25,231)
				Retirement benefit obligations	117,000	125,000		Income taxes	154	264
				Class A common stock	2,000	2,000		Net income	(11,684)	(25,495)
				Class B common stock	4,000	4,000		Earnings common share		
				Additional paid-in capital	11,058,000	11,254,000		Primary	\$(0.24)	\$(0.54)
				Accumulated deficit	(747,000)	(1,889,000)		Fully Diluted	\$(0.24)	\$(0.54)
				Cash flow hedge adjustments	9,000	22,000		Common Shares:		
				Benefit plan adjustments	(327,000)	(309,000)		Full Diluted	49,338	47,450
				Foreign currency translation	(1,225,000)	(964,000)		Year-end	49,883	48,099

NN, INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	213,609	244,190
Cost & expenses	202,170	226,812
Operating income	(6,253)	(6,930)
Other income (expense), net	(219)	(692)
Equity earnings	(4,620)	(4,412)
Net before taxes	(17,323)	(18,861)
Income taxes	2,084	291
Net income	(14,787)	(14,740)
Balance for common	(23,808)	(22,253)
Earnings common share		
Primary	\$(0.48)	\$(0.46)
Fully Diluted	\$(0.48)	\$(0.46)
Common Shares:		
Full Diluted	49,255	48,281
Year-end	50,287	50,032

NORTHFIELD BANCORP INC (DE)**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	104,694	107,419
Operating income	24,662	17,689
Net before taxes	24,662	17,689
Income taxes	7,215	5,518
Net income	17,447	12,171
Earnings common share		
Primary	\$0.43	\$0.29
Fully Diluted	\$0.43	\$0.29
Common Shares:		
Full Diluted	40,562	42,204
Year-end	41,820	43,467

NOVAVAX, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	905,895,000	509,339,000
Cost & expenses	289,311,000	493,172,000
Operating income	616,584,000	16,167,000
Other income (expense), net	21,957,000	11,385,000
Net before taxes	627,300,000	19,298,000
Income taxes	2,146,000	4,467,000
Net income	625,154,000	14,831,000
Earnings common share		
Primary	\$3.87	\$0.10
Fully Diluted	\$3.55	\$0.10
Common Shares:		
Full Diluted	177,410,000	145,121,000
Year-end	162,155,109	159,891,014

NUVALENT INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	199,383	117,738
Operating income	(199,383)	(117,738)
Gains or losses	(7,470)	
Net before taxes	(183,933)	(101,095)
Income taxes	302	553
Net income	(184,235)	(101,648)
Earnings common share		
Primary	\$(2.57)	\$(1.58)
Fully Diluted	\$(2.57)	\$(1.58)
Common Shares:		
Full Diluted	71,726	64,378
Year-end	72,015	64,720

NWPX INFRASTRUCTURE INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	249,297	242,720
Cost & expenses	230,492	220,411
Operating income	18,805	22,309
Other income (expense), net	28	(221)
Net before taxes	17,435	18,791
Income taxes	4,408	4,934
Net income	13,027	13,857
Earnings common share		
Primary	\$1.31	\$1.40
Fully Diluted	\$1.30	\$1.38
Common Shares:		
Full Diluted	10,041	10,025
Year-end	9,821	9,919

O'REILLY AUTOMOTIVE, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	8,661,982	8,248,441
Cost & expenses	7,006,046	6,632,662
Operating income	1,655,936	1,615,779
Other income (expense), net	1,222	4,962
Net before taxes	1,545,806	1,511,946
Income taxes	338,726	341,860
Net income	1,207,080	1,170,086
Earnings common share		
Primary	\$1.41	\$1.33
Fully Diluted	\$1.40	\$1.32
Common Shares:		
Full Diluted	861,368	888,750
Year-end	850,561	873,581

ODP CORP (THE)**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	06/28/25	06/29/24
Total Revenues	3,286,000	3,586,000
Cost & expenses	3,309,000	3,545,000
Operating income	(23,000)	41,000
Other income (expense), net	(6,000)	(1,000)
Net before taxes	(37,000)	35,000
Income taxes	(8,000)	8,000
Income contin. oper.		27,000
Net income	(29,000)	(58,000)
Earnings common share		
Primary	\$(0.97)	\$(1.59)
Fully Diluted	\$(0.97)	\$(1.59)
Common Shares:		
Full Diluted	30,000	36,000
Year-end	30,084	34,321

OLAPLEX HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	203,262	202,849
Cost & expenses	174,167	144,929
Operating income	7,272	35,895
Other income (expense), net	1,165	(1,211)
Net before taxes	(8,184)	18,048
Income taxes	(907)	4,523
Net income	(7,277)	13,525
Earnings common share		
Primary	\$(0.01)	\$0.02
Fully Diluted	\$(0.01)	\$0.02
Common Shares:		
Full Diluted	665,323	663,517
Year-end	666,089	661,830

OLEMA PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Cost & expenses	82,737,000	67,869,000
Operating income	(82,737,000)	(67,869,000)
Other income (expense), net	(2,000)	57,000
Net income	(74,173,000)	(61,352,000)
Earnings common share		
Primary	\$(0.87)	\$(1.10)
Fully Diluted	\$(0.87)	\$(1.10)
Common Shares:		
Full Diluted	85,462,021	55,928,363
Year-end	68,627,886	57,258,367

OMNICELL INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	560,230	522,939
Cost & expenses	563,729	541,562
Operating income	(3,499)	(18,623)
Net before taxes	923	(9,634)
Income taxes	2,307	2,307
Net income	(1,384)	(11,941)
Earnings common share		
Primary	\$(0.03)	\$(0.26)
Fully Diluted	\$(0.03)	\$(0.26)
Common Shares:		
Full Diluted	46,692	45,842
Year-end	46,419	45,994

ORASURE TECHNOLOGIES INC.**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	61,173,000	108,467,000
Cost & expenses	96,949,000	118,300,000
Operating income	(35,776,000)	(9,833,000)
Other income (expense), net	2,913,000	6,557,000
Equity earnings	1,326,000	560,000
Net before taxes	(32,863,000)	(3,276,000)
Income taxes		363,000
Net income	(35,733,000)	(4,199,000)
Earnings common share		
Primary	\$(0.48)	\$(0.06)
Fully Diluted	\$(0.48)	\$(0.06)
Common Shares:		
Full Diluted	74,703,000	74,127,000
Year-end	73,735,000	74,568,000

ORIC PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	71,782	65,007
Operating income	(71,782)	(65,007)
Net income	(66,376)	(56,974)
Earnings common share		
Primary	\$(0.89)	\$(0.83)
Fully Diluted	\$(0.89)	\$(0.83)
Common Shares:		
Full Diluted	74,603	68,849
Year-end	86,187	67,672

ORTHOPEDIATRICS CORP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	113,493	97,487
Cost & expenses	135,131	112,876
Operating income	(21,638)	(15,389)
Other income (expense), net	6,353	(96)
Net before taxes	(17,527)	(16,383)
Income taxes	245	(2,549)
Net income	(17,772)	(13,834)
Earnings common share		
Primary	\$(0.76)	\$(0.60)
Fully Diluted	\$(0.76)	\$(0.60)
Common Shares:		
Full Diluted	23,346	22,983
Year-end	25,073	24,217

OUTSET MEDICAL INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	61,171	55,556
Cost & expenses	94,435	123,232
Operating income	(33,264)	(67,676)
Other income (expense), net	(7,685)	
Net before taxes	(44,105)	(74,085)
Income taxes	219	313
Net income	(44,324)	(74,398)
Earnings common share		
Primary	\$(3.57)	\$(21.75)
Fully Diluted	\$(3.57)	\$(21.75)
Common Shares:		
Full Diluted	12,420	3,426
Year-end	17,766	3,472

PACIFIC BIOSCIENCES OF CALIFORNIA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	76,919	74,823
Cost & expenses	187,831	322,303
Operating income	(473,787)	(257,208)
Other income (expense), net	8,990	12,828
Net before taxes	(468,272)	
Income taxes	(267)	
Net income	(468,005)	(251,497)
Earnings common share		
Primary	\$(1.57)	\$(0.93)
Fully Diluted	\$(1.57)	\$(0.93)
Common Shares:		
Full Diluted	298,519	270,982
Year-end	300,350	272,491

PALLADYNE AI CORP**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	2,725,000	6,154,000
Cost & expenses	17,750,000	19,294,000
Operating income	(15,025,000)	(13,140,000)
Other income (expense), net	2,000	2,000
Gains or losses	29,351,000	(132,000)
Net income	15,272,000	(12,552,000)
Earnings common share		
Primary	\$0.42	\$(0.48)
Fully Diluted	\$0.39	\$(0.48)
Common Shares:		
Full Diluted	39,567,022	25,938,483
Year-end	40,370,914	26,769,694

PALOMAR HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	249,603,000	249,603,000
Cost & expenses	165,941,000	113,304,000
Operating income	113,593,000	67,730,000
Net before taxes	113,593,000	67,730,000
Income taxes	24,143,000	15,619,000
Net income	89,450,000	52,111,000
Earnings common share		
Primary	\$3.35	\$2.09
Fully Diluted	\$3.24	\$2.04
Common Shares:		
Full Diluted	27,568,913	25,554,445
Year-end	26,777,198	24,984,638

PAPA JOHN'S INTERNATIONAL, INC.**Earnings, 6 mos. to** (Consol. – \$000):

	06/29/25	06/30/24
Total Revenues	1,047,475	1,021,810
Cost & expenses	961,858	924,598
Operating income	48,455	61,944
Net before taxes	27,792	39,985
Income taxes	8,778	12,535
Net income	19,014	27,450
Balance for common	18,295	27,450
Earnings common share		
Primary	\$0.56	\$0.82
Fully Diluted	\$0.56	\$0.82
Common Shares:		
Full Diluted	32,932	32,871
Year-end	32,753	32,622

PARK-OHIO HOLDINGS CORP.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	805,500	850,200
Cost & expenses	766,500	801,600
Operating income	39,000	48,600
Other income (expense), net	3,600	2,700
Net before taxes	20,400	27,400
Income taxes	3,700	5,900
Income contin. oper.	16,700	21,500
Net income	16,400	20,100
Earnings common share		
Primary	\$1.28	\$1.74
Fully Diluted	\$1.26	\$1.68
Common Shares:		
Full Diluted	13,900	12,800
Year-end	14,263	13,180

PATRICK INDUSTRIES INC**Earnings, 6 mos. to** (Consol. – \$):

	06/29/25	06/30/24
Total Revenues	2,050,974,000	1,758,989,000
Cost & expenses	1,849,545,000	1,758,989,000
Operating income	152,291,000	144,031,000
Other income (expense), net	(24,420,000)	(24,420,000)
Net before taxes	89,890,000	103,598,000
Income taxes	19,216,000	20,621,000
Net income	70,674,000	82,977,000
Earnings common share		
Primary	\$2.17	\$2.55
Fully Diluted	\$2.07	\$2.50
Common Shares:		
Full Diluted	34,116,000	33,187,500
Year-end	33,278,676	33,602,342

PAYLOCITY HOLDING CORP
Annual Report

Consolidated Income Statement, Years Ended Jun. 30			
(\$000):			
	2025	2024	2023
Recurring & other revenue	...	...	1,098,036
Interest income on funds held for clients	...	...	76,562
Implementation services & other revenues	123,420	...	...
Interest income on funds held for clients	...	120,835	...
Total revenues	1,595,221	1,402,515	1,174,598
Cost of Revenues	498,223	441,729	...
Cost of revenues	...	...	367,039
Gross profit (loss)	1,096,998	960,786	807,559
Sales & marketing expenses	374,216	334,954	296,716
Research and development	205,851	178,333	...
Research & development expenses	...	...	163,994
General & administrative expenses	212,907	187,406	191,823
Total operating expenses	792,974	700,693	652,533
Operating income (loss)	304,024	260,093	155,026
Other income (expense)	5,039	16,922	...
Other income (expense) (loss)	...	...	3,588
before income taxes	309,063	277,015	158,614
Current federal income taxes	65,188	30,900	1,702
Current state & local income taxes	...	...	2,625
Deferred federal income taxes	(4,072)	26,438	17,973
Deferred state & local income taxes	...	...	(4,508)
Current Tax - State and local	18,918	11,524	...
Deferred Tax - State and local	940	1,387	...
International	999	...	...
International	(37)	...	...
Income tax expense (benefit)	81,936	70,249	17,792
Net income (loss)	227,127	206,766	140,822
Weighted average shares outstanding - basic	55,649	56,214	55,706
Weighted average shares outstanding - diluted	56,550	56,976	56,596
Year end shares outstanding	55,366	55,514	55,912
Net income (loss) per share - basic	\$4.08	\$3.68	\$2.53
Net income (loss) per share - diluted	\$4.02	\$3.63	\$2.49
Number of full time employees	6,700	6,400	6,100
Total number of employees	6,700	6,400	...
Number of common stockholders	6	16	15
Cost of revenues	498,223	441,729	...

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2025	2024
Cash and cash equivalents	398,070	401,811
Accounts receivable, gross	44,479	35,372
Allowance for doubtful accounts	2,837	2,375

Accounts receivable, net	41,642	32,997
Deferred contract costs	117,177	97,859
Prepaid expenses and other	50,943	39,765
Funds held for clients	2,704,137	2,952,060
Total current assets	3,311,969	3,524,492
Long-term prepaid expenses	7,739	7,077
Capitalized software, net	132,317	...
Capitalized internal-use software, net	...	116,412
Office equipment	12,793	13,102
Computer equipment	67,372	63,138
Furniture & fixtures	13,317	13,081
Leasehold improvements	50,747	49,392
Time clocks rented by clients	10,913	9,738
Office equipment	2,779	2,771
Total property & equipment, gross	157,921	151,222
Accumulated depreciation	103,711	...
Less: accumulated depreciation	...	90,582
Property and equipment, net	54,210	...
Property & equipment, net	...	60,640
Operating lease right-of-use assets	35,997	33,792
Intangible assets, net	92,671	...
Intangibles assets, net	...	28,291
Goodwill	343,100	108,937
Long-term deferred contract costs	393,671	348,003
Deferred income tax assets	17,754	17,816
Total assets	4,389,428	4,245,460
Accounts payable	17,347	8,638
Accrued payroll & personnel costs	106,808	93,248
Operating lease liabilities	8,621	7,634
Deferred revenue	35,721	25,949
Other accrued expenses	193,081	158,311
Other	41,931	31,480
Client fund obligations	2,694,842	2,950,411
Total current liabilities	2,905,270	3,117,360
Long-term operating lease liabilities	46,772	46,814
Other long-term liabilities	8,580	6,398
Deferred income tax liabilities	32,559	41,824
Total liabilities	3,155,681	3,212,396
Common Stock	55	56
Additional paid-in capital	327,518	360,488
Retained earnings	900,583	673,456
Accumulated other comprehensive loss	5,591	(936)
Total stockholders' equity (deficit)	1,233,747	1,033,064
Total Equity	1,233,747	1,033,064

Recent Dividends:**1. Paylocity Holding Corp common.**

No dividends paid.

Annual Dividends:**1. Paylocity Holding Corp common.**

No dividends paid.

PAYONEER GLOBAL INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	417,892,000	362,898,000
Operating income	59,396,000	84,685,000
Other income (expense), net	(1,777,000)	3,723,000
Gains or losses	...	2,767,000
Net before taxes	57,619,000	91,175,000
Income taxes	17,562,000	29,776,000
Net income	40,057,000	61,399,000
Earnings common share		
Primary	\$0.11	\$0.17
Fully Diluted	\$0.10	\$0.16

Common Shares:		
Full Diluted	385,250,558	376,727,575
Year-end	362,236,351	352,689,391

PDF SOLUTIONS INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	99,506	82,971
Cost & expenses	100,498	84,149
Operating income	(2,438)	1,475
Net before taxes	(2,925)	1,475
Income taxes	(1,039)	163
Net income	(1,886)	1,312
Earnings common share		
Primary	\$(0.05)	\$0.03
Fully Diluted	\$(0.05)	\$0.03
Common Shares:		
Full Diluted	39,118	38,989
Year-end	39,163	38,431

PELOTON INTERACTIVE INC**Annual Report****Consolidated Income Statement, Years Ended Jun. 30**
(\$000):

	2025	2024	2023
Product	705,900	943,000	...
Subscription And Circulation	516,600	551,000	...
General and administrative	527,300	651,000	...
Sales and marketing ..	421,600	658,900	...
Revenue - connected fitness products	...	...	1,130,200
Connected Fitness Products	817,100	991,700	...
Subscription	1,673,700	1,708,700	...
Subscription	...	...	1,670,100
Total revenue	2,490,800	2,700,500	2,800,200
Connected Fitness Products	...	...	1,328,800
Subscription	...	...	547,900
Total cost of revenue	1,222,500	1,494,000	1,876,700
Gross profit (loss)	1,268,300	1,206,500	923,500
Research & development	234,200	304,800	318,400
Impairment expense ..	64,100	57,300	144,500
Restructuring expense	33,800	66,100	189,400
Supplier settlements	23,500	(2,600)	22,000
Sales & marketing ..	...	...	648,200
General & administrative	...	...	798,100
Total operating expenses	1,304,500	1,735,500	2,120,600
Income (loss) from operations	(36,200)	(529,000)	(1,197,100)
Interest expense	134,500	112,500	...
Interest expense	...	...	97,100
Interest income	32,700	35,100	...
Interest income	...	...	26,400
Foreign exchange gain (loss)	22,400	...	...
Foreign exchange losses	...	...	7,000
Other income (expense), net	100	700	2,900
Net gain on debt refinancing	...	(53,600)	...
Total other income (expense), net	(79,300)	(23,200)	(60,900)
Income (loss) before provision for income taxes - U.S.	...	...	(1,101,900)
Income (loss) before provision for income taxes - foreign	...	...	(156,100)
Income (loss) before provision for income taxes	(115,600)	(552,100)	(1,258,000)

Current state income tax expense (benefit)	800	800	600
Current foreign income tax expense (benefit)	1,900	...	4,600
Total current income tax expense (benefit)	2,700	800	...
Deferred foreign income tax expense (benefit)	700	(1,000)	(1,500)
Total deferred income tax expense (benefit)	700	(1,000)	...
Income tax expense (benefit)	3,400	(200)	3,700
Net loss	...	...	(1,261,700)
Net income (loss)	(119,000)	(551,900)	(1,261,700)
Net income (loss) attributable to common stockholders	...	...	(1,261,700)
Weighted average shares outstanding - basic	390,038	365,546	346,671
Weighted average shares outstanding - diluted	390,038	365,546	346,671
Year end shares outstanding	406,417	376,262	356,768
Net earnings (loss) per share - basic	\$(0.30)	\$(1.51)	\$(3.64)
Net earnings (loss) per share - diluted	\$(0.30)	\$(1.51)	\$(3.64)
Full-Time Employees (Period End)	2,605	2,853	...
Total number of employees	2,605	2,853	3,584
Foreign currency translation adjustments	...	(900)	3,600
Common Shareholders - Number	103	106	109

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

	2025	2024
Cash and cash equivalents	1,039,500	697,600
Accounts receivable, net of allowances	101,200	103,600
Raw materials	22,700	29,800
Finished products	337,600	487,600
Inventories	205,600	329,700
Reserves	(154,800)	(187,700)
Prepaid expenses and other current assets	91,300	135,100
Total current assets	1,437,600	1,266,000
Leasehold improvements	257,000	292,400
Furniture & fixtures	18,200	22,500
Construction in progress	400	1,100
Software	160,500	178,000
Machinery & equipment	10,300	12,100
Customer-leased equipment	51,300	76,900
Equipment - Gross	39,600	41,800
Total property & equipment, gross	537,300	624,900
Less: accumulated depreciation & amortization	298,300	271,200
Property and equipment, net	239,000	353,700
Intangible Assets - excluding Goodwill - Net - Total	5,600	...
Intangible assets, net	...	15,000
Goodwill	41,200	41,200
Restricted cash	46,200	53,200
Operating lease right-of-use assets, net	338,900	435,000
Other assets	16,800	21,000
Total assets	2,125,300	2,185,200
Accrued settlement costs	...	18,100
Inventory received but not billed	28,100	30,700

Accrued music licensing royalties	145,200	...
Employee-related liabilities	46,200	42,900
Return reserve liability	...	10,600
Accrued professional services	11,000	24,300
Accrued marketing	7,400	16,100
Accrued capital expenditures	...	137,200
Other accrued expenses	...	51,900
Content costs for past use reserve	...	9,800
Recall related costs	...	5,300
Other	52,200	...
Accrued general and administrative	15,800	...
Accounts payable & accrued expenses	66,700	85,400
Current portion of long term debt	208,500	10,000
Operating lease liabilities, current	70,100	75,300
Other current liabilities	2,000	3,900
Deferred revenue and customer deposits	150,700	163,700
Accounts Payable and Accrued Expenses - Balancing value	372,700	432,300
Total current liabilities	803,900	685,200
Convertible senior notes, net	343,600	540,000
Operating lease liabilities, non-current	407,500	503,300
Other non-current liabilities	37,200	25,700
Long-Term Debt excluding Capitalized Leases	946,900	950,100
Total liabilities	2,539,100	2,704,300
Additional paid-in capital	5,183,800	4,948,600
Accumulated other comprehensive income	5,100	15,900
Accumulated deficit	(5,602,600)	(5,483,700)
Common stock Class A	10	9
Common Stock - Class B	0	0
Balancing Item - Shareholders Equity	(110)	91
Total stockholders' equity (deficit)	(413,800)	(519,100)
Total Equity	(413,800)	(519,100)

Recent Dividends:**1. Peloton Interactive Inc class A common.**

No dividends paid.

2. Peloton Interactive Inc class B common.

No dividends paid.

Annual Dividends:**1. Peloton Interactive Inc class A common.**

No dividends paid.

2. Peloton Interactive Inc class B common.

No dividends paid.

PENN ENTERTAINMENT INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	3,437,500	3,269,900
Cost & expenses	3,098,700	2,999,000
Operating income	120,300	53,100
Other income (expense), net	228,400	14,700
Net before taxes	147,300	(157,800)
Income taxes	54,100	(15,800)
Net income	93,200	(142,000)
Balance for common	...	(141,500)
Earnings common share		
Primary	\$0.63	\$(0.93)
Fully Diluted	\$0.59	\$(0.93)
Common Shares:		
Full Diluted	164,700	152,000
Year-end	145,453	152,117

PENNANT GROUP INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024	Other income (expense), net	210,000	204,000	Income taxes	663	(30,931)
Total Revenues	429,343	325,660	Gains or losses	31,000		Net income	2,999	32,247
Cost & expenses	401,049	304,775	Net before taxes	615,000	699,000	Earnings common share		
Operating income	24,178	18,086	Income contin. oper.	569,000	611,000	Primary	\$0.08	\$1.07
Other income (expense), net	186	83	Net income	775,000	653,000	Fully Diluted	\$0.08	\$1.04
Net before taxes	21,955	14,755	Earnings common share			Common Shares:		
Income taxes	5,452	3,603	Primary	\$0.58	\$0.41	Full Diluted	30,785	30,842
Net income	16,503	11,152	Fully Diluted	\$0.57	\$0.41	Year-end	30,256	29,944
Earnings common share			Common Shares:					
Primary	\$0.43	\$0.35	Full Diluted	233,000	197,000	POWELL INDUSTRIES, INC.		
Fully Diluted	\$0.42	\$0.35	Year-end	197,744	197,264	Earnings, 9 mos. to Jun 30(Consol. – \$000):		
Common Shares:						2025	2024	
Full Diluted	35,284	30,583	PLAYSTUDIOS INC			Total Revenues	806,335	737,293
Year-end	34,490	30,150	Earnings, 6 mos. to Jun 30(Consol. – \$):			Cost & expenses	651,720	614,636
			2025	2024		Operating income	154,615	122,657
PEPGEN INCORPORATION			Total Revenues	122,047,000	150,418,000	Net before taxes	166,012	135,591
Earnings, 6 mos. to Jun 30(Consol. – \$000):			Cost & expenses	109,108,000	132,864,000	Income taxes	36,685	31,795
2025	2024		Operating income	(6,228,000)	(5,666,000)	Net income	129,327	103,796
Cost & expenses	55,253	50,223	Other income (expense), net	(1,005,000)	(370,000)	Earnings common share		
Operating income	(55,253)	(50,223)	Gains or losses	110,000	653,000	Primary	\$10.72	\$8.67
Other income (expense), net		12	Net before taxes	(5,271,000)	(2,589,000)	Fully Diluted	\$10.63	\$8.52
Net income	(53,289)	(46,355)	Income taxes	557,000	589,000	Common Shares:		
Earnings common share			Net income	(5,828,000)	(3,178,000)	Full Diluted	12,166	12,180
Primary	\$(1.63)	\$(1.52)	Earnings common share			Year-end	12,069	11,988
Fully Diluted	\$(1.63)	\$(1.52)	Primary	\$(0.05)	\$(0.02)			
Common Shares:			Fully Diluted	\$(0.05)	\$(0.02)	POWER INTEGRATIONS INC.		
Full Diluted	32,712	30,563	Common Shares:			Earnings, 6 mos. to Jun 30(Consol. – \$000):		
Year-end	32,800	32,417	Full Diluted	125,351,000	134,025,000	2025	2024	
			Year-end	125,241,000	124,589,000	Total Revenues	221,381	197,886
PERFORMANT HEALTHCARE INC						Cost & expenses	216,008	195,458
Earnings, 6 mos. to Jun 30(Consol. – \$000):			PLAYTIKA HOLDING CORP			Operating income	5,373	2,428
2025	2024		Earnings, 6 mos. to Jun 30(Consol. – \$000):			Other income (expense), net	5,857	6,691
Total Revenues	71,072	56,696	2025	2024		Net before taxes	11,230	9,119
Cost & expenses	68,282	63,358	Total Revenues	1,402,000	1,278,200	Income taxes	1,071	316
Operating income	2,790	(6,662)	Cost & expenses	1,224,500	1,039,400	Net income	10,159	8,803
Net before taxes	2,397	(6,981)	Operating income	177,500	238,800	Earnings common share		
Income taxes	400	32	Other income (expense), net	(100)		Primary	\$0.18	\$0.15
Net income	1,997	(7,013)	Net before taxes	86,200	195,200	Fully Diluted	\$0.18	\$0.15
Earnings common share			Income taxes	22,400	55,600	Common Shares:		
Primary	\$0.03	\$(0.09)	Net income	63,800	139,600	Full Diluted	56,787	57,104
Fully Diluted	\$0.03	\$(0.09)	Earnings common share			Year-end	56,158	56,778
Common Shares:			Primary	\$0.17	\$0.38			
Full Diluted	79,847	76,925	Fully Diluted	\$0.17	\$0.38	POWERFLEET INC		
Year-end	78,997	76,920	Common Shares:			Earnings, 3 mos. to Jun 30(Consol. – \$):		
			Full Diluted	375,800	371,300	2025	2024	
PHATHOM PHARMACEUTICALS INC			Year-end	376,300	371,900	Total Revenues	104,121,000	75,430,000
Earnings, 6 mos. to Jun 30(Consol. – \$000):						Cost & expenses	106,160,000	93,665,000
2025	2024		PLIANT THERAPEUTICS INC			Operating income	(2,039,000)	(18,235,000)
Total Revenues	68,023	9,236	Earnings, 6 mos. to Jun 30(Consol. – \$000):			Other income (expense), net	(1,243,000)	(624,000)
Cost & expenses	206,809	156,490	2025	2024		Net before taxes	(9,872,000)	(21,246,000)
Operating income	(138,786)	(147,254)	Cost & expenses	104,527	113,031	Income taxes	362,000	1,053,000
Other income (expense), net	(179)	(49)	Operating income	(104,527)	(113,031)	Net income	(10,234,000)	(22,299,000)
Net income	(170,126)	(174,298)	Net income	(99,466)	(102,809)	Balance for common	(10,234,000)	(22,337,000)
Earnings common share			Earnings common share			Earnings common share		
Primary	\$(2.36)	\$(2.98)	Primary	\$(1.62)	\$(1.71)	Primary	\$(0.08)	\$(0.21)
Fully Diluted	\$(2.36)	\$(2.98)	Fully Diluted	\$(1.62)	\$(1.71)	Fully Diluted	\$(0.08)	\$(0.21)
Common Shares:			Common Shares:			Common Shares:		
Full Diluted	72,219	58,465	Full Diluted	61,305	60,282	Full Diluted	133,313,000	107,136,000
Year-end	70,104	58,601	Year-end	61,386	60,425	Year-end	133,443,000	107,578,000
PLAINS ALL AMERICAN PIPELINE LP			PMV PHARMACEUTICALS INC			Consolidated Balance Sheet Items, as of (\$):		
Earnings, 6 mos. to Jun 30(Consol. – \$000):			Earnings, 6 mos. to Jun 30(Consol. – \$000):			Assets:	2025	
2025	2024		2025	2024		Cash & equivalents	31,196,000	
Total Revenues	22,119,000	24,396,000	Cost & expenses	44,441	38,391	Inventories	23,892,000	
Cost & expenses	21,059,000	23,259,000	Operating income	(44,441)	(38,391)	Current assets	167,779,000	
Operating income	594,000	688,000	Other income (expense), net	(21)	(18)	Net property & equip.	62,712,000	
Other income (expense), net	241,000	204,000	Net before taxes	(40,837)	(32,656)	Total assets	930,782,000	
Net before taxes	618,000	702,000	Income taxes	(2,191)	(16,173)	Liabilities:		
Income contin. oper.	607,000	639,000	Net income	(38,646)	(16,483)	Current liabilities	156,603,000	
Net income	813,000	681,000	Earnings common share			Long-term debt	232,954,000	
Balance for common	493,000	382,000	Primary	\$(0.74)	\$(0.32)	Stockholders' equity	460,730,000	
Earnings common share			Fully Diluted	\$(0.74)	\$(0.32)	Net current assets	11,176,000	
Primary	\$0.41	\$0.49	Common Shares:					
Fully Diluted	\$0.41	\$0.49	Full Diluted	51,982	51,462	PRA GROUP INC		
Common Shares:			Year-end	52,993	51,522	Earnings, 6 mos. to Jun 30(Consol. – \$):		
Full Diluted	704,000	701,000				2025	2024	
Year-end	703,304	701,081	POTBELLY CORP			Total Revenues	539,815,000	
			Earnings, 6 mos. to (Consol. – \$000):			Cost & expenses	391,347,000	378,840,000
PLAINS GP HOLDINGS LP			06/29/25	06/30/24		Operating income	159,688,000	155,618,000
Earnings, 6 mos. to Jun 30(Consol. – \$000):			Total Revenues	237,390	230,850	Other income (expense), net	(255,000)	(160,000)
2025	2024		Cost & expenses	225,789	220,586	Gains or losses	38,403,000	
Total Revenues	22,119,000	24,396,000	Operating income	3,952	4,237	Net before taxes	74,504,000	47,955,000
Cost & expenses	21,062,000	23,262,000	Other income (expense), net		(2,376)	Income taxes	19,727,000	11,088,000
Operating income	591,000	685,000	Net before taxes	3,662	1,316	Net income	54,777,000	36,867,000

Primary	\$1.17	\$0.64
Fully Diluted	\$1.16	\$0.63
Common Shares:		
Full Diluted	39,536,000	39,497,000
Year-end	39,074,000	39,417,000

PRECISION BIOSCIENCES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	47,000	
Cost & expenses	44,036,000	47,523,000
Operating income	(43,989,000)	19,959,000
Gains or losses	(2,500,000)	18,243,000
Invest. income	677,000	763,000
Net income	(44,085,000)	41,337,000
Earnings common share		
Primary	\$(4.33)	\$6.87
Fully Diluted	\$(4.33)	\$6.81
Common Shares:		
Full Diluted	10,174,193	6,067,620
Year-end	11,636,981	7,123,370

PRIME MEDICINE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,569	591
Cost & expenses	108,338	104,604
Operating income	(105,769)	(104,013)
Other income (expense), net	55	81
Gains or losses	(1,561)	(759)
Invest. income	869	2,316
Net income	(104,481)	(101,088)
Earnings common share		
Primary	\$(0.81)	\$(0.90)
Fully Diluted	\$(0.81)	\$(0.90)
Common Shares:		
Full Diluted	128,439	111,828
Year-end	134,494	120,031

PRIVIA HEALTH GROUP INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,001,250	837,569
Cost & expenses	988,212	828,009
Operating income	8,554	5,921
Net before taxes	13,893	11,871
Income taxes	4,559	4,172
Net income	9,334	7,699
Earnings common share		
Primary	\$0.06	\$0.05
Fully Diluted	\$0.05	\$0.05
Common Shares:		
Full Diluted	128,149	125,316
Year-end	122,673	119,479

PROCEPT BIOROBOTICS CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	148,344	97,892
Cost & expenses	197,970	152,369
Operating income	(49,626)	(54,477)
Net income	(44,316)	(51,583)
Earnings common share		
Primary	\$(0.80)	\$(1.01)
Fully Diluted	\$(0.80)	\$(1.01)
Common Shares:		
Full Diluted	55,182	51,316
Year-end	55,577	51,900

PROGYNY INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	656,912	582,165
Cost & expenses	608,384	542,955
Operating income	48,528	39,210
Other income (expense), net	6,924	6,240
Net before taxes	53,614	47,582
Income taxes	21,443	14,199
Net income	32,171	33,383
Earnings common share		
Primary	\$0.38	\$0.35
Fully Diluted	\$0.36	\$0.34
Common Shares:		
Full Diluted	89,508	99,456
Year-end	85,928	90,711

PROTAGONIST THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	33,867	259,120
Cost & expenses	95,218	91,604
Operating income	(61,351)	167,516
Other income (expense), net	118	78
Net before taxes	(46,254)	179,374
Income taxes	172	2,650
Net income	(46,426)	176,724
Earnings common share		
Primary	\$(0.73)	\$2.89
Fully Diluted	\$(0.73)	\$2.77
Common Shares:		
Full Diluted	63,239	63,910
Year-end	62,108	58,762

PROTARA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	30,710	22,512
Operating income	(30,710)	(22,512)
Other income (expense), net	503	
Net income	(26,874)	(20,608)
Earnings common share		
Primary	\$(0.65)	\$(1.26)
Fully Diluted	\$(0.65)	\$(1.26)
Common Shares:		
Full Diluted	41,494	16,327
Year-end	38,582	20,630

PTC THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	1,354,971,000	396,822,000
Cost & expenses	411,844,000	428,098,000
Operating income	935,268,000	(85,671,000)
Other income (expense), net	(12,042,000)	(434,000)
Net before taxes	858,776,000	170,429,000
Income taxes	57,063,000	20,326,000
Net income	801,713,000	190,755,000
Earnings common share		
Primary	\$10.22	\$(2.49)
Fully Diluted	\$9.29	\$(2.49)
Common Shares:		
Full Diluted	86,502,578	76,610,598
Year-end	79,378,145	76,900,123

PUBMATIC INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	134,920	133,968
Cost & expenses	152,284	143,478
Operating income	(17,364)	(9,510)
Other income (expense), net	(3,002)	4,286
Net before taxes	(17,394)	(320)
Income taxes	(2,700)	163
Net income	(14,694)	(483)
Earnings common share		
Primary	\$(0.31)	\$(0.01)
Fully Diluted	\$(0.31)	\$(0.01)
Common Shares:		
Full Diluted	47,763	49,910
Year-end	45,658	49,586

PUMA BIOTECHNOLOGY INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	98,443,000	90,849,000
Cost & expenses	87,823,000	95,327,000
Operating income	10,620,000	(4,478,000)
Other income (expense), net	769,000	247,000
Net before taxes	9,432,000	(8,746,000)
Income taxes	603,000	598,000
Net income	8,829,000	(9,344,000)
Earnings common share		
Primary	\$0.18	\$(0.19)
Fully Diluted	\$0.18	\$(0.19)
Common Shares:		
Full Diluted	50,003,709	48,240,835
Year-end	49,892,725	48,460,120

Q32 BIO INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	21,400,000	32,762,000
Operating income	(21,400,000)	(32,762,000)
Other income (expense), net	880,000	18,438,000
Equity earnings		1,625,000
Net income	(20,520,000)	(15,949,000)
Earnings common share		
Primary	\$(1.68)	\$(2.46)
Fully Diluted	\$(1.68)	\$(4.44)
Common Shares:		
Full Diluted	12,197,615	7,149,202
Year-end	12,197,615	11,995,206

QUANTERIX CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	54,810	66,447
Cost & expenses	118,277	93,521
Operating income	(63,467)	(27,074)
Other income (expense), net	108	197
Invest. income	3,894	
Net before taxes	(53,503)	(19,248)
Income taxes	(2,986)	297
Net income	(50,517)	(19,545)
Earnings common share		
Primary	\$(1.30)	\$(0.51)
Fully Diluted	\$(1.30)	\$(0.51)
Common Shares:		
Full Diluted	38,801	38,232
Year-end	38,873	38,398

QUIDELORTHO CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	06/29/25	06/30/24
Total Revenues	1,306,700	1,348,000
Cost & expenses	1,358,900	3,119,900
Operating income	(148,100)	(1,875,500)
Other income (expense), net	(9,800)	(6,300)
Gains or losses	5,000	14,300
Net before taxes	(238,400)	(1,961,800)
Income taxes	29,700	(108,100)
Net income	(268,100)	(1,853,700)
Earnings common share		
Primary	\$(3.97)	\$(27.67)
Fully Diluted	\$(3.97)	\$(27.67)
Common Shares:		
Full Diluted	67,600	67,000
Year-end	67,700	67,100

QUINCE THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	25,285	39,410
Operating income	(25,285)	(39,410)
Other income (expense), net	(988)	(308)
Gains or losses	(5,409)	(803)
Net before taxes	(30,965)	(38,811)
Income taxes	114	67
Net income	(31,079)	(38,878)
Earnings common share		
Primary	\$(0.69)	\$(0.90)
Fully Diluted	\$(0.69)	\$(0.90)
Common Shares:		
Full Diluted	45,314	43,053
Year-end	53,624	43,277

QVC GROUP INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	4,341,000	4,749,000
Cost & expenses	6,392,000	4,244,000
Operating income	(2,258,000)	310,000
Other income (expense), net	9,000	(6,000)
Gains or losses	(36,000)	(17,000)
Invest. income		27,000
Net before taxes	(2,514,000)	78,000
Income taxes	(214,000)	38,000
Net income	(2,300,000)	40,000
Earnings common share		
Primary	\$(289.11)	\$2.50
Fully Diluted	\$(289.11)	\$2.50
Common Shares:		
Full Diluted	8,032	7,900
Year-end	8,068	7,938

RALLYBIO CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	424	299
Cost & expenses	20,151	37,121
Operating income	(19,727)	(36,822)
Other income (expense), net	292	310
Gains or losses	(874)	(1,172)
Net income	(19,142)	(35,265)
Earnings common share		
Primary	\$(0.43)	\$(0.83)
Fully Diluted	\$(0.43)	\$(0.83)
Common Shares:		
Full Diluted	44,808	42,451
Year-end	41,707	41,488

RANI THERAPEUTICS HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	172	
Cost & expenses	22,690	26,557
Operating income	(22,518)	(26,557)
Net income	(23,962)	(28,140)
Earnings common share		
Primary	\$(0.40)	\$(0.55)
Fully Diluted	\$(0.40)	\$(0.55)
Common Shares:		
Full Diluted	34,999	26,179
Year-end	39,237	26,489

RAPID7 INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	424,446	413,092
Cost & expenses	421,053	398,153
Operating income	3,393	14,939
Net before taxes	15,143	17,407
Income taxes	4,700	9,463
Net income	10,443	7,944
Earnings common share		
Primary	\$0.16	\$0.13
Fully Diluted	\$0.16	\$0.11
Common Shares:		
Full Diluted	64,462	74,135
Year-end	64,707	62,702

RAPPORT THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	56,604	37,894
Operating income	(56,604)	(37,894)
Gains or losses		(7,390)
Net income	(50,795)	(40,790)
Earnings common share		
Primary	\$(1.44)	\$(1.12)
Fully Diluted	\$(1.44)	\$(1.12)
Common Shares:		
Full Diluted	35,356	36,576
Year-end	36,498	36,576

RAPT THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	38,800	61,848
Operating income	(38,800)	(61,848)
Other income (expense), net	3,992	3,664
Net income	(34,808)	(58,184)
Earnings common share		
Primary	\$(1.29)	\$(12.00)
Fully Diluted	\$(1.29)	\$(12.00)
Common Shares:		
Full Diluted	26,938	4,844
Year-end	16,501	4,363

RCI HOSPITALITY HOLDINGS INC**Earnings, 9 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	208,504	222,370
Cost & expenses	166,477	195,446
Operating income	30,790	15,286
Gains or losses	974	
Net before taxes	19,967	3,151
Income taxes	3,648	378
Net income	16,319	2,773

Earnings common share

Primary	\$1.84	\$0.30
Fully Diluted	\$1.84	\$0.30
Common Shares:		
Full Diluted	8,859	9,332
Year-end	8,757	9,130

RED ROCK RESORTS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,024,134	975,300
Cost & expenses	605,434	587,966
Operating income	322,381	295,758
Other income (expense), net	9,798	(12,958)
Gains or losses	(7,499)	(1,923)
Net before taxes	222,938	166,242
Income taxes	28,735	18,061
Net income	194,203	148,181
Earnings common share		
Primary	\$1.71	\$1.33
Fully Diluted	\$1.69	\$1.29
Common Shares:		
Full Diluted	103,060	103,720
Year-end	59,459	59,548

REGENXBIO INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	110,371	37,917
Cost & expenses	161,522	157,817
Operating income	(51,151)	(119,900)
Other income (expense), net	5,880	5,937
Net income	(64,788)	(116,319)
Earnings common share		
Primary	\$(1.26)	\$(2.41)
Fully Diluted	\$(1.26)	\$(2.41)
Common Shares:		
Full Diluted	51,423	48,167
Year-end	50,389	49,317

RELAY THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	8,355	10,007
Cost & expenses	170,072	201,127
Operating income	(161,717)	(191,120)
Other income (expense), net	(641)	23
Net income	(147,440)	(173,599)
Earnings common share		
Primary	\$(0.87)	\$(1.32)
Fully Diluted	\$(0.87)	\$(1.32)
Common Shares:		
Full Diluted	170,255	131,832
Year-end	171,692	133,325

RELMADA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	28,439,742	41,806,644
Operating income	(28,439,742)	(41,806,644)
Gains or losses	141,934	5,248
Invest. income	110,156	186,247
Net income	(27,425,907)	(39,596,248)
Earnings common share		
Primary	\$(0.86)	\$(1.31)
Fully Diluted	\$(0.86)	\$(1.31)
Common Shares:		
Full Diluted	31,807,943	30,153,186
Year-end	33,191,622	30,174,202

REMITLY GLOBAL INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	773,476	575,541
Cost & expenses	734,878	603,671
Operating income	26,876	(35,715)
Other income (expense), net	(4,719)	4,178
Net before taxes	23,056	(28,883)
Income taxes	5,168	4,288
Net income	17,888	(33,171)
Earnings common share		
Primary	\$0.09	\$(0.17)
Fully Diluted	\$0.08	\$(0.17)
Common Shares:		

Full Diluted	218,704	191,651
Year-end	206,091	195,096

REPLIGEN CORP.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	351,538,000	312,021,000
Cost & expenses	331,064,000	302,802,000
Operating income	20,474,000	9,219,000
Other income (expense), net	3,216,000	(3,751,000)
Net before taxes	26,158,000	12,722,000
Income taxes	5,462,000	3,713,000
Net income	20,696,000	9,009,000
Earnings common share		
Primary	\$0.37	\$0.16
Fully Diluted	\$0.37	\$0.16
Common Shares:		
Full Diluted	56,509,000	56,477,000
Year-end	56,253,009	55,902,860

REPLIMUNE GROUP INC**Earnings, 3 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	90,422	57,367
Operating income	(90,422)	(57,367)
Other income (expense), net	5,725	5,555
Net income	(86,693)	(53,772)
Earnings common share		
Primary	\$(0.95)	\$(0.78)
Fully Diluted	\$(0.95)	\$(0.78)
Common Shares:		
Full Diluted	91,516	69,186
Year-end	77,807	68,310

Consolidated Balance Sheet Items, as of (\$000):

	2025	2024
Assets:		
Cash & equivalents	97,373	
Current assets	413,371	
Net property & equip.	14,679	
Total assets	469,507	
Liabilities:		
Current liabilities	59,564	
Long-term debt	69,334	
Stockholders' equity	336,715	
Net current assets	353,807	

REVOLUTION MEDICINES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	505,474	297,502
Operating income	(505,474)	(297,502)
Other income (expense), net	(909)	(2,793)
Gains or losses	(2,139)	5,812
Net income	(461,203)	(249,236)
Earnings common share		
Primary	\$(2.45)	\$(1.51)
Fully Diluted	\$(2.45)	\$(1.51)
Common Shares:		
Full Diluted	188,366	164,936
Year-end	186,901	165,647

ROCKET PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	135,537	141,087
Operating income	(135,537)	(141,087)
Other income (expense), net	4,410	5,006
Net income	(130,253)	(131,700)
Earnings common share		
Primary	\$(1.18)	\$(1.40)
Fully Diluted	\$(1.18)	\$(1.40)
Common Shares:		
Full Diluted	110,559	93,760
Year-end	107,884	90,957

ROCKY BRANDS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	219,720,000	211,164,000
Cost & expenses	200,646,000	198,672,000
Operating income	15,862,000	12,492,000
Other income (expense), net	22,000	
Net before taxes	10,988,000	1,707,000
Income taxes	2,438,000	399,000
Net income	8,550,000	1,308,000

Earnings common share		
Primary	\$1.15	\$0.18
Fully Diluted	\$1.14	\$0.18
Common Shares:		
Full Diluted	7,493,000	7,466,000
Year-end	7,461,167	7,444,881

ROOT INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues		544,100
Cost & expenses	681,300	534,900
Operating income	51,000	9,200
Net income	40,400	(14,000)
Balance for common	38,400	
Earnings common share		
Primary	\$2.51	\$(0.95)
Fully Diluted	\$2.36	\$(0.95)
Common Shares:		
Full Diluted	17,100	14,800
Year-end	15,400	15,000

ROYAL GOLD INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	403,080,000	322,999,000
Cost & expenses	73,980,000	70,878,000
Operating income	264,952,000	177,609,000
Gains or losses	(34,000)	383,000
Net before taxes	266,979,000	174,652,000
Income taxes	20,927,000	46,025,000
Net income	246,052,000	128,627,000
Earnings common share		
Primary	\$3.73	\$1.95
Fully Diluted	\$3.73	\$1.95
Common Shares:		
Full Diluted	65,806,160	65,753,899
Year-end	65,760,321	65,656,625

RSE COLLECTION LLC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, EisnerAmper LLP, as it appeared in Co.'s 2024 Annual Report: "Opinion on the Financial Statements We have audited the accompanying balance sheets of RSE Collection, LLC (the "Company") on a consolidated basis and for each listed Series as of December 31, 2024 and 2023, and the related statements of operations, members' equity, and cash flows for the Company on a consolidated basis and for each listed Series for each of the years then ended and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company on a consolidated basis and for each listed Series as of December 31, 2024 and 2023, and the results of their operations and their cash flows for the Company on a consolidated basis and for each listed Series for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company and each listed Series will continue as a going concern. As discussed in Note A to the financial statements, the Company and each listed Series have experienced recurring losses, and negative cash flows from operations, and their lack of liquidity raise substantial doubt about their ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note A. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

RSE COLLECTION LLC**History:** Incorporated in Delaware on Aug. 24, 2016.

Business Summary: RSE Collection is engaged in the identification, acquisition, marketing and management of collectible items (including collectible automobiles, memorabilia and alcohol) and digital assets, collectively referred to as "Collectible Assets" or the "Asset Class," for the benefit of the investors.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiaries

#77LE1
#69BM1
#55PS1

#93XJ1
#83FB1
#90FM1
#98DV1
#91MV1
#94DV1
#92LD1
#72MC1
#11BM1
#63CC1
#76PT1
#75RA1
#65AG1
#90MM1
#61JE1
#65FM1
#99SS1
#94FS1
#61MG1
#92CC1
#88LL1
#MEEB11275
#82TAYLOR
#HOLMES
#HULK180
#05JAYZ
#JUSTINIAN
#67ICEBOWL
#DKCCOUNTRY
#FALCON
#MARIOWRDL
#82AV1
#SUPERBWL1
#MEEB7985
#BONDWATCH
#95FF1
#MAYC857
#PUNK2981
#WOW2221
#NIKONI
#LOTF
#DOOD6778
#BAKC7820
#NBAJAM
#SANDBOX1
#WOW6586
#AZUKI6704
#58PELE4
#OBAMABALL
#BART
#HOMER
#SI1
#GOLD1
#VERSTAPP1
#96TIGER
#88ZELDA
#STARWARS3
#YEEZY
#MAYC9114
#VFRNDS1
#MBIRD2754
#VEEFRND1
#TREASURE
#KENNERSET
#LEDZEPPI
#VEEVIPER
#BEEPLE1
#WARHOL1
#GAMEBOY
#CROESUS
#SACHS1
#32RUTH
#ELON1
#105.ETH
#R2D2
#VADER
#WARHOL2
#JEKYLL
#BUFFETT1
#DRACULA10
#PAPPY1
#1857COIN
#ANDYPELE
#BOBAFETT

#ELVIS
#GBOYCOLOR
#JETFIRE
#POPEBALL
#RABBIT
#GRATEFUL1
#BOBAPROTO
#ARSHAM1
#SCARFACE
#ARSHAM2
#LEBRON
#94VTTT
#52MANTLE
#71MAYS
#RLEXPEPSI
#TWOCITIES
#FROST
#BIRKINBLU
#SMURF
#EINSTEIN
#HONUS
#75ALI
#BIRKINBOR
#SPIDER1
#BATMAN3
#ULYSSES
#ROOSEVELT
#56MANTLE
#AGHOWL
#18ZION
#SNOOPY
#APOLLO11
#YOKO
#HIMALAYA
#55CLEMENTE
#LOTR
#CATCHER
#BOND1
#SUPER21
#BIRKINTAN
#GMTBLACK1
#61JFK
#LINCOLN
#STARWARS1
#68MAYS
#56TEDWILL
#CAPTAIN3
#CHURCHILL
#SHKSPR4
#03JORDAN
#39TEDWILL
#94JETER
#2020TOPPS
#05LATOUR
#16SCREAG
#14DRC
#86RICE
#57MANTLE
#SOBLACK
#GATSBY
#93DAYTONA
#09TROUT
#57STARR
#03KOB2
#16PETRUS
#ALICE
#SPIDER10
#62MANTLE
#BATMAN6
#79STELLA
#TKAM
#DIMAGGIO2
#13BEAUX
#ANMLFARM
#00BRADY
#85NES
#69KAREEM
#59JFK
#04LEBRON
#GOLDENEYE
#MOONSHOE
#03LEBRON2
#GRAPES
#98KANGA

#06BRM
#DUNE
#86FLEER
#WILDBGUN
#13GIANNIS
#04MESSI
#AVENGES7
#03TACHE
#99TMB2
#BULLSRING
#70AARON
#96CHARZRD
#01TIGER
#ICECLIMB
#09COBB
#96JORDAN2
#JUNGLEBOX
#59FLASH
#FOSSILBOX
#POKEBLUE
#98GTA
#PICNIC
#DOMINOS
#09CURRY
#09BEAUX
#KEROUAC
#62BOND
#71TOPPS
#DEATON
#98ZELDA
#03JORDAN2
#91JORDAN
#17DUJAC
#MOSASAUR
#03LEBRON3
#95TOPSUN
#09TROUT2
#59BOND
#OPEECHIE
#ROCKETBOX
#94JORDAN
#18LUKA
#FANFOUR5
#11BELAIR
#76PAYTON
#85MJPROMO
#96KOBE
#99CHARZRD
#MARADONA
#POKEYELOW
#POKELUGIA
#VANHALEN
#81MONTANA
#00MOUTON
#07DURANT
#56AARON
#85LEMIEUX
#87JORDAN
#AC23
#APPLE1
#GWLOTTO
#GYMBOX
#HUCKFINN
#NEOBOX
#NEWTON
#NICKLAUS1
#POKEMON2
#POKERED
#RIVIERA
#SMB3
#WALDEN
#WZRDOFOZ
#60ALI
#TORNEK
#DIMAGGIO3
#POKEMON3
#58PELE3
#09CURRY2
#8SERVING
#80ALI
#BATMAN2
#FLASH123
#85GPK
#HGWELLS

#66ORR
#CONGRESS
#GRIFFEYJR
#01HALO
#87ZELDA
#EINSTEIN2
#SANTANA
#01TIGER2
#86JORDAN2
#TOPPSTRIO
#81BIRD
#97KOBE
#XMEN94
#09BLEROY
#04MESSI2
#THEROCK
#XLXMEN1
#03LEBRON5
#METEORITE
#SLASH
#00BRADY2
#89TMNT
#NESWWF
#PUNK9670
#18ALLEN
#CASTLEII
#BAYC601
#60MANTLE
#PUNK8103
#GHOST1
#BROSGRIMM
#KIRBY
#03RONALDO
#MARX
#09HARDEN
#MEEB15511
#90BATMAN
#93JETER
#SIMPSONS1
#SPIDER129
#NESDK3
#BAYC7359
#CURIO10
#WILDTHING
#1776
#98JORDAN2
#MACALLAN1
#BAYC9159
#FANTASY7
#SURFER4
#WILT100
#PENGUIN
#KARUIZAWA
#KOMBAT
#APPLELISA
#98MANNING
#GIJOE
#BEATLES1
#SQUIG5847
#PACQUIAO
#83JOBS
#BATMAN181
#POPEYE
#PUNK5883
#HAMILTON1
#OBIWAN
#SMB2
#GIANNIS2
#86BONDS
#MOBYDICK
#03SERENA
#BAYC4612
#18OSAKA
#05RODGERS
#IROBOT
#LEICAGOLD
#FORTNITE
#IOMMI
#MARIO64
#GWTW
#NEWWORLD
#JAWA
#GWLETTER
#MARIOKART

#96KOBE2
#SHOWCASE4
#BAYC8827
#BRADBURY
#MACALLAN2
#BEATLES2
#92TIGER
#DOOD6921
#HIRST1
#GRIFFEY2
#SKYWALKER
#85GPK2
#19HAALAND
#MEGALODON
#KELLER
#GODFATHER
#MAYC5750
#SUPREMEPB
#MTICKET
#COOLCAT
#MACALLAN3
#BLASTOISE
#SUPERMAN6
#MOONPASS
#90FANTASY
#03KOBE
#05MJLJ
#FAUBOURG2
#OHTANI2

Officers

Christopher J. Bruno, President; Chief Executive Officer
Maximillian F. Niederste-Ostholt, Chief Financial Officer
Robert A. Petrozzo, Chief Product Officer

Directors

Christopher J. Bruno, Director
Joshua Silberstein, Director
Gustave Macheras, Director
Yan Zhao, Director

Auditors: EisnerAmper LLP

No. of Stockholders: July 15, 2021, 17,942, approx. record

Address: 46 HOWARD ST, STE 215, New York, NY 10013

Tel: 201 564-0493

Web: www.rallyrd.com

Email: regulatory@rallyrd.com

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2024	2023	2022
Storage	115,492	90,144	95,026
Transportation	12,345	17,229	47,550
Insurance	107,377	36,713	31,132
Professional fees	...	10,551	27,044
Maintenance	5,595	...	...
Bookkeeping & accounting fees	99,064	26,511	20,722
Marketing expense ...	3,300	5,200	25,192
Banking fees	258	...	423
Transaction fee	...	6,038	324
Interest expense	2,756	...	...
Gain on sale	2,512,123	396,271	317,801
Loss on sale	(145,226)	(7,163)	(28,918)
Loss on sale of digital assets	...	...	(239)
Loss on impairment ..	2,154,113	994,357	226,780
Investment income (loss)	...	4,412	21,400
Income (loss) before income taxes ..	(133,403)	(793,223)	(164,148)
Provision for income taxes	516,834	121,339	60,971
Net income (loss)	(650,237)	(914,562)	(225,119)
Year end shares outstanding	3,302,820	...	...

□ As reported by the Company

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2024	2023
Cash & cash equivalents	251,413	117,244
Pre-paid insurance	3,226	3,964
Other receivable	377,590	6,500
Due from the manager or its affiliates	19,415	415
Total current assets	651,644	128,123
Collectible automobiles - owned	26,872,300	8,811,095
Other assets	...	41,383
Total assets	27,523,944	8,980,602
Accounts payable	56,935	23,085
Income taxes payable	18,771	6,603
Insurance payable	185	1,689
Due to the manager or its affiliates	152,636	323,411
Total current liabilities	228,527	354,788
Total liabilities	228,527	354,788
Membership contributions	32,502,716	9,304,951
Capital contribution	4,773,228	1,676,932
Distribution to RSE Collection or its affiliates	(19,709)	...
Accumulated surplus (deficit)	(9,960,818)	(2,356,069)
Members' equity	27,295,417	8,625,813

As reported by the Company

Auditor's Report:

The following is an excerpt from the Report of the Independent Auditors, EisnerAmper LLP, as it appeared in Co.'s 2024 Annual Report:

Opinion on the Financial Statements

We have audited the accompanying balance sheets of RSE Collection, LLC (the "Company") on a consolidated basis and for each listed Series as of December 31, 2024 and 2023, and the related statements of operations, members' equity, and cash flows for the Company on a consolidated basis and for each listed Series for each of the years then ended and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company on a consolidated basis and for each listed Series as of December 31, 2024 and 2023, and the results of their operations and their cash flows for the Company on a consolidated basis and for each listed Series for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying financial statements have been prepared assuming that the Company and each listed Series will continue as a going concern. As discussed in Note A to the financial statements, the Company and each listed Series have experienced recurring losses, and negative cash flows from operations, and their lack of liquidity raise substantial doubt about their ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note A. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

Capital Stock: 1. RSE Collection LLC series #77LE1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

2. RSE Collection LLC series #69BM1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

3. RSE Collection LLC series #55PS1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

4. RSE Collection LLC series #93XJ1; no par.

OUTSTANDING-Dec. 31, 2024, units 5,000; no par.

5. RSE Collection LLC series #83FB1; no par.

OUTSTANDING-Dec. 31, 2024, units 5,000; no par.

6. RSE Collection LLC series #90FM1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

7. RSE Collection LLC series #98DV1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

8. RSE Collection LLC series #99LE1; no par.

OUTSTANDING-Dec. 31, 2023, units 2,000; no par.

9. RSE Collection LLC series #91MV1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

10. RSE Collection LLC series #94DV1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

11. RSE Collection LLC series #92LD1; no par.

OUTSTANDING-Dec. 31, 2024, units 3,000; no par.

12. RSE Collection LLC series #72MC1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

13. RSE Collection LLC series #11BM1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

14. RSE Collection LLC series #80LC1; no par.

OUTSTANDING-Dec. 31, 2023, units 5,000; no par.

15. RSE Collection LLC series #63CC1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

16. RSE Collection LLC series #76PT1; no par.

OUTSTANDING-Dec. 31, 2024, units 3,000; no par.

17. RSE Collection LLC series #75RA1; no par.

OUTSTANDING-Dec. 31, 2024, units 3,000; no par.

18. RSE Collection LLC series #65AG1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

19. RSE Collection LLC series #90MM1; no par.

OUTSTANDING-Dec. 31, 2024, units 5,000; no par.

20. RSE Collection LLC series #61JE1; no par.

OUTSTANDING-Dec. 31, 2024, units 3,000; no par.

21. RSE Collection LLC series #65FM1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

22. RSE Collection LLC series #94LD1; no par.

OUTSTANDING-Dec. 31, 2023, units 5,000; no par.

23. RSE Collection LLC series #99SS1; no par.

OUTSTANDING-Dec. 31, 2024, units 1,000; no par.

24. RSE Collection LLC series #94FS1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

25. RSE Collection LLC series #61MG1; no par.

OUTSTANDING-Dec. 31, 2024, units 5,000; no par.

26. RSE Collection LLC series #92CC1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

27. RSE Collection LLC series #88LL1; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

28. RSE Collection LLC series #MEEB11275; no par.

OUTSTANDING-Dec. 31, 2024, units 20,000; no par.

29. RSE Collection LLC series #82TAYLOR; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

30. RSE Collection LLC series #HOLMES; no par.

OUTSTANDING-Dec. 31, 2024, units 2,500; no par.

31. RSE Collection LLC series #HULK180; no par.

OUTSTANDING-Dec. 31, 2024, units 10,000; no par.

32. RSE Collection LLC series #05JAYZ; no par.

OUTSTANDING-Dec. 31, 2024, units 3,700; no par.

33. RSE Collection LLC series #JUSTINIAN; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

34. RSE Collection LLC series #67ICEBOWL; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

35. RSE Collection LLC series #DKCOUNTRY; no par.

OUTSTANDING-Dec. 31, 2024, units 3,000; no par.

36. RSE Collection LLC series #FALCON; no par.

OUTSTANDING-Dec. 31, 2024, units 10,000; no par.

37. RSE Collection LLC series #MARIOWRLD; no par.

OUTSTANDING-Dec. 31, 2024, units 33,000; no par.

38. RSE Collection LLC series #82AV1; no par.

OUTSTANDING-Dec. 31, 2024, units 14,875; no par.

39. RSE Collection LLC series #SUPERBWL1; no par.

OUTSTANDING-Dec. 31, 2024, units 4,000; no par.

40. RSE Collection LLC series #MEEB7985; no par.

OUTSTANDING-Dec. 31, 2024, units 7,600; no par.

41. RSE Collection LLC series #BONDWATCH; no par.

OUTSTANDING-Dec. 31, 2024, units 20,000; no par.

42. RSE Collection LLC series #95FF1; no par.

OUTSTANDING-Dec. 31, 2024, units 12,000; no par.

43. RSE Collection LLC series #MAYC857; no par.

OUTSTANDING-Dec. 31, 2024, units 10,800; no par.

44. RSE Collection LLC series #PUNK2981; no par.

OUTSTANDING-Dec. 31, 2024, units 6,200; no par.

45. RSE Collection LLC series #WOW2221; no par.

OUTSTANDING-Dec. 31, 2024, units 4,000; no par.

46. RSE Collection LLC series #NIKONI; no par.

OUTSTANDING-Dec. 31, 2024, units 7,000; no par.

47. RSE Collection LLC series #LOTF; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

48. RSE Collection LLC series #DOOD6778; no par.

OUTSTANDING-Dec. 31, 2024, units 6,000; no par.

49. RSE Collection LLC series #BAKC7820; no par.

OUTSTANDING-Dec. 31, 2024, units 6,200; no par.

50. RSE Collection LLC series #NBAJAM; no par.

OUTSTANDING-Dec. 31, 2024, units 9,400; no par.

51. RSE Collection LLC series #SANDBOX1; no par.

OUTSTANDING-Dec. 31, 2024, units 21,000; no par.

52. RSE Collection LLC series #WOW6586; no par.

OUTSTANDING-Dec. 31, 2024, units 10,400; no par.

53. RSE Collection LLC series #AZUKI6704; no par.

OUTSTANDING-Dec. 31, 2024, units 6,400; no par.

54. RSE Collection LLC series #58PELE4; no par.

OUTSTANDING-Dec. 31, 2024, units 8,000; no par.

55. RSE Collection LLC series #OBAMABALL; no par.

OUTSTANDING-Dec. 31, 2024, units 10,500; no par.

56. RSE Collection LLC series #BART; no par.

OUTSTANDING-Dec. 31, 2024, units 3,000; no par.

57. RSE Collection LLC series #HOMER; no par.

OUTSTANDING-Dec. 31, 2024, units 3,000; no par.

58. RSE Collection LLC series #SI1; no par.

OUTSTANDING-Dec. 31, 2024, units 5,000; no par.

59. RSE Collection LLC series #GOLD1; no par.

OUTSTANDING-Dec. 31, 2024, units 5,000; no par.

60. RSE Collection LLC series #VERSTAPPI; no par.

OUTSTANDING-Dec. 31, 2024, units 4,000; no par.

61. RSE Collection LLC series #96TIGER; no par.

OUTSTANDING-Dec. 31, 2024, units 11,000; no par.

62. RSE Collection LLC series #88ZELDA; no par.

OUTSTANDING-Dec. 31, 2024, units 12,000; no par.

63. RSE Collection LLC series #STARWARS3; no par.

OUTSTANDING-Dec. 31, 2024, units 2,000; no par.

64. RSE Collection LLC series #YEEZY; no par.

OUTSTANDING-Dec. 31, 2024, units 5,000; no par.

65. RSE Collection LLC series #MAYC9114; no par.

OUTSTANDING-Dec. 31, 2024, units 17,500; no par.

66. RSE Collection LLC series #VFRNDS1; no par.

OUTSTANDING-Dec. 31, 2024, units 27,500; no par.

67. RSE Collection LLC series #MBIRD2754; no par.

OUTSTANDING-Dec. 31, 2024, units 12,000; no par.

68. RSE Collection LLC series #VEEFRND1; no par.

OUTSTANDING-Dec. 31, 2024, units 6,720; no par.

69. RSE Collection LLC series #85FT1; no par.

OUTSTANDING-Dec. 31, 2022, units 2,000; no par.

70. RSE Collection LLC series #88LJ1; no par.

OUTSTANDING-Dec. 31, 2022, units 2,000; no par.

71. RSE Collection LLC series #89FG2; no par.

AUTHORIZED-units 1,700.

OUTSTANDING-July 15, 2021, units 1,700; no par.

72. RSE Collection LLC series #80PN1; no par.

OUTSTANDING-Dec. 31, 2022, units 5,000; no par.

73. RSE Collection LLC series #89FT1; no par.

AUTHORIZED-units 4,000.

OUTSTANDING-July 15, 2021, units 4,000; no par.

74. RSE Collection LLC series #95BL1; no par.

OUTSTANDING-Dec. 31, 2022, units 2,000; no par.

75. RSE Collection LLC series #88PT1; no par.

OUTSTANDING-Dec. 31, 2022, units 2,200; no par.

76. RSE Collection LLC series #89PS1; no par.

AUTHORIZED-units 2,000.

OUTSTANDING-July 15, 2021, units 2,000; no par.

77. RSE Collection LLC series #88BM1; no par.

OUTSTANDING-Dec. 31, 2022, units 3,000; no par.

78. RSE Collection LLC series #02BZ1; no par.

OUTSTANDING-Dec. 31, 2022, units 3,000; no par.

79. RSE Collection LLC series #02AX1; no par.

OUTSTANDING-Dec. 31, 2022, units 2,000; no par.

80. RSE Collection LLC series #93FS1; no par.

AUTHORIZED-units 2,000.

OUTSTANDING-July 15, 2021, units 2,000; no par.

81. RSE Collection LLC series #VEEFRIEND; no par.

AUTHORIZED-27,500 shs.

OUTSTANDING-June 29, 2022, 27,500 shs; no par.

82. RSE Collection LLC series #TREASURE; no par.

OUTSTANDING-Dec. 31, 2024, units 4,500; no par.

83. RSE Collection LLC series #MACWORLD1; no par.

OUTSTANDING-Dec. 31, 2023, units 20,000; no par.

84. RSE Collection LLC series #KENNERSET; no par.

OUTSTANDING-Dec. 31, 2024, units 1,250; no par.

85. RSE Collection LLC series #LEDZEPP1; no par.

OUTSTANDING-Dec. 31, 2024, units 8,000; no par.

86. RSE Collection LLC series #VEEVIPER; no par.

OUTSTANDING-Dec. 31, 2024, units 15,000; no par.

87. RSE Collection LLC series #BEEPLE1; no par.

OUTSTANDING-Dec. 31, 2024, units 13,600; no par.

88. RSE Collection LLC series #WARHOL1; no par.

OUTSTANDING-Dec. 31, 2024, units 17,000; no par.

89. RSE Collection LLC series #GAMEBOY; no par.

OUTSTANDING-Dec. 31, 2024, units 4,500; no par.

90. RSE Collection LLC series #CROESUS; no par.

OUTSTANDING—Dec. 31, 2024, units 3,750; no par.

94. RSE Collection LLC series #105.ETH; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

95. RSE Collection LLC series #R2D2; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

96. RSE Collection LLC series #VADER; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

97. RSE Collection LLC series #WARHOL2; no par.
OUTSTANDING—Dec. 31, 2024, units 6,500; no par.

98. RSE Collection LLC series #JEKYLL; no par.
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.

99. RSE Collection LLC series #BUFFETT1; no par.
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.

100. RSE Collection LLC series #DRACULA10; no par.
OUTSTANDING—Dec. 31, 2024, units 4,000; no par.

101. RSE Collection LLC series #SCARFACE; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

102. RSE Collection LLC series #ARSHAM2; no par.
OUTSTANDING—Dec. 31, 2024, units 31,500; no par.

103. RSE Collection LLC series #LEBRON; no par.
OUTSTANDING—Dec. 31, 2024, units 50,000; no par.

104. RSE Collection LLC series #4VTTT; no par.
OUTSTANDING—Dec. 31, 2024, units 29,500; no par.

105. RSE Collection LLC series #52MANTLE; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

106. RSE Collection LLC series #71MAYS; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

107. RSE Collection LLC series #RLEXPEPSI; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

108. RSE Collection LLC series #TWCOTITIES; no par.
OUTSTANDING—Dec. 31, 2024, units 200; no par.

109. RSE Collection LLC series #FROST; no par.
OUTSTANDING—Dec. 31, 2024, units 200; no par.

110. RSE Collection LLC series #BIRKINBLU; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

111. RSE Collection LLC series #SMURF; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

112. RSE Collection LLC series #EINSTEIN; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

113. RSE Collection LLC series #HONUS; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

114. RSE Collection LLC series #75ALI; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

115. RSE Collection LLC series #BIRKINBOR; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

116. RSE Collection LLC series #SPIDER1; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

117. RSE Collection LLC series #BATMAN3; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

118. RSE Collection LLC series #BATMAN3; no par.
OUTSTANDING—Dec. 31, 2024, units 500; no par.

119. RSE Collection LLC series #ROOSEVELT; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

120. RSE Collection LLC series #56MANTLE; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

121. RSE Collection LLC series #AGHOWL; no par.
OUTSTANDING—Dec. 31, 2024, units 500; no par.

122. RSE Collection LLC series #18ZION; no par.
OUTSTANDING—Dec. 31, 2024, units 500; no par.

123. RSE Collection LLC series #SNOOPY; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

124. RSE Collection LLC series #APOLLO11; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

125. RSE Collection LLC series #YOKO; no par.
OUTSTANDING—Dec. 31, 2024, units 200; no par.

126. RSE Collection LLC series #HIMALAYA; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

127. RSE Collection LLC series #55CLEMENTE; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

128. RSE Collection LLC series #LOTR; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

129. RSE Collection LLC series #CATCHER; no par.
OUTSTANDING—Dec. 31, 2024, units 500; no par.

130. RSE Collection LLC series #BOND1; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

131. RSE Collection LLC series #SUPER21; no par.
OUTSTANDING—Dec. 31, 2024, units 8,500; no par.

132. RSE Collection LLC series #BIRKINTAN; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

133. RSE Collection LLC series #GMTBLACK1; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

134. RSE Collection LLC series #61JFK; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

135. RSE Collection LLC series #LINCOLN; no par.

OUTSTANDING—Dec. 31, 2024, units 4,000; no par.

136. RSE Collection LLC series #STARWAR51; no par.
OUTSTANDING—Dec. 31, 2024, units 12,000; no par.

137. RSE Collection LLC series #68MAYS; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

138. RSE Collection LLC series #56TEDWILL; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

139. RSE Collection LLC series #CAPTAIN3; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

140. RSE Collection LLC series #CHURCHILL; no par.
OUTSTANDING—Dec. 31, 2024, units 7,500; no par.

141. RSE Collection LLC series #SHKSPR4; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

142. RSE Collection LLC series #03JORDAN; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

143. RSE Collection LLC series #39TEDWILL; no par.
OUTSTANDING—Dec. 31, 2024, units 5,600; no par.

144. RSE Collection LLC series #94JETER; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

145. RSE Collection LLC series #2020TOPPS; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

146. RSE Collection LLC series #05LATOUR; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

147. RSE Collection LLC series #16SCREAG; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

148. RSE Collection LLC series #14DRC; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

149. RSE Collection LLC series #86RICE; no par.
OUTSTANDING—Dec. 31, 2024, units 23,000; no par.

150. RSE Collection LLC series #57MANTLE; no par.
OUTSTANDING—Dec. 31, 2024, units 8,000; no par.

151. RSE Collection LLC series #SOBLACK; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

152. RSE Collection LLC series #GATSBY; no par.
OUTSTANDING—Dec. 31, 2024, units 4,000; no par.

153. RSE Collection LLC series #93DAYTONA; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

154. RSE Collection LLC series #09TROUT; no par.
OUTSTANDING—Dec. 31, 2024, units 11,250; no par.

155. RSE Collection LLC series #57STARR; no par.
OUTSTANDING—Dec. 31, 2024, units 8,000; no par.

156. RSE Collection LLC series #03KOBEE; no par.
OUTSTANDING—Dec. 31, 2024, units 5,750; no par.

157. RSE Collection LLC series #16PETRUS; no par.
OUTSTANDING—Dec. 31, 2024, units 9,000; no par.

158. RSE Collection LLC series #ALICE; no par.
OUTSTANDING—Dec. 31, 2024, units 12,000; no par.

159. RSE Collection LLC series #SPIDER10; no par.
OUTSTANDING—Dec. 31, 2024, units 4,200; no par.

160. RSE Collection LLC series #62MANTLE; no par.
OUTSTANDING—Dec. 31, 2024, units 6,000; no par.

161. RSE Collection LLC series #BATMAN6; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

162. RSE Collection LLC series #79STELLA; no par.
OUTSTANDING—Dec. 31, 2024, units 13,800; no par.

163. RSE Collection LLC series #TKAM; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

164. RSE Collection LLC series #DIMAGGIO2; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

165. RSE Collection LLC series #13BEAUX; no par.
OUTSTANDING—Dec. 31, 2024, units 5,100; no par.

166. RSE Collection LLC series #ANMLFARM; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

167. RSE Collection LLC series #00BRADY; no par.
OUTSTANDING—Dec. 31, 2024, units 3,750; no par.

168. RSE Collection LLC series #85NES; no par.
OUTSTANDING—Dec. 31, 2024, units 8,000; no par.

169. RSE Collection LLC series #69KAREEM; no par.
OUTSTANDING—Dec. 31, 2024, units 2,500; no par.

170. RSE Collection LLC series #59JFK; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

171. RSE Collection LLC series #04LEBRON; no par.
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.

172. RSE Collection LLC series #GOLDENEYE; no par.
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.

173. RSE Collection LLC series #MOONSHOE; no par.
OUTSTANDING—Dec. 31, 2024, units 18,000; no par.

174. RSE Collection LLC series #03LEBRON2; no par.
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.

175. RSE Collection LLC series #GRAPES; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

176. RSE Collection LLC series #98KANGA; no par.
OUTSTANDING—Dec. 31, 2024, units 21,250; no par.

177. RSE Collection LLC series #06BRM; no par.

OUTSTANDING—Dec. 31, 2024, units 1,850; no par.

178. RSE Collection LLC series #DUNE; no par.
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.

179. RSE Collection LLC series #86FLEER; no par.
OUTSTANDING—Dec. 31, 2024, units 16,500; no par.

180. RSE Collection LLC series #WILDGUN; no par.
OUTSTANDING—Dec. 31, 2024, units 4,000; no par.

181. RSE Collection LLC series #86FLEER; no par.
OUTSTANDING—Dec. 31, 2024, units 16,500; no par.

182. RSE Collection LLC series #WILDGUN; no par.
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.

183. RSE Collection LLC series #13GIANNIS; no par.
OUTSTANDING—Dec. 31, 2024, units 20,000; no par.

184. RSE Collection LLC series #04MESSI; no par.
OUTSTANDING—Dec. 31, 2024, units 9,000; no par.

185. RSE Collection LLC series #AVENGE57; no par.
OUTSTANDING—Dec. 31, 2024, units 20,000; no par.

186. RSE Collection LLC series #03TACHE; no par.
OUTSTANDING—Dec. 31, 2024, units 15,600; no par.

187. RSE Collection LLC series #99TMB2; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

188. RSE Collection LLC series #BULLSRING; no par.
OUTSTANDING—Dec. 31, 2024, units 9,000; no par.

189. RSE Collection LLC series #70AARON; no par.
OUTSTANDING—Dec. 31, 2024, units 6,000; no par.

190. RSE Collection LLC series #96CHARZRD; no par.
OUTSTANDING—Dec. 31, 2024, units 6,500; no par.

191. RSE Collection LLC series #01TIGER; no par.
OUTSTANDING—Dec. 31, 2024, units 4,900; no par.

192. RSE Collection LLC series #CECLIMB; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

193. RSE Collection LLC series #09COBB; no par.
OUTSTANDING—Dec. 31, 2024, units 8,000; no par.

194. RSE Collection LLC series #96JORDAN2; no par.
OUTSTANDING—Dec. 31, 2024, units 10,800; no par.

195. RSE Collection LLC series #JUNGLEBOX; no par.
OUTSTANDING—Dec. 31, 2024, units 6,900; no par.

196. RSE Collection LLC series #59FLASH; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

197. RSE Collection LLC series #POKEBLUE; no par.
OUTSTANDING—Dec. 31, 2024, units 2,400; no par.

198. RSE Collection LLC series #98GTA; no par.
OUTSTANDING—Dec. 31, 2024, units 3,150; no par.

199. RSE Collection LLC series #PICNIC; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

200. RSE Collection LLC series #DOMINOS; no par.
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.

201. RSE Collection LLC series #09CURRY; no par.
OUTSTANDING—Dec. 31, 2024, units 2,500; no par.

202. RSE Collection LLC series #09BEAUX; no par.
OUTSTANDING—Dec. 31, 2024, units 6,800; no par.

203. RSE Collection LLC series #KEROUAC; no par.
OUTSTANDING—Dec. 31, 2024, units 15,500; no par.

204. RSE Collection LLC series #62BOND; no par.
OUTSTANDING—Dec. 31, 2024, units 15,500; no par.

205. RSE Collection LLC series #71TOPPS; no par.
OUTSTANDING—Dec. 31, 2024, units 17,000; no par.

206. RSE Collection LLC series #DEATON; no par.
OUTSTANDING—Dec. 31, 2024, units 11,400; no par.

207. RSE Collection LLC series #98ZELDA; no par.
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.

208. RSE Collection LLC series #03JORDAN2; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

209. RSE Collection LLC series #91JORDAN; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

210. RSE Collection LLC series #17DUJAC; no par.
OUTSTANDING—Dec. 31, 2024, units 3,250; no par.

211. RSE Collection LLC series #MOSASAUR; no par.
OUTSTANDING—Dec. 31, 2024, units 6,000; no par.

212. RSE Collection LLC series #03LEBRON3; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

213. RSE Collection LLC series #95TOPSUN; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

214. RSE Collection LLC series #95TOPSUN; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

215. RSE Collection LLC series #09TROUT2; no par.
OUTSTANDING—Dec. 31, 2024, units 11,200; no par.

216. RSE Collection LLC series #59BOND; no par.
OUTSTANDING—Dec. 31, 2024, units 10,250; no par.

217. RSE Collection LLC series #OPEECHEE; no par.
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.

218. RSE Collection LLC series #ROCKETBOX; no par.
OUTSTANDING—Dec. 31, 2024, units 4,750; no par.

219. RSE Collection LLC series #94JORDAN; no par.

- OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 220. RSE Collection LLC series #18LUKA; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,300; no par.
- 221. RSE Collection LLC series #FANFOURS; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 222. RSE Collection LLC series #11BELAIR; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 223. RSE Collection LLC series #76PAYTON; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 224. RSE Collection LLC series #85MJPRMO; no par.**
OUTSTANDING—Dec. 31, 2024, units 3,500; no par.
- 225. RSE Collection LLC series #96KOB; no par.**
OUTSTANDING—Dec. 31, 2024, 7,000 shs; no par.
- 226. RSE Collection LLC series #99CHARZRD; no par.**
OUTSTANDING—Dec. 31, 2024, units 35,000; no par.
- 227. RSE Collection LLC series #MARADONA; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 228. RSE Collection LLC series #POKEYELOW; no par.**
OUTSTANDING—Dec. 31, 2024, units 11,000; no par.
- 229. RSE Collection LLC series #POKELUGIA; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 230. RSE Collection LLC series #VANHALEN; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 231. RSE Collection LLC series #81MONTANA; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 232. RSE Collection LLC series #00MOUTON; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 233. RSE Collection LLC series #07DURANT; no par.**
OUTSTANDING—Dec. 31, 2024, units 9,000; no par.
- 234. RSE Collection LLC series #56AARON; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 235. RSE Collection LLC series #85LEMIEUX; no par.**
OUTSTANDING—Dec. 31, 2024, units 17,500; no par.
- 236. RSE Collection LLC series #87JORDAN; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 237. RSE Collection LLC series #AC23; no par.**
OUTSTANDING—Dec. 31, 2024, units 4,000; no par.
- 238. RSE Collection LLC series #APPLE1; no par.**
OUTSTANDING—Dec. 31, 2024, units 33,000; no par.
- 239. RSE Collection LLC series #GWLOTTO; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,500; no par.
- 240. RSE Collection LLC series #GYMBOX; no par.**
OUTSTANDING—Dec. 31, 2024, units 3,000; no par.
- 241. RSE Collection LLC series #HUCKFINN; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 242. RSE Collection LLC series #NEOBOX; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 243. RSE Collection LLC series #NEWTON; no par.**
OUTSTANDING—Dec. 31, 2024, units 30,000; no par.
- 244. RSE Collection LLC series #NICKLAUS1; no par.**
OUTSTANDING—Dec. 31, 2024, units 4,000; no par.
- 245. RSE Collection LLC series #POKEMON2; no par.**
OUTSTANDING—Dec. 31, 2024, units 41,500; no par.
- 246. RSE Collection LLC series #POKERED; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 247. RSE Collection LLC series #RIVIERA; no par.**
OUTSTANDING—Dec. 31, 2024, units 6,000; no par.
- 248. RSE Collection LLC series #SMB3; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 249. RSE Collection LLC series #WALDEN; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 250. RSE Collection LLC series #WZRDOFOZ; no par.**
OUTSTANDING—Dec. 31, 2024, units 6,000; no par.
- 251. RSE Collection LLC series #60ALI; no par.**
OUTSTANDING—Dec. 31, 2024, units 23,500; no par.
- 252. RSE Collection LLC series #TORNEK; no par.**
OUTSTANDING—Dec. 31, 2024, units 33,000; no par.
- 253. RSE Collection LLC series #DIMAGGIO3; no par.**
OUTSTANDING—Dec. 31, 2024, units 22,500; no par.
- 254. RSE Collection LLC series #POKEMON3; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 255. RSE Collection LLC series #58PELE3; no par.**
OUTSTANDING—Dec. 31, 2024, units 11,250; no par.
- 256. RSE Collection LLC series #09CURRY2; no par.**
OUTSTANDING—Dec. 31, 2024, units 21,000; no par.
- 257. RSE Collection LLC series #8SERVING; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 258. RSE Collection LLC series #80ALI; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 259. RSE Collection LLC series #BATMAN2; no par.**
OUTSTANDING—Dec. 31, 2024, units 8,500; no par.
- 260. RSE Collection LLC series #FLASH123; no par.**
OUTSTANDING—Dec. 31, 2024, units 3,625; no par.
- 261. RSE Collection LLC series #85GPK; no par.**
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.
- 262. RSE Collection LLC series #HGWELLS; no par.**
OUTSTANDING—Dec. 31, 2024, units 7,500; no par.
- 263. RSE Collection LLC series #66ORR; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 264. RSE Collection LLC series #CONGRESS; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 265. RSE Collection LLC series #GRIFFEYJR; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,500; no par.
- 266. RSE Collection LLC series #01HALO; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,500; no par.
- 267. RSE Collection LLC series #87ZELDA; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 268. RSE Collection LLC series #EINSTEIN2; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 269. RSE Collection LLC series #SANTANA; no par.**
OUTSTANDING—Dec. 31, 2024, units 15,000; no par.
- 270. RSE Collection LLC series #01TIGER2; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 271. RSE Collection LLC series #86JORDAN2; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 272. RSE Collection LLC series #TOPPSTRIO; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 273. RSE Collection LLC series #81BIRD; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 274. RSE Collection LLC series #97KOB; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 275. RSE Collection LLC series #XMEN94; no par.**
OUTSTANDING—Dec. 31, 2024, units 12,000; no par.
- 276. RSE Collection LLC series #09RBLEROY; no par.**
OUTSTANDING—Dec. 31, 2024, units 4,300; no par.
- 277. RSE Collection LLC series #04MESSI2; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 278. RSE Collection LLC series #THEROCK; no par.**
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.
- 279. RSE Collection LLC series #XLXMEN1; no par.**
OUTSTANDING—Dec. 31, 2024, units 8,000; no par.
- 280. RSE Collection LLC series #03LEBRON5; no par.**
OUTSTANDING—Dec. 31, 2024, units 8,500; no par.
- 281. RSE Collection LLC series #METEORITE; no par.**
OUTSTANDING—Dec. 31, 2024, units 17,500; no par.
- 282. RSE Collection LLC series #SLASH; no par.**
OUTSTANDING—Dec. 31, 2024, units 13,000; no par.
- 283. RSE Collection LLC series #00BRADY2; no par.**
OUTSTANDING—Dec. 31, 2024, units 32,500; no par.
- 284. RSE Collection LLC series #89TMNT; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 285. RSE Collection LLC series #NESWWF; no par.**
OUTSTANDING—Dec. 31, 2024, units 6,000; no par.
- 286. RSE Collection LLC series #PUNK9670; no par.**
OUTSTANDING—Dec. 31, 2024, units 7,200; no par.
- 287. RSE Collection LLC series #18ALLEN; no par.**
OUTSTANDING—Dec. 31, 2024, units 12,000; no par.
- 288. RSE Collection LLC series #CASTLEII; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 289. RSE Collection LLC series #BAYC601; no par.**
OUTSTANDING—Dec. 31, 2024, units 16,500; no par.
- 290. RSE Collection LLC series #60MANTLE; no par.**
OUTSTANDING—Dec. 31, 2024, units 42,500; no par.
- 291. RSE Collection LLC series #PUNK8103; no par.**
OUTSTANDING—Dec. 31, 2024, units 60,000; no par.
- 292. RSE Collection LLC series #GHOST1; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 293. RSE Collection LLC series #BROSGRIMM; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 294. RSE Collection LLC series #KIRBY; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 295. RSE Collection LLC series #03RONALDO; no par.**
OUTSTANDING—Dec. 31, 2024, units 12,500; no par.
- 296. RSE Collection LLC series #MARX; no par.**
OUTSTANDING—Dec. 31, 2024, units 8,000; no par.
- 297. RSE Collection LLC series #09HARDEN; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 298. RSE Collection LLC series #MEEB15511; no par.**
OUTSTANDING—Aug. 11, 2025, units 15,000; no par.
- 299. RSE Collection LLC series #90BATMAN; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 300. RSE Collection LLC series #93JETER; no par.**
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.
- 301. RSE Collection LLC series #SIMPSONSI; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 302. RSE Collection LLC series #SPIDER129; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 303. RSE Collection LLC series #NESDK3; no par.**
OUTSTANDING—Dec. 31, 2024, units 22,800; no par.
- 304. RSE Collection LLC series #BAYC7359; no par.**
OUTSTANDING—Dec. 31, 2024, units 19,000; no par.
- 305. RSE Collection LLC series #CURIO10; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 306. RSE Collection LLC series #WILDTHING; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 307. RSE Collection LLC series #1776; no par.**
OUTSTANDING—Dec. 31, 2024, units 80,000; no par.
- 308. RSE Collection LLC series #98JORDAN2; no par.**
OUTSTANDING—Dec. 31, 2024, units 16,500; no par.
- 309. RSE Collection LLC series #MACALLAN1; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 310. RSE Collection LLC series #BAYC9159; no par.**
OUTSTANDING—Dec. 31, 2024, units 39,000; no par.
- 311. RSE Collection LLC series #FANTASY7; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 312. RSE Collection LLC series #SURFER4; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 313. RSE Collection LLC series #WILT100; no par.**
OUTSTANDING—Dec. 31, 2024, units 11,500; no par.
- 314. RSE Collection LLC series #PENGUIN; no par.**
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.
- 315. RSE Collection LLC series #KARUIZAWA; no par.**
OUTSTANDING—Dec. 31, 2024, units 13,000; no par.
- 316. RSE Collection LLC series #KOMBAT; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 317. RSE Collection LLC series #APPLELISA; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 318. RSE Collection LLC series #89MANNING; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 319. RSE Collection LLC series #GJJOE; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 320. RSE Collection LLC series #BEATLES1; no par.**
OUTSTANDING—Dec. 31, 2024, units 6,000; no par.
- 321. RSE Collection LLC series #SQUIG5847; no par.**
OUTSTANDING—Dec. 31, 2024, units 6,000; no par.
- 322. RSE Collection LLC series #PACQUIAO; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 323. RSE Collection LLC series #83JOBS; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 324. RSE Collection LLC series #BATMAN181; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 325. RSE Collection LLC series #POPEYE; no par.**
OUTSTANDING—Dec. 31, 2024, units 11,000; no par.
- 326. RSE Collection LLC series #PUNK5883; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 327. RSE Collection LLC series #HAMILTON1; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 328. RSE Collection LLC series #OBIWAN; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 329. RSE Collection LLC series #SMB2; no par.**
OUTSTANDING—Dec. 31, 2024, units 20,000; no par.
- 330. RSE Collection LLC series #GIANNIS2; no par.**
OUTSTANDING—Dec. 31, 2024, units 41,500; no par.
- 331. RSE Collection LLC series #86BONDS; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 332. RSE Collection LLC series #MOBYDICK; no par.**
OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
- 333. RSE Collection LLC series #03SERENA; no par.**
OUTSTANDING—Dec. 31, 2024, units 8,500; no par.
- 334. RSE Collection LLC series #BAYC4612; no par.**
OUTSTANDING—Dec. 31, 2024, units 100,000; no par.
- 335. RSE Collection LLC series #18OSAKA; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 336. RSE Collection LLC series #05RODGERS; no par.**
OUTSTANDING—Dec. 31, 2024, units 7,000; no par.
- 337. RSE Collection LLC series #IROBOT; no par.**
OUTSTANDING—Dec. 31, 2024, units 1,000; no par.
- 338. RSE Collection LLC series #LEICAGOLD; no par.**
OUTSTANDING—Dec. 31, 2024, units 4,000; no par.
- 339. RSE Collection LLC series #FORTNITE; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 340. RSE Collection LLC series #IOMMI; no par.**
OUTSTANDING—Dec. 31, 2024, units 6,500; no par.
- 341. RSE Collection LLC series #MARIO64; no par.**
OUTSTANDING—Dec. 31, 2024, units 12,500; no par.
- 342. RSE Collection LLC series #GWTW; no par.**
OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
- 343. RSE Collection LLC series #NEWWORLD; no par.**
OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
- 344. RSE Collection LLC series #JAWA; no par.**
OUTSTANDING—Dec. 31, 2024, units 9,000; no par.
- 345. RSE Collection LLC series #GWLETTER; no par.**

OUTSTANDING—Dec. 31, 2024, units 7,500; no par.
346. RSE Collection LLC series #MARIOKART; no par.
 OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
347. RSE Collection LLC series #96KOB2; no par.
 OUTSTANDING—Dec. 31, 2024, units 22,500; no par.
348. RSE Collection LLC series #SHOWCASE4; no par.
 OUTSTANDING—Dec. 31, 2024, units 11,000; no par.
349. RSE Collection LLC series #BAYC8827; no par.
 OUTSTANDING—Dec. 31, 2024, units 82,000; no par.
350. RSE Collection LLC series #BRADBURY; no par.
 OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
351. RSE Collection LLC series #MACALLAN2; no par.
 OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
352. RSE Collection LLC series #BEATLES2; no par.
 OUTSTANDING—Dec. 31, 2024, units 2,500; no par.
353. RSE Collection LLC series #92TIGER; no par.
 OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
354. RSE Collection LLC series #DOOD6921; no par.
 OUTSTANDING—Dec. 31, 2024, units 11,000; no par.
355. RSE Collection LLC series #HIRST1; no par.
 OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
356. RSE Collection LLC series #GRIFFEY2; no par.
 OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
357. RSE Collection LLC series #SKYWALKER; no par.
 OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
358. RSE Collection LLC series #85GPK2; no par.
 OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
359. RSE Collection LLC series #19HAALAND; no par.
 OUTSTANDING—Dec. 31, 2024, units 20,000; no par.
360. RSE Collection LLC series #MEGALODON; no par.
 OUTSTANDING—Dec. 31, 2024, units 30,000; no par.
361. RSE Collection LLC series #KELLER; no par.
 OUTSTANDING—Dec. 31, 2024, units 3,000; no par.
362. RSE Collection LLC series #GODFATHER; no par.
 OUTSTANDING—Dec. 31, 2024, units 1,000; no par.
363. RSE Collection LLC series #MAYC5750; no par.
 OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
364. RSE Collection LLC series #SUPREMEPB; no par.
 OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
365. RSE Collection LLC series #MJTICKET; no par.
 OUTSTANDING—Dec. 31, 2024, units 20,000; no par.
366. RSE Collection LLC series #COOLCAT; no par.
 OUTSTANDING—Dec. 31, 2024, units 4,000; no par.
367. RSE Collection LLC series #MACALLAN3; no par.
 OUTSTANDING—Dec. 31, 2024, units 4,100; no par.
368. RSE Collection LLC series #BLASTOISE; no par.
 OUTSTANDING—Dec. 31, 2024, units 50,000; no par.
369. RSE Collection LLC series #SUPERMAN6; no par.
 OUTSTANDING—Dec. 31, 2024, units 3,000; no par.
370. RSE Collection LLC series #MOONPASS; no par.
 OUTSTANDING—Dec. 31, 2024, units 1,300; no par.
371. RSE Collection LLC series #90FANTASY; no par.
 OUTSTANDING—Dec. 31, 2024, units 3,000; no par.
372. RSE Collection LLC series #03KOB2; no par.
 OUTSTANDING—Dec. 31, 2024, units 6,250; no par.
373. RSE Collection LLC series #05MJLJ; no par.
 OUTSTANDING—Dec. 31, 2024, units 20,500; no par.
374. RSE Collection LLC series #FAUBOURG2; no par.
 OUTSTANDING—Dec. 31, 2024, units 11,000; no par.
375. RSE Collection LLC series #OHTANI2; no par.
 OUTSTANDING—Dec. 31, 2024, units 6,125; no par.
376. RSE Collection LLC series #PAPPY1; no par.
 OUTSTANDING—Dec. 31, 2024, units 2,000; no par.
377. RSE Collection LLC series #1857COIN; no par.
 OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
378. RSE Collection LLC series #ANDYPELE; no par.
 OUTSTANDING—Dec. 31, 2024, units 6,500; no par.
379. RSE Collection LLC series #BOBAFET; no par.
 OUTSTANDING—Dec. 31, 2024, units 2,600; no par.
380. RSE Collection LLC series #ELVIS; no par.
 OUTSTANDING—Dec. 31, 2024, units 5,000; no par.
381. RSE Collection LLC series #GBOYCOLOR; no par.
 OUTSTANDING—Dec. 31, 2024, units 1,625; no par.
382. RSE Collection LLC series #JETFIRE; no par.
 OUTSTANDING—Dec. 31, 2024, units 1,700; no par.
383. RSE Collection LLC series #POPEBALL; no par.
 OUTSTANDING—Dec. 31, 2024, units 4,750; no par.
384. RSE Collection LLC series #RABBIT; no par.
 OUTSTANDING—Dec. 31, 2024, units 10,000; no par.
385. RSE Collection LLC series #54AARON; no par.
 OUTSTANDING—Dec. 31, 2023, units 17,000; no par.
386. RSE Collection LLC series #GRATEFUL1; no par.
 OUTSTANDING—Dec. 31, 2024, units 12,500; no par.
387. RSE Collection LLC series #BOBAPROTO; no par.

OUTSTANDING—Dec. 31, 2024, units 15,000; no par.
388. RSE Collection LLC series #ARSHAM1; no par.
 OUTSTANDING—Dec. 31, 2024, units 6,750; no par.
389. RSE Collection LLC series #94CSI; no par.
 OUTSTANDING—Dec. 31, 2022, units 10,000; no par.

RSE INNOVATION LLC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, EisnerAmper LLP, as it appeared in Co.'s 2024 Annual Report: "Opinion on the Financial Statements We have audited the accompanying balance sheets of RSE Innovation, LLC (the "Company") on a consolidated basis and for each listed Series as of December 31, 2024 and 2023, and the related statements of operations, members' equity, and cash flows for the Company on a consolidated basis and for each listed Series for the years then ended and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company on a consolidated basis and for each listed Series as of December 31, 2024 and 2023, and the results of their operations and their cash flows for the Company on a consolidated basis and for each listed Series for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company and each listed Series will continue as a going concern. As discussed in Note A to the financial statements, the Company does not have any cash or cash equivalents, and it does not expect to generate any income or cash flows from operations for the foreseeable future, as a result, its lack of liquidity raises substantial doubt about its ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note A. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

RSE INNOVATION LLC

History: Incorporated in Delaware on May 20, 2020.

Business Summary: RSE Innovation is engaged in the identification, acquisition, marketing and management of certain assets including digital assets and noteworthy real estate assets, and of collectible items, including historical documents, memorabilia, alcohol and archaeological artifacts, collectively referred to as "Innovation Assets" or the "Asset Class," for the benefit of the investors. Co. is wholly owned and managed by RSE Innovation Manager, LLC.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiaries

#URL1
 #URL2
 #MANTLE319
 #URL5

Officers

Christopher J. Bruno, President; Chief Executive Officer
 Robert A. Petrozzo, Chief Products Officer
 Maximillian F. Niederstre-Osthold, Chief Financial Officer

Directors

Christopher J. Bruno, Director
 Joshua Silberstein, Director
 Gustave Macheras, Director
 Yan Zhao, MBA, Director

Auditors: EisnerAmper LLP

Transfer Agent: RSE Transfer Agent LLC

No. of Stockholders: Apr. 6, 2022, 500

Address: 46 Howard Street Suite 215, New York, NY 10013

Tel: 201 564-0493

Web: www.rallyrd.com

Email: regulatory@rallyrd.com

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2024	2023	2022
Leasing revenue	...	...	69,666
Revenue	3,970	6,943	...
Maintenance	2,579	1,820	...
Bookkeeping & accounting fees	936	526	441
Ongoing Registrar Fees	44	...	...

Property tax	268	243	...
Utilities	2,716	56	...
Insurance	1,789	1,256	...
Interest expense	10,958	...	...
Write-off of Capitalized Expense ..	...	2,250	...
Banking fees	...	...	136
Income (loss) before income taxes ..	(15,320)	792	69,089
Provision for Income Taxes	948	1,991	...
Net income (loss)	(16,268)	(1,199)	69,089
Year end shares outstanding	128,000	80,500	...
Number of common stockholders	...	0	...

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2024	2023
Cash & cash equivalents	52,152	51,935
Prepaid insurance	799	732
Prepaid Utilities and other	209	...
Accounts Receivable, net	8,334	4,364
Total current assets	61,494	57,031
Innovation Asset - Deposit	1,375,000	...
Innovation asset - owned	1,387,866	485,441
Total assets	2,824,360	542,472
Accounts Payable	959	86
Income taxes payable	551	1,283
Accrued Property Tax	267	...
Accrued interest	10,958	...
Notes Payable	1,250,000	...
Due to the manager or its affiliates	125,029	29
Total current liabilities	1,387,764	1,398
Total liabilities	1,387,764	1,398
Membership contributions	1,439,400	535,475
Capital contribution for operating expense	15,175	7,375
Retained earnings (accumulated deficit)	(17,979)	(1,776)
Members' equity	1,436,596	541,074

Auditor's Report:

The following is an excerpt from the Report of the Independent Auditors, EisnerAmper LLP, as it appeared in Co.'s 2024 Annual Report:

"Opinion on the Financial Statements

We have audited the accompanying balance sheets of RSE Innovation, LLC (the "Company") on a consolidated basis and for each listed Series as of December 31, 2024 and 2023, and the related statements of operations, members' equity, and cash flows for the Company on a consolidated basis and for each listed Series for the years then ended and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company on a consolidated basis and for each listed Series as of December 31, 2024 and 2023, and the results of their operations and their cash flows for the Company on a consolidated basis and for each listed Series for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying financial statements have been prepared assuming that the Company and each listed Series will continue as a going concern. As discussed in Note A to the financial statements, the Company does not have any cash or cash equivalents, and it does not expect to generate any income or cash flows from operations for the foreseeable future, as a result, its lack of liquidity raises substantial doubt about its ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note A. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

Capital Stock: 1. RSE Innovation LLC series #URL1; no par.

OUTSTANDING—Dec. 31, 2024, units 19,500; no par.

VOTING RIGHTS—Entitled to one vote per unit.

2. RSE Innovation LLC series #URL5; no par.

OUTSTANDING—Dec. 31, 2024, units 47,500; no par.

3. RSE Innovation LLC series #MANTLE319; no par.

OUTSTANDING—Dec. 31, 2024, units 47,000; no par.

4. RSE Innovation LLC series #URL2; no par.

OUTSTANDING—Dec. 31, 2024, units 14,000; no par.

PRIMARY EXCHANGE—National Bulletin Board (NBB): RRUL

S.

PRICE RANGE—

	2024	2023	2022
HIGH	5.50	4.00	3.05
LOW	4.80	3.95	3.05

RUMBLE INC**Earnings, 6 mos. to Jun 30**(Consol. — \$):

	2025	2024
Total Revenues	48,791,421	40,202,999
Cost & expenses	104,919,062	108,030,752
Operating income	(63,022,510)	(73,818,114)
Other income (expense), net	(47,377)	(73,577)
Gains or losses	25,142,843	(723,695)
Net before taxes	(32,843,813)	(69,919,268)
Income taxes	31,310	151,472
Net income	(32,875,123)	(70,070,740)
Earnings common share		
Primary	\$(0.13)	\$(0.35)
Fully Diluted	\$(0.13)	\$(0.35)
Common Shares:		
Full Diluted	248,754,135	202,998,041
Year-end	338,861,536	283,168,891

RUSH ENTERPRISES INC.**Earnings, 6 mos. to Jun 30**(Consol. — \$000):

	2025	2024
Total Revenues	3,781,537	3,899,027
Cost & expenses	3,544,595	3,631,694
Operating income	202,075	235,091
Other income (expense), net	(812)	221
Net before taxes	175,674	197,875
Income taxes	42,068	47,603
Net income	133,606	150,272
Earnings common share		
Primary	\$1.68	\$1.91
Fully Diluted	\$1.63	\$1.84
Common Shares:		
Full Diluted	81,445	81,467
Year-end	77,738	78,569

RXSIGHT INC**Earnings, 6 mos. to Jun 30**(Consol. — \$000):

	2025	2024
Total Revenues	71,531	64,399
Cost & expenses	96,208	83,402
Operating income	(24,677)	(19,003)
Net before taxes	(19,266)	(15,154)
Income taxes	50	25
Net income	(19,976)	(15,179)
Earnings common share		
Primary	\$(0.49)	\$(0.40)
Fully Diluted	\$(0.49)	\$(0.40)
Common Shares:		
Full Diluted	40,627	37,650
Year-end	40,913	39,617

SAB BIOTHERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. — \$):

	2025	2024
Total Revenues		1,207,712
Cost & expenses	20,504,163	22,800,026
Operating income	(20,504,163)	(21,592,314)
Other income (expense), net	842,257	842,962
Gains or losses	4,408,713	7,685,192
Net income	(15,311,043)	(12,361,200)
Earnings common share		
Primary	\$(1.65)	\$(1.34)
Fully Diluted	\$(1.65)	\$(1.34)
Common Shares:		
Full Diluted	9,293,018	9,248,503
Year-end	9,291,697	9,229,274

SABRE CORP**Earnings, 6 mos. to Jun 30**(Consol. — \$000):

	2025	2024
Total Revenues	1,389,275	1,408,683
Cost & expenses	1,208,746	1,270,766
Operating income	180,529	137,917
Other income (expense), net	(84,276)	(37,101)

Net before taxes	(124,781)	(127,493)
Income taxes	79,614	9,328
Income contin. oper.	(204,395)	(136,821)
Net income	(220,983)	(140,590)
Earnings common share		
Primary	\$(0.57)	\$(0.37)
Fully Diluted	\$(0.57)	\$(0.37)
Common Shares:		
Full Diluted	388,601	381,640
Year-end	394,498	385,663

SAFETY INSURANCE GROUP, INC.**Earnings, 6 mos. to Jun 30**(Consol. — \$000):

	2025	2024
Total Revenues		538,016
Cost & expenses	552,425	491,174
Operating income	65,057	46,842
Net before taxes	65,057	46,842
Income taxes	14,224	10,128
Net income	50,833	36,714
Balance for common	50,604	36,552
Earnings common share		
Primary	\$3.44	\$2.49
Fully Diluted	\$3.43	\$2.48
Common Shares:		
Full Diluted	14,764	14,709
Year-end	14,894	14,836

SANA BIOTECHNOLOGY INC**Earnings, 6 mos. to Jun 30**(Consol. — \$000):

	2025	2024
Cost & expenses	145,605	160,096
Operating income	(145,605)	(160,096)
Other income (expense), net	847	(3,906)
Net income	(143,189)	(157,766)
Earnings common share		
Primary	\$(0.60)	\$(0.70)
Fully Diluted	\$(0.60)	\$(0.70)
Common Shares:		
Full Diluted	237,996	225,872
Year-end	230,510	222,209

SANGAMO THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. — \$):

	2025	2024
Total Revenues	24,743,000	837,000
Cost & expenses	72,226,000	89,447,000
Operating income	(47,483,000)	(88,610,000)
Other income (expense), net	(3,649,000)	
Net before taxes	(50,437,000)	(85,045,000)
Income taxes	146,000	172,000
Net income	(50,583,000)	(85,217,000)
Earnings common share		
Primary	\$(0.21)	\$(0.44)
Fully Diluted	\$(0.21)	\$(0.44)
Common Shares:		
Full Diluted	238,711,000	194,049,000
Year-end	272,803,887	208,201,140

SAREPTA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. — \$):

	2025	2024
Total Revenues	1,355,947,000	776,395,000
Cost & expenses	1,539,488,000	740,989,000
Operating income	(184,809,000)	34,204,000
Other income (expense), net	3,223,000	24,750,000
Gains or losses		(10,100,000)
Invest. income	(54,007,000)	
Net before taxes	(229,880,000)	55,025,000
Income taxes	20,736,000	12,446,000
Net income	(250,616,000)	42,579,000
Earnings common share		
Primary	\$(2.57)	\$0.45
Fully Diluted	\$(2.57)	\$0.44
Common Shares:		
Full Diluted	97,685,000	99,129,000
Year-end	97,706,074	95,282,600

SCHOLAR ROCK HOLDING CORP**Earnings, 6 mos. to Jun 30**(Consol. — \$000):

	2025	2024
Cost & expenses	189,199	117,917
Operating income	(189,199)	(117,917)
Other income (expense), net	(171)	2,556

Net income	(184,754)	(115,361)
Earnings common share		
Primary	\$(1.65)	\$(1.20)
Fully Diluted	\$(1.65)	\$(1.20)
Common Shares:		
Full Diluted	112,273	96,353
Year-end	96,000	79,992

SCHRODINGER INC**Earnings, 6 mos. to Jun 30**(Consol. — \$000):

	2025	2024
Total Revenues	114,310	83,932
Cost & expenses	218,102	204,094
Operating income	(103,792)	(120,162)
Gains or losses	(8,516)	2,304
Net before taxes	(102,666)	(108,232)
Income taxes	315	539
Net income	(102,981)	(108,771)
Earnings common share		
Primary	\$(1.41)	\$(1.50)
Fully Diluted	\$(1.41)	\$(1.50)
Common Shares:		
Full Diluted	73,244	72,501
Year-end	73,585	72,785

SCPHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. — \$000):

	2025	2024
Total Revenues	27,793	14,156
Cost & expenses	59,844	44,443
Operating income	(32,051)	(30,287)
Other income (expense), net	8	1,783
Gains or losses	(4,162)	
Net income	(37,766)	(31,198)
Earnings common share		
Primary	\$(0.70)	\$(0.80)
Fully Diluted	\$(0.70)	\$(0.80)
Common Shares:		
Full Diluted	53,698	38,968
Year-end	53,290	36,140

SCRIPPS (EW) COMPANY (THE)**Earnings, 6 mos. to Jun 30**(Consol. — \$000):

	2025	2024
Total Revenues	1,064,473	1,135,093
Cost & expenses	884,736	958,843
Operating income	104,079	99,094
Other income (expense), net	(43,245)	16,756
Net before taxes	(41,569)	8,810
Income taxes	(2,152)	5,755
Net income	(39,417)	3,055
Balance for common	(70,527)	(25,754)
Earnings common share		
Primary	\$(0.81)	\$(0.30)
Fully Diluted	\$(0.81)	\$(0.30)
Common Shares:		
Full Diluted	87,420	85,282
Year-end	88,333	86,118

SENECA FOODS CORP.**Earnings, 3 mos. to** (Consol. — \$000):

	06/28/25	06/29/24
Total Revenues	297,458	304,727
Cost & expenses	274,243	279,284
Operating income	23,215	25,443
Other income (expense), net	1,906	1,403
Net before taxes	19,711	16,501
Income taxes	4,826	3,840
Net income	14,885	12,661
Balance for common	14,862	12,640
Earnings common share		
Primary	\$2.16	\$1.82
Fully Diluted	\$2.14	\$1.80
Common Shares:		
Full Diluted	6,949	7,029
Year-end	6,862	6,943

Consolidated Balance Sheet Items, as of (\$000):

	2025
Assets:	
Cash & equivalents	12,072
Inventories	614,435
Current assets	732,315
Net property & equip.	325,492
Total assets	1,159,344
Liabilities:	

Current liabilities	178,346
Long-term debt	283,795
Stockholders' equity	644,172
Net current assets	553,969

SERA PROGNOSTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	55	24
Cost & expenses	18,625	18,374
Operating income	(18,570)	(18,350)
Other income (expense), net	228	626
Net income	(16,233)	(16,400)
Earnings common share		
Primary	\$(0.36)	\$(0.50)
Fully Diluted	\$(0.36)	\$(0.50)
Common Shares:		
Full Diluted	45,537	32,576
Year-end	38,026	33,354

SERES THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	52,117	63,309
Operating income	(52,117)	(63,309)
Other income (expense), net	11,414	1,332
Gains or losses	52,366	
Income contin. oper.		(59,099)
Net income	12,827	(73,003)
Earnings common share		
Primary	\$1.47	\$(9.81)
Fully Diluted	\$1.47	\$(9.81)
Common Shares:		
Full Diluted	8,732	7,440
Year-end	8,754	151,634

SERVICE PROPERTIES TRUST**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	721,771	701,539
Operating income	(148,821)	58,878
Other income (expense), net	590	(19,043)
Equity earnings	4,473	8,054
Net before taxes	(148,821)	(142,648)
Income taxes		1,531
Net income	(154,594)	(152,233)
Earnings common share		
Primary	\$(0.93)	\$(0.92)
Fully Diluted	\$(0.93)	\$(0.92)
Common Shares:		
Full Diluted	165,679	165,178
Year-end	166,861	165,904

SI-BONE INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	95,920	77,836
Cost & expenses	110,404	99,957
Operating income	(14,484)	(22,121)
Other income (expense), net	6	(89)
Net income	(12,694)	(19,843)
Earnings common share		
Primary	\$(0.30)	\$(0.48)
Fully Diluted	\$(0.30)	\$(0.48)
Common Shares:		
Full Diluted	42,564	41,126
Year-end	43,014	41,511

SIGA TECHNOLOGIES INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	88,160,818	47,240,746
Cost & expenses	44,736,348	34,885,508
Operating income	43,424,470	12,355,238
Other income (expense), net	3,277,288	3,260,433
Net before taxes	46,701,758	15,615,671
Income taxes	11,626,878	3,505,715
Net income	35,074,880	12,109,956
Earnings common share		
Primary	\$0.49	\$0.17
Fully Diluted	\$0.49	\$0.17
Common Shares:		
Full Diluted	71,678,838	71,748,362
Year-end	71,539,755	71,305,893

SIGHT SCIENCES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	37,072	40,635
Cost & expenses	62,598	68,010
Operating income	(25,526)	(27,375)
Other income (expense), net	(115)	(2,012)
Invest. income	2,174	3,174
Net before taxes	(26,014)	(28,563)
Income taxes	81	32
Net income	(26,095)	(28,595)
Earnings common share		
Primary	\$(0.51)	\$(0.58)
Fully Diluted	\$(0.51)	\$(0.58)
Common Shares:		
Full Diluted	51,558	49,695
Year-end	52,033	50,136

SILGAN HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	3,005,822	2,698,403
Cost & expenses	2,707,747	2,444,831
Operating income	298,075	253,572
Equity earnings	(1,717)	
Net before taxes	206,448	173,582
Income taxes	51,259	42,321
Net income	156,906	131,261
Earnings common share		
Primary	\$1.47	\$1.23
Fully Diluted	\$1.46	\$1.23
Common Shares:		
Full Diluted	107,294	107,033
Year-end	106,993	106,779

SILVACO GROUP INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	26,140	30,849
Cost & expenses	55,915	66,250
Operating income	(29,775)	(35,401)
Other income (expense), net		(718)
Net before taxes	(28,995)	(35,991)
Income taxes	(313)	1,019
Net income	(28,682)	(37,010)
Earnings common share		
Primary	\$(0.99)	\$(1.65)
Fully Diluted	\$(0.99)	\$(1.65)
Common Shares:		
Full Diluted	29,005	22,406
Year-end	29,603	26,294

SITIME CORP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	129,808	76,888
Cost & expenses	182,529	144,246
Operating income	(52,721)	(67,358)
Other income (expense), net	210	(416)
Net before taxes	(43,954)	(55,478)
Income taxes	102	(5)
Net income	(44,056)	(55,473)
Earnings common share		
Primary	\$(1.85)	\$(2.42)
Fully Diluted	\$(1.85)	\$(2.42)
Common Shares:		
Full Diluted	23,790	22,881
Year-end	26,004	23,132

SOLAREDGE TECHNOLOGIES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	508,909	469,804
Cost & expenses	727,128	803,691
Operating income	(218,219)	(333,887)
Other income (expense), net	4,165	18,551
Equity earnings	575	863
Net before taxes	(211,309)	(323,265)
Income taxes	11,383	(35,999)
Net income	(223,267)	(288,129)
Earnings common share		
Primary	\$(3.83)	\$(5.06)
Fully Diluted	\$(3.83)	\$(5.06)
Common Shares:		

Full Diluted	58,346	56,914
Year-end	59,134	56,952

SOLID BIOSCIENCES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	81,745	54,650
Operating income	(81,745)	(54,650)
Other income (expense), net	395	242
Gains or losses	(2,550)	
Net income	(78,762)	(49,375)
Earnings common share		
Primary	\$(0.98)	\$(1.25)
Fully Diluted	\$(0.98)	\$(1.25)
Common Shares:		
Full Diluted	80,318	39,545
Year-end	77,603	38,551

SOLID POWER INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	13,556,000	11,028,000
Cost & expenses	63,455,000	63,746,000
Operating income	(49,899,000)	(52,718,000)
Other income (expense), net	(673,000)	
Gains or losses	2,663,000	202,000
Equity earnings	(606,000)	
Net before taxes	(41,088,000)	(42,970,000)
Income taxes	6,000	511,000
Net income	(40,488,000)	(43,481,000)
Earnings common share		
Primary	\$(0.22)	\$(0.24)
Fully Diluted	\$(0.22)	\$(0.24)
Common Shares:		
Full Diluted	180,871,314	179,186,027
Year-end	180,714,274	178,640,611

SONOS INC**Earnings, 9 mos. to (Consol. – \$000):**

	06/28/25	06/29/24
Total Revenues	1,155,376	1,262,676
Cost & expenses	1,171,435	1,241,353
Operating income	(16,059)	21,323
Other income (expense), net	(5,176)	4,507
Net before taxes	(16,165)	35,135
Income taxes	7,121	20,188
Net income	(23,286)	14,947
Earnings common share		
Primary	\$(0.19)	\$0.12
Fully Diluted	\$(0.19)	\$0.12
Common Shares:		
Full Diluted	120,805	127,886
Year-end	120,781	120,973

SOTERA HEALTH CO**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	548,864	524,770
Cost & expenses	378,765	363,648
Operating income	4,074	129,973
Other income (expense), net	(58,957)	(22,841)
Net before taxes	4,074	26,156
Income taxes	9,372	11,079
Net income	(5,298)	15,077
Balance for common	(5,298)	15,044
Earnings common share		
Primary	\$(0.02)	\$0.05
Fully Diluted	\$(0.02)	\$0.05
Common Shares:		
Full Diluted	283,747	284,264
Year-end	284,046	283,214

SOUNDHOUND AI INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	71,812,000	25,056,000
Cost & expenses	14,833,000	74,344,000
Operating income	50,046,000	(50,514,000)
Other income (expense), net	7,641,000	(13,769,000)
Net before taxes	57,283,000	(69,398,000)
Income taxes	2,075,000	933,000
Net income	55,208,000	(70,331,000)
Balance for common	54,911,000	(70,747,000)
Earnings common share		

Primary	\$0.14	\$(0.23)
Fully Diluted	\$0.13	\$(0.23)
Common Shares:		
Full Diluted	414,145,877	309,213,583
Year-end	405,591,274	347,889,013

STAAR SURGICAL CO.**Earnings, 6 mos. to (Consol. – \$000):**

	06/27/25	06/28/24
Total Revenues	86,909	176,361
Cost & expenses	174,274	166,744
Operating income	(87,365)	9,617
Other income (expense), net	251	901
Net before taxes	(80,401)	8,123
Income taxes	(9,378)	4,083
Net income	(71,023)	4,040
Earnings common share		
Primary	\$(1.44)	\$0.08
Fully Diluted	\$(1.44)	\$0.08
Common Shares:		
Full Diluted	49,432	49,529
Year-end	49,285	49,161

STEEL DYNAMICS INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	8,934,318	9,326,637
Cost & expenses	8,262,525	8,001,230
Operating income	657,999	1,310,098
Other income (expense), net	40,033	45,492
Net before taxes	668,520	1,330,893
Income taxes	149,650	311,703
Net income	518,870	1,019,190
Earnings common share		
Primary	\$3.45	\$6.42
Fully Diluted	\$3.44	\$6.39
Common Shares:		
Full Diluted	149,885	158,467
Year-end	147,788	155,618

STEPSTONE GROUP INC**Earnings, 3 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	186,401	186,401
Cost & expenses	423,316	139,250
Operating income	(20,350)	54,842
Other income (expense), net	39,777	7,209
Invest. income	940	1,415
Net before taxes	(20,350)	54,842
Income taxes	(8,339)	6,797
Net income	(12,011)	48,045
Earnings common share		
Primary	\$(0.49)	\$0.20
Fully Diluted	\$(0.49)	\$0.20
Common Shares:		
Full Diluted	77,847	68,594
Year-end	78,553	67,932

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2025	2024
Cash & equivalents	244,131	
Current assets	442,608	
Total assets	4,782,411	
Liabilities:		
Current liabilities	2,677,021	
Long-term debt	269,594	
Stockholders' equity	153,932	
Net current assets	(2,234,413)	

STOKE THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	172,386	9,048
Cost & expenses	88,446	66,762
Operating income	83,940	(57,714)
Other income (expense), net	57	(476)
Net before taxes	90,675	
Income taxes	1,278	
Net income	89,397	(52,069)
Earnings common share		
Primary	\$1.54	\$(1.02)
Fully Diluted	\$1.50	\$(1.02)
Common Shares:		
Full Diluted	59,681	51,288
Year-end	54,723	52,306

SUMMIT THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	635,288	102,006
Operating income	(628,621)	(103,858)
Other income (expense), net	(53)	
Invest. income	6,842	4,407
Net income	(628,621)	(103,858)
Earnings common share		
Primary	\$(0.85)	\$(0.15)
Fully Diluted	\$(0.85)	\$(0.15)
Common Shares:		
Full Diluted	740,358	704,845
Year-end	742,807	724,320

SUNRUN INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,073,607	982,054
Cost & expenses	1,300,744	1,293,224
Operating income	(227,137)	(311,170)
Other income (expense), net	(59,927)	154,308
Net before taxes	(761,635)	(556,228)
Income taxes	(205,480)	(13,150)
Net income	(556,155)	(543,078)
Earnings common share		
Primary	\$1.45	\$0.23
Fully Diluted	\$1.28	\$0.23
Common Shares:		
Full Diluted	259,539	244,755
Year-end	230,321	223,298

SUPERIOR GROUP OF COMPANIES INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	281,142,000	270,578,000
Cost & expenses	277,717,000	262,008,000
Operating income	930,000	5,242,000
Net before taxes	930,000	5,242,000
Income taxes	137,000	730,000
Net income	793,000	4,512,000
Earnings common share		
Primary	\$0.05	\$0.28
Fully Diluted	\$0.05	\$0.27
Common Shares:		
Full Diluted	15,573,692	16,611,375
Year-end	15,917,963	16,792,577

SURMODICS INC**Earnings, 9 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	87,574	92,851
Cost & expenses	96,681	95,267
Operating income	(11,733)	(5,032)
Net before taxes	(13,555)	(6,369)
Income taxes	623	1,724
Net income	(14,178)	(8,093)
Earnings common share		
Primary	\$(0.99)	\$(0.57)
Fully Diluted	\$(0.99)	\$(0.57)
Common Shares:		
Full Diluted	14,263	14,141
Year-end	14,298	14,265

SUTRO BIOPHARMA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	81,144	38,714
Cost & expenses	153,003	143,990
Operating income	(71,859)	(105,276)
Other income (expense), net	(18,991)	(5,983)
Net before taxes	(87,478)	(106,223)
Income taxes	(11)	8
Net income	(87,467)	(106,231)
Earnings common share		
Primary	\$(1.04)	\$(1.49)
Fully Diluted	\$(1.04)	\$(1.49)
Common Shares:		
Full Diluted	83,847	71,341
Year-end	84,720	81,862

TAKE-TWO INTERACTIVE SOFTWARE, INC.**Earnings, 3 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	1,503,800,000	1,338,200,000
Cost & expenses	1,431,800,000	1,478,300,000
Operating income	21,600,000	(184,900,000)
Gains or losses		(3,103,000)
Net before taxes	(13,800,000)	(212,200,000)
Income taxes	(1,900,000)	49,800,000
Net income	(11,900,000)	(262,000,000)
Earnings common share		
Primary	\$(0.07)	\$(1.52)
Fully Diluted	\$(0.07)	\$(1.52)
Common Shares:		
Full Diluted	180,800,000	172,300,000
Year-end	184,400,000	175,100,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2025
Cash & equivalents	2,025,000,000
Current assets	3,280,200,000
Net property & equip.	436,700,000
Total assets	9,684,200,000
Liabilities:	
Current liabilities	2,816,100,000
Long-term debt	2,516,100,000
Stockholders' equity	3,480,900,000
Net current assets	464,100,000

TALKSPACE INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	106,492,000	91,474,000
Cost & expenses	107,999,000	96,639,000
Operating income	(2,875,000)	(5,165,000)
Net before taxes	(24,000)	(1,743,000)
Income taxes	199,000	197,000
Net income	(223,000)	(1,940,000)
Earnings common share		
Primary	\$.	\$(0.01)
Fully Diluted	\$.	\$(0.01)
Common Shares:		
Full Diluted	168,098,647	168,997,734
Year-end	167,944,188	168,169,158

TANDEM DIABETES CARE INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	475,100,000	413,584,000
Cost & expenses	647,788,000	486,036,000
Operating income	(172,688,000)	(72,452,000)
Other income (expense), net	(6,917,000)	(1,268,000)
Net before taxes	(179,811,000)	(69,272,000)
Income taxes	3,145,000	4,257,000
Net income	(182,956,000)	(73,529,000)
Earnings common share		
Primary	\$(2.74)	\$(1.13)
Fully Diluted	\$(2.74)	\$(1.13)
Common Shares:		
Full Diluted	66,729,000	65,160,000
Year-end	67,531,000	65,435,000

TARSUS PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	180,995	68,427
Cost & expenses	229,459	139,413
Operating income	(48,464)	(70,986)
Other income (expense), net	(226)	(1,478)
Gains or losses		(792)
Net income	(45,460)	(69,021)
Earnings common share		
Primary	\$(1.11)	\$(1.89)
Fully Diluted	\$(1.11)	\$(1.89)
Common Shares:		
Full Diluted	40,869	36,531
Year-end	42,211	38,030

TASKUS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	571,878	465,398
Cost & expenses	477,435	388,384
Operating income	64,600	46,280
Other income (expense), net	1,500	2,905
Net before taxes	56,802	38,157
Income taxes	15,607	13,845

Net income	41,195	24,312
Earnings common share		
Primary	\$0.46	\$0.27
Fully Diluted	\$0.44	\$0.27
Common Shares:		
Full Diluted.....	93,116	91,740
Year-end	89,746	88,629

TAYSHA GENE THERAPIES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	4,288	
Cost & expenses	52,462	50,152
Operating income	(48,174)	(45,629)
Other income (expense), net	(224)	37
Gains or losses	(3,162)	(2,474)
Net income	(48,411)	(44,989)
Earnings common share		
Primary	\$(0.17)	\$(0.19)
Fully Diluted	\$(0.17)	\$(0.19)
Common Shares:		
Full Diluted.....	283,727	232,035
Year-end	272,730	201,381

TEADS HOLDING CO**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	629,453	431,112
Cost & expenses	676,148	443,336
Operating income	(46,695)	(12,224)
Other income (expense), net	1,225	
Net before taxes	(88,108)	(9,579)
Income taxes	(18,952)	(2,339)
Net income	(69,156)	(7,240)
Earnings common share		
Primary	\$(0.80)	\$(0.15)
Fully Diluted	\$(0.80)	\$(0.15)
Common Shares:		
Full Diluted.....	86,269	49,094
Year-end	94,969	49,215

TELA BIO INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	38,717	32,694
Cost & expenses	58,270	49,090
Operating income	(19,553)	(16,396)
Other income (expense), net	858	798
Net before taxes	(21,102)	
Income taxes	85	
Net income	(21,187)	(18,261)
Earnings common share		
Primary	\$(0.47)	\$(0.74)
Fully Diluted	\$(0.47)	\$(0.74)
Common Shares:		
Full Diluted.....	45,316	24,621
Year-end	39,584	24,676

TELOS CORP. (MD)**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	66,584	58,117
Cost & expenses	85,489	75,199
Operating income	(18,905)	(17,082)
Other income (expense), net	1,114	2,316
Net before taxes	(18,079)	(15,101)
Income taxes	42	34
Net income	(18,121)	(15,135)
Earnings common share		
Primary	\$(0.25)	\$(0.21)
Fully Diluted	\$(0.25)	\$(0.21)
Common Shares:		
Full Diluted.....	72,940	71,323
Year-end	72,442	72,223

TEMPUS AI INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	570,372	311,789
Cost & expenses	700,835	898,555
Operating income	(130,463)	(586,766)
Other income (expense), net	10,291	(6,299)
Net before taxes	(156,848)	(616,849)
Income taxes	(45,968)	106

Net income	(110,880)	(616,955)
Balance for common.....	(110,880)	(657,476)
Earnings common share		
Primary	\$(0.64)	\$(9.02)
Fully Diluted	\$(0.64)	\$(9.02)
Common Shares:		
Full Diluted.....	171,960	72,930
Year-end	173,625	154,319

TENABLE HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	486,432	437,202
Cost & expenses	511,591	454,950
Operating income	(25,159)	(17,748)
Other income (expense), net	499	(1,217)
Net before taxes	(29,803)	(23,552)
Income taxes	7,838	5,406
Net income	(37,641)	(28,958)
Earnings common share		
Primary	\$(0.31)	\$(0.25)
Fully Diluted	\$(0.31)	\$(0.25)
Common Shares:		
Full Diluted.....	120,533	118,111
Year-end	120,987	118,990

TENAYA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	51,620	64,585
Operating income	(51,620)	(64,585)
Other income (expense), net	24	81
Net income	(50,147)	(61,659)
Earnings common share		
Primary	\$(0.37)	\$(0.74)
Fully Diluted	\$(0.37)	\$(0.74)
Common Shares:		
Full Diluted.....	136,477	83,344
Year-end	162,976	78,867

TEXAS ROADHOUSE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	07/01/25	06/25/24
Total Revenues	2,959,702	2,662,419
Cost & expenses	2,579,084	2,302,067
Operating income	281,074	275,944
Other income (expense), net	1,651	543
Net before taxes	285,070	279,578
Income taxes	42,318	40,513
Net income	242,752	239,065
Earnings common share		
Primary	\$3.58	\$3.49
Fully Diluted	\$3.57	\$3.48
Common Shares:		
Full Diluted.....	66,656	67,077
Year-end	66,451	66,728

THE REALREAL INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	325,221	288,734
Cost & expenses	347,877	325,473
Operating income	(22,656)	(36,739)
Other income (expense), net	37,709	4,177
Gains or losses	47,040	(9,953)
Net before taxes	51,218	(47,703)
Income taxes	184	106
Net income	51,034	(47,809)
Earnings common share		
Primary	\$0.45	\$(0.45)
Fully Diluted	\$(0.27)	\$(0.45)
Common Shares:		
Full Diluted.....	120,179	106,047
Year-end	115,236	108,496

THE TRADE DESK INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,310,060	1,075,803
Cost & expenses	1,138,831	952,426
Operating income	171,229	123,377
Net before taxes	208,970	158,525
Income taxes	68,163	41,836
Net income	140,807	116,689

Earnings common share		
Primary	\$0.29	\$0.24
Fully Diluted	\$0.28	\$0.23
Common Shares:		
Full Diluted.....	499,340	499,117
Year-end	489,898	491,600

TONIX PHARMACEUTICALS HOLDING CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	4,427,000	4,690,000
Cost & expenses	48,777,000	103,357,000
Operating income	(44,350,000)	(98,667,000)
Other income (expense), net	(2,322,000)	(1,198,000)
Gains or losses		6,150,000
Net income	(45,101,000)	(93,715,000)
Earnings common share		
Primary	\$(6.80)	\$(2,733.00)
Fully Diluted	\$(6.80)	\$(2,733.00)
Common Shares:		
Full Diluted.....	6,631,111	34,289
Year-end	7,546,276	98,326

TPG PARTNERS LLC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	1,775,801	1,547,899
Operating income	133,514	(39,808)
Invest. income	(2,878)	(21,850)
Net before taxes	133,514	(39,808)
Income taxes	15,575	26,776
Net income	117,939	(66,584)
Balance for common.....	12,860	(7,655)
Earnings common share		
Primary	\$0.10	\$(0.08)
Fully Diluted	\$(0.05)	\$(0.08)
Common Shares:		
Full Diluted.....	369,753	95,402
Year-end	144,597	102,813

TPI COMPOSITES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	612,402	603,863
Cost & expenses	674,600	678,976
Operating income	(62,198)	(75,113)
Other income (expense), net	1,050	2,702
Net before taxes	(117,128)	(116,721)
Income taxes	(262)	5,654
Income contin. oper.....	(116,866)	(122,375)
Net income	(116,540)	(152,557)
Balance for common.....		(152,557)
Earnings common share		
Primary	\$(2.41)	\$(3.22)
Fully Diluted	\$(2.41)	\$(3.22)
Common Shares:		
Full Diluted.....	48,343	47,354
Year-end	48,730	47,554

TRACTOR SUPPLY CO.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	06/28/25	06/29/24
Total Revenues	7,906,682	7,641,456
Cost & expenses	6,837,554	6,603,314
Operating income	826,949	824,584
Net before taxes	789,325	801,070
Income taxes	179,913	177,707
Net income	609,412	623,363
Earnings common share		
Primary	\$1.15	\$5.78
Fully Diluted	\$1.14	\$5.75
Common Shares:		
Full Diluted.....	533,152	108,381
Year-end	529,990	107,447

TRANSCAT INC**Earnings, 3 mos. to Jun 30**(Consol. – \$):

	06/28/25	06/29/24
Total Revenues	76,424,000	66,707,000
Cost & expenses	71,086,000	61,608,000
Operating income	5,338,000	5,099,000
Other income (expense), net	(333,000)	(131,000)
Net before taxes	4,565,000	5,228,000
Income taxes	1,304,000	820,000

Net income	3,261,000	4,408,000
Earnings common share		
Primary	\$0.35	\$0.49
Fully Diluted	\$0.35	\$0.48
Common Shares:		
Full Diluted	9,389,000	9,196,000
Year-end	9,318,490	9,144,731

Consolidated Balance Sheet Items, as of (\$):

Assets:	2025	
Cash & equivalents	1,861,000	
Inventories	15,392,000	
Current assets	79,654,000	
Net property & equip.	52,161,000	
Total assets	392,536,000	
Liabilities:		
Current liabilities	27,280,000	
Long-term debt	33,182,000	
Stockholders' equity	292,536,000	
Net current assets	52,374,000	

TRAVERE THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	95,490,000	
Cost & expenses	251,507,000	302,431,000
Operating income	(55,327,000)	206,941,000
Other income (expense), net	24,000	(3,257,000)
Net before taxes	(53,922,000)	205,334,000
Income taxes	59,000	276,000
Income contin. oper.	(205,610,000)	
Income discount. oper.	(860,000)	
Net income	(53,981,000)	206,470,000
Earnings common share		
Primary	\$(0.61)	\$(2.67)
Fully Diluted	\$(0.61)	\$(2.67)
Common Shares:		
Full Diluted	88,652,428	77,318,369
Year-end	89,102,347	76,456,562

TREACE MEDICAL CONCEPTS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	99,957	95,563
Cost & expenses	132,513	135,913
Operating income	(32,556)	(40,350)
Other income (expense), net	252	186
Net income	(33,320)	(39,882)
Earnings common share		
Primary	\$(0.53)	\$(0.64)
Fully Diluted	\$(0.53)	\$(0.64)
Common Shares:		
Full Diluted	62,843	61,937
Year-end	63,042	62,175

TREVI THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Cost & expenses	25,192	25,195
Operating income	(25,192)	(25,195)
Other income (expense), net	(13)	(6)
Net before taxes	(22,673)	(23,270)
Income taxes	(32)	(16)
Net income	(22,641)	(23,254)
Earnings common share		
Primary	\$(0.18)	\$(0.23)
Fully Diluted	\$(0.18)	\$(0.23)
Common Shares:		
Full Diluted	124,016	100,279
Year-end	121,776	72,592

TRIMBLE INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	07/04/25	06/28/24
Total Revenues	1,716,300	1,824,100
Cost & expenses	1,438,600	1,600,100
Operating income	225,300	170,800
Other income (expense), net	4,600	9,900
Gains or losses	4,800	1,717,600
Net before taxes	199,700	1,835,000
Income taxes	43,800	461,400
Net income	155,900	1,373,600
Earnings common share		
Primary	\$0.65	\$5.60
Fully Diluted	\$0.64	\$5.56

Common Shares:		
Full Diluted	242,900	246,900
Year-end	238,000	245,400

TRUBRIDGE INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	172,937,000	169,717,000
Cost & expenses	148,133,000	156,679,000
Operating income	11,787,000	(2,737,000)
Other income (expense), net	280,000	1,514,000
Net before taxes	5,620,000	(9,538,000)
Income taxes	2,581,000	(3,296,000)
Net income	3,039,000	(6,242,000)
Balance for common	2,933,000	(6,025,000)
Earnings common share		
Primary	\$0.20	\$(0.42)
Fully Diluted	\$0.20	\$(0.42)
Common Shares:		
Full Diluted	14,446,000	14,273,000
Year-end	15,015,000	14,946,000

TRUECAR INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	91,808	
Cost & expenses	104,271	96,252
Operating income	(19,777)	(22,674)
Net before taxes	(17,754)	(19,358)
Income taxes	9	10
Net income	(17,763)	(19,368)
Earnings common share		
Primary	\$(0.20)	\$(0.21)
Fully Diluted	\$(0.20)	\$(0.21)
Common Shares:		
Full Diluted	87,587	91,542
Year-end	88,416	92,024

TRUPANION INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	695,532	620,921
Cost & expenses	686,633	624,218
Operating income	9,102	(12,796)
Other income (expense), net	14,849	5,913
Net before taxes	9,102	(12,796)
Income taxes	1,172	(82)
Net income	7,930	(12,714)
Earnings common share		
Primary	\$0.19	\$(0.30)
Fully Diluted	\$0.18	\$(0.30)
Common Shares:		
Full Diluted	43,544	41,998
Year-end	42,988	42,160

TSCAN THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	5,247	1,102
Cost & expenses	80,150	66,589
Operating income	(74,903)	(65,487)
Net income	(71,079)	(61,803)
Earnings common share		
Primary	\$(0.55)	\$(0.59)
Fully Diluted	\$(0.55)	\$(0.59)
Common Shares:		
Full Diluted	129,705	104,151
Year-end	56,748	52,933

TTEC HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	1,047,799	1,110,723
Cost & expenses	959,148	1,262,209
Operating income	43,065	(201,702)
Other income (expense), net	3,293	1,994
Net before taxes	16,125	(239,813)
Income taxes	19,603	56,455
Net income	(3,478)	(296,268)
Earnings common share		
Primary	\$(0.14)	\$(6.35)
Fully Diluted	\$(0.14)	\$(6.35)
Common Shares:		
Full Diluted	47,918	47,498
Year-end	48,400	47,608

TURTLE BEACH CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	120,678,000	132,326,000
Cost & expenses	119,471,000	142,150,000
Operating income	1,207,000	(9,824,000)
Other income (expense), net	(1,102,000)	(722,000)
Net before taxes	(3,950,000)	(12,916,000)
Income taxes	(355,000)	(5,547,000)
Net income	(3,595,000)	(7,369,000)
Earnings common share		
Primary	\$(0.17)	\$(0.37)
Fully Diluted	\$(0.17)	\$(0.37)
Common Shares:		
Full Diluted	20,587,000	19,795,000
Year-end	19,823,915	20,753,358

ULTRALIFE CORP**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	99,307	84,910
Cost & expenses	93,652	76,930
Operating income	5,655	7,980
Other income (expense), net	(72)	411
Net before taxes	3,559	7,453
Income taxes	810	1,556
Net income	2,749	5,897
Earnings common share		
Primary	\$0.17	\$0.21
Fully Diluted	\$0.17	\$0.21
Common Shares:		
Full Diluted	16,671	16,661
Year-end	16,642	16,623

UNITED-GUARDIAN, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	5,319,352	6,645,149
Cost & expenses	4,012,977	4,503,864
Operating income	1,306,375	2,141,285
Other income (expense), net	155,260	198,080
Invest. income	36,926	31,995
Net before taxes	1,498,561	2,371,360
Net income	1,187,721	1,881,667
Earnings common share		
Primary	\$0.26	\$0.41
Fully Diluted	\$0.26	\$0.41
Common Shares:		
Full Diluted	4,594,319	4,594,319
Year-end	4,594,319	4,594,319

UNIVERSAL LOGISTICS HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	06/28/25	06/29/24
Total Revenues	776,183	954,070
Cost & expenses	668,919	774,366
Operating income	35,573	122,194
Other income (expense), net	727	2,003
Net before taxes	19,225	111,235
Income taxes	4,895	28,044
Net income	14,330	83,191
Earnings common share		
Primary	\$0.54	\$3.16
Fully Diluted	\$0.54	\$3.16
Common Shares:		
Full Diluted	26,341	26,341
Year-end	26,330	26,317

UPSTART HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	470,662	255,424
Cost & expenses	470,616	378,378
Operating income	46	(122,954)
Other income (expense), net	3,192	3,915
Net before taxes	3,238	(119,039)
Income taxes	78	29
Net income	3,160	(119,068)
Earnings common share		
Primary	\$0.03	\$(1.36)
Fully Diluted	\$0.03	\$(1.36)
Common Shares:		
Full Diluted	103,178	87,733
Year-end	96,091	89,084

UPWORK INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	387,645	384,066
Cost & expenses	316,390	353,236
Operating income	71,255	30,830
Other income (expense), net	12,195	12,342
Net before taxes	83,450	43,172
Income taxes	12,994	2,510
Net income	70,456	40,662
Earnings common share		
Primary	\$0.53	\$0.30
Fully Diluted	\$0.50	\$0.30
Common Shares:		
Full Diluted	141,866	140,798
Year-end	132,506	132,007

USIO INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	41,970,040	41,050,274
Cost & expenses	41,646,225	40,417,169
Operating income	(636,554)	(490,898)
Other income (expense), net		261,413
Net before taxes	(470,213)	(34,696)
Income taxes	131,411	140,000
Net income	(601,624)	(174,696)
Earnings common share		
Primary	\$(0.02)	\$(0.01)
Fully Diluted	\$(0.02)	\$(0.01)
Common Shares:		
Full Diluted	26,577,052	26,454,848
Year-end	26,475,698	27,331,969

VAREX IMAGING CORP**Earnings, 9 mos. to** (Consol. – \$000):

	07/04/25	06/28/24
Total Revenues	615,700	605,300
Cost & expenses	663,100	584,100
Operating income	(47,400)	21,200
Other income (expense), net	(5,800)	(1,600)
Net before taxes	(73,300)	2,500
Income taxes	8,800	(200)
Net income	(82,100)	2,700
Earnings common share		
Primary	\$(2.00)	\$0.06
Fully Diluted	\$(2.00)	\$0.06
Common Shares:		
Full Diluted	41,300	41,200
Year-end	41,521	40,861

VAXCYTE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	407,012	267,453
Operating income	(407,012)	(267,453)
Other income (expense), net	35,713	520
Invest. income		49
Net income	(307,291)	(223,723)
Earnings common share		
Primary	\$(2.26)	\$(1.95)
Fully Diluted	\$(2.26)	\$(1.95)
Common Shares:		
Full Diluted	135,863	114,474
Year-end	129,816	110,576

VEECO INSTRUMENTS INC (DE)**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	333,396	350,363
Cost & expenses	305,236	307,880
Operating income	26,518	38,767
Other income (expense), net	(653)	
Net before taxes	27,606	39,821
Income taxes	3,926	3,023
Net income	23,680	36,798
Earnings common share		
Primary	\$0.41	\$0.66
Fully Diluted	\$0.40	\$0.61
Common Shares:		
Full Diluted	60,072	61,733
Year-end	60,161	56,773

VENTYX BIOSCIENCES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	59,430	77,480
Operating income	(59,430)	(77,480)
Other income (expense), net	(30)	(52)
Net income	(54,427)	(70,522)
Earnings common share		
Primary	\$(0.76)	\$(1.07)
Fully Diluted	\$(0.76)	\$(1.07)
Common Shares:		
Full Diluted	71,165	66,192
Year-end	71,235	70,663

VERACYTE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	244,637	211,272
Cost & expenses	245,758	209,703
Operating income	(2,364)	(50)
Other income (expense), net	449	192
Net before taxes	8,678	5,453
Income taxes	2,611	1,583
Net income	6,067	3,870
Earnings common share		
Primary	\$0.08	\$0.05
Fully Diluted	\$0.08	\$0.05
Common Shares:		
Full Diluted	79,905	76,600
Year-end	78,599	76,744

VERASTEM INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	2,137	10,000
Cost & expenses	90,076	56,336
Operating income	(87,939)	(46,336)
Other income (expense), net	(1,975)	(54)
Gains or losses	10,499	4,189
Net income	(78,037)	(42,119)
Earnings common share		
Primary	\$(1.30)	\$(1.57)
Fully Diluted	\$(1.30)	\$(1.57)
Common Shares:		
Full Diluted	60,191	26,846
Year-end	61,523	26,876

VERITONE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	46,476	48,211
Cost & expenses	73,308	78,585
Operating income	(40,952)	(44,676)
Other income (expense), net	899	(528)
Net before taxes	(46,115)	(50,700)
Income taxes	558	(1,123)
Income contin. oper.		(49,577)
Net income	(46,673)	(47,429)
Earnings common share		
Primary	\$(0.95)	\$(1.26)
Fully Diluted	\$(0.95)	\$(1.26)
Common Shares:		
Full Diluted	48,989	37,584
Year-end	47,583	37,964

VERTEX INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	361,621	317,885
Cost & expenses	348,932	301,687
Operating income	622	5,980
Net before taxes	3,389	5,513
Income taxes	(6,780)	(2,335)
Net income	10,169	7,848
Earnings common share		
Primary	\$0.06	\$0.05
Fully Diluted	\$0.06	\$0.05
Common Shares:		
Full Diluted	160,823	161,011
Year-end	159,398	155,326

VIASAT INC**Earnings, 3 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	1,171,054,000	1,126,460,000
Cost & expenses	1,058,641,000	1,000,510,000

Operating income	46,672,000	59,735,000
Other income (expense), net	(5,452,000)	
Equity earnings	(3,733,000)	(2,746,000)
Net before taxes	(44,847,000)	(23,249,000)
Income taxes	6,610,000	1,184,000
Net income	(47,724,000)	(21,687,000)
Earnings common share		
Primary	\$(0.43)	\$(0.26)
Fully Diluted	\$(0.43)	\$(0.26)
Common Shares:		
Full Diluted	131,578,000	126,580,000
Year-end	134,184,592	127,738,637

Consolidated Balance Sheet Items, as of (\$):

Assets:	2025
Cash & equivalents	1,177,492,000
Inventories	284,216,000
Current assets	2,455,805,000
Net property & equip.	7,339,470,000
Total assets	14,895,806,000
Liabilities:	
Current liabilities	1,161,343,000
Long-term debt	6,532,615,000
Stockholders' equity	4,562,228,000
Net current assets	1,294,462,000

VIATRIS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	6,836,400	7,460,000
Cost & expenses	9,485,600	7,496,000
Operating income	(2,649,200)	(36,000)
Other income (expense), net	(432,800)	133,000
Net before taxes	(3,314,100)	(187,200)
Income taxes	(267,500)	25,300
Net income	(3,046,600)	(212,500)
Earnings common share		
Primary	\$(2.58)	\$(0.18)
Fully Diluted	\$(2.58)	\$(0.18)
Common Shares:		
Full Diluted	1,182,700	1,193,100
Year-end	1,165,713	1,193,269

VICTORY CAPITAL HOLDINGS INC (DE)**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	354,466	224,920
Operating income	187,122	195,406
Other income (expense), net	8,083	7,960
Net before taxes	167,387	167,663
Income taxes	46,678	37,721
Net income	120,709	129,942
Balance for common	105,702	
Earnings common share		
Primary	\$1.61	\$2.01
Fully Diluted	\$1.59	\$1.97
Common Shares:		
Full Diluted	66,358	66,025
Year-end	66,926	64,809

VIR BIOTECHNOLOGY INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	4,246	59,451
Cost & expenses	262,210	298,162
Operating income	(257,964)	(238,711)
Other income (expense), net	154	(822)
Gains or losses	3,000	(5,486)
Net before taxes	(231,737)	(204,890)
Income taxes	186	(1,236)
Net income	(231,923)	(203,654)
Earnings common share		
Primary	\$(1.68)	\$(1.50)
Fully Diluted	\$(1.68)	\$(1.50)
Common Shares:		
Full Diluted	137,961	135,757
Year-end	138,886	136,590

VIRTUS INVESTMENT PARTNERS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	446,426	446,426
Cost & expenses	316,413	335,084
Operating income	81,805	76,511
Other income (expense), net	2,135	1,147
Gains or losses	2,980	1,863
Invest. income	(12,853)	(11,401)
Net before taxes	95,548	84,468
Income taxes	24,753	20,579
Net income	70,795	63,889
Earnings common share		
Primary	\$10.29	\$6.66
Fully Diluted	\$10.15	\$6.54
Common Shares:		
Full Diluted	6,997	7,264
Year-end	6,748	7,082

VITAL FARMS INC**Earnings, 6 mos. to (Consol. – \$000):**

	06/29/25	06/30/24
Total Revenues	346,956	295,316
Cost & expenses	301,393	254,008
Operating income	45,563	41,308
Other income (expense), net	(781)	(364)
Net before taxes	46,873	42,836
Income taxes	13,334	7,474
Net income	33,539	35,362
Earnings common share		
Primary	\$0.76	\$0.84
Fully Diluted	\$0.73	\$0.79
Common Shares:		
Full Diluted	45,816	44,600
Year-end	44,662	42,972

VOR BIOPHARMA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	307,575	61,361
Operating income	(307,575)	(61,361)
Interest income		2,718
Gains or losses	(1,299,922)	
Net income	(1,606,155)	(58,643)
Balance for common		(58,643)
Earnings common share		
Primary	\$(12.84)	\$(0.86)
Fully Diluted	\$(12.84)	\$(0.86)
Common Shares:		
Full Diluted	125,049	68,165
Year-end	125,646	68,358

WARNER BROS DISCOVERY INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	18,791,000	19,671,000
Cost & expenses	16,019,000	26,514,000
Operating income	(222,000)	(10,475,000)
Other income (expense), net	3,173,000	654,000
Net before taxes	2,020,000	(10,854,000)
Income taxes	881,000	129,000
Net income	1,139,000	(10,983,000)
Earnings common share		
Primary	\$0.46	\$(4.48)
Fully Diluted	\$0.45	\$(4.48)
Common Shares:		
Full Diluted	2,500,000	2,447,000
Year-end	2,475,000	2,451,000

WARNER MUSIC GROUP CORP**Earnings, 9 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	4,839,000	4,796,000
Cost & expenses	4,102,000	3,949,000
Operating income	551,000	680,000
Other income (expense), net	(48,000)	(9,000)
Net before taxes	384,000	550,000
Income taxes	123,000	120,000
Net income	261,000	430,000
Balance for common		389,000
Earnings common share		
Primary	\$0.49	\$0.75
Fully Diluted	\$0.49	\$0.75
Common Shares:		
Full Diluted	520,003	517,399
Year-end	521,267	517,918

WENDY'S CO (THE)**Earnings, 6 mos. to (Consol. – \$000):**

	06/29/25	06/30/24
Total Revenues	1,105,480	1,105,480
Cost & expenses	815,253	844,746
Operating income	187,386	180,663
Other income (expense), net	5,853	13,147
Net before taxes	130,817	132,280
Income taxes	36,475	35,644
Net income	94,342	96,636
Earnings common share		
Primary	\$0.48	\$0.47
Fully Diluted	\$0.48	\$0.47
Common Shares:		
Full Diluted	197,166	206,578
Year-end	191,345	204,149

WERNER ENTERPRISES, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,465,262	1,529,878
Cost & expenses	1,263,967	1,347,737
Operating income	60,489	35,199
Other income (expense), net	1,124	(233)
Net before taxes	45,702	21,446
Income taxes	12,301	5,998
Net income	33,401	15,448
Earnings common share		
Primary	\$0.55	\$0.25
Fully Diluted	\$0.55	\$0.25
Common Shares:		
Full Diluted	61,532	63,291
Year-end	59,830	61,808

WESTROCK COFFEE CO**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	494,655	400,889
Cost & expenses	522,737	427,429
Operating income	(28,082)	(26,540)
Other income (expense), net	2,970	(233)
Gains or losses		1,653
Equity earnings	(3,507)	110
Net before taxes	(50,830)	(40,152)
Income taxes	1,458	1,170
Net income	(48,781)	(41,432)
Balance for common	(48,609)	(41,258)
Earnings common share		
Primary	\$(0.51)	\$(0.47)
Fully Diluted	\$(0.51)	\$(0.47)
Common Shares:		
Full Diluted	94,480	88,209
Year-end	94,708	88,366

WEYCO GROUP, INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	126,251,000	135,490,000
Cost & expenses	115,327,000	120,578,000
Operating income	10,924,000	14,912,000
Other income (expense), net	(186,000)	(238,000)
Net before taxes	12,155,000	16,543,000
Income taxes	4,356,000	4,286,000
Net income	7,799,000	12,257,000
Earnings common share		
Primary	\$0.82	\$1.30
Fully Diluted	\$0.81	\$1.28
Common Shares:		
Full Diluted	9,612,000	9,564,000
Year-end	9,539,379	9,490,681

WILLDAN GROUP INC**Earnings, 6 mos. to (Consol. – \$):**

	07/04/25	06/28/24
Total Revenues	325,859,000	263,485,000
Cost & expenses	297,063,000	244,455,000
Operating income	18,852,000	11,809,000
Other income (expense), net	510,000	1,530,000
Net before taxes	15,374,000	9,242,000
Income taxes	(4,749,000)	1,706,000
Net income	20,123,000	7,536,000
Earnings common share		
Primary	\$1.41	\$0.55
Fully Diluted	\$1.36	\$0.54

Common Shares:

Full Diluted	14,778,000	14,001,000
Year-end	14,611,000	13,916,000

WW INTERNATIONAL INC**Earnings, 6 mos. to (Consol. – \$000):**

	06/30/25	06/29/24
Total Revenues	375,735	408,621
Cost & expenses	351,946	642,020
Operating income	23,789	(233,399)
Other income (expense), net	1,136,301	1,683
Net before taxes	1,120,503	(285,020)
Income taxes	1,146	39,613
Net income	1,119,357	(324,633)
Earnings common share		
Primary	\$111.94	\$(4.09)
Fully Diluted	\$111.94	\$(4.09)
Common Shares:		
Full Diluted	10,000	79,345
Year-end		79,704

WYNN RESORTS LTD**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	3,438,194	3,595,841
Cost & expenses	2,596,677	2,611,904
Operating income	533,189	632,599
Other income (expense), net	(45,621)	2,462
Gains or losses	(30,651)	(2,397)
Net before taxes	179,976	350,720
Income taxes	21,610	27,949
Net income	158,366	322,771
Earnings common share		
Primary	\$1.33	\$2.31
Fully Diluted	\$1.33	\$2.30
Common Shares:		
Full Diluted	104,749	111,222
Year-end	103,977	111,375

XENCOR, INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	76,340	39,904
Cost & expenses	152,695	149,937
Operating income	(76,355)	(110,033)
Other income (expense), net	(863)	(30,136)
Net before taxes	(79,340)	
Income taxes	117	
Net income	(79,457)	(142,898)
Earnings common share		
Primary	\$(1.07)	\$(2.29)
Fully Diluted	\$(1.07)	\$(2.29)
Common Shares:		
Full Diluted	73,975	61,444
Year-end	71,297	61,766

XERIS BIOPHARMA HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	131,658	88,703
Cost & expenses	124,845	105,714
Operating income	1,392	(22,432)
Other income (expense), net		(2,690)
Gains or losses		3,975
Net before taxes		(32,929)
Income taxes		1,056
Net income	(11,148)	(33,985)
Earnings common share		
Primary	\$(0.07)	\$(0.24)
Fully Diluted	\$(0.07)	\$(0.24)
Common Shares:		
Full Diluted	155,972	144,373
Year-end	161,225	148,937

XEROX HOLDINGS CORP**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	3,033,000	3,080,000
Cost & expenses	3,014,000	3,080,000
Operating income	(123,000)	(129,000)
Other income (expense), net	(45,000)	(42,000)
Net before taxes	(127,000)	(125,000)
Income taxes	69,000	(30,000)
Net income	(196,000)	(95,000)

Balance for common	(203,000)	(102,000)
Earnings common share		
Primary	\$(1.62)	\$(0.83)
Fully Diluted	\$(1.62)	\$(0.83)
Common Shares:		
Full Diluted	125,452	124,062
Year-end	125,806	124,319

Y-MABS THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	40,429	42,729
Cost & expenses	52,576	59,426
Operating income	(12,147)	(16,697)
Other income (expense), net	3,723	1,079
Net before taxes	(8,424)	(15,618)
Income taxes	12	260
Net income	(8,436)	(15,878)
Earnings common share		
Primary	\$(0.19)	\$(0.36)
Fully Diluted	\$(0.19)	\$(0.36)
Common Shares:		
Full Diluted	45,212	43,901
Year-end	45,438	44,567

ZENTALIS PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	40,560	40,560
Cost & expenses	81,681	130,473
Operating income	(81,681)	(89,913)
Other income (expense), net	6,528	12,085
Net before taxes		(77,828)
Income taxes		409
Net income	(75,153)	(78,237)
Earnings common share		
Primary	\$(1.05)	\$(1.10)
Fully Diluted	\$(1.05)	\$(1.10)
Common Shares:		
Full Diluted	71,836	70,969
Year-end	72,135	71,107

ZIFF DAVIS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	680,845,000	635,285,000
Cost & expenses	498,794,000	570,855,000
Operating income	68,613,000	64,430,000
Other income (expense), net	(8,589,000)	5,163,000
Gains or losses		(14,485,000)
Invest. income	4,340,000	3,051,000
Equity earnings	(11,745,000)	(8,172,000)
Net before taxes	51,710,000	54,586,000
Income taxes	12,873,000	15,221,000
Net income	50,582,000	47,537,000
Earnings common share		
Primary	\$1.20	\$1.04
Fully Diluted	\$1.19	\$1.02
Common Shares:		
Full Diluted	43,655,507	50,889,579
Year-end	41,168,057	44,740,322

ZILLOW GROUP INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	1,253,000	1,101,000
Cost & expenses	1,273,000	1,184,000
Operating income	(20,000)	(83,000)
Other income (expense), net	40,000	66,000
Net before taxes		(36,000)
Income taxes		4,000
Net income	10,000	(40,000)
Earnings common share		
Primary	\$0.04	\$(0.17)
Fully Diluted	\$0.04	\$(0.17)
Common Shares:		
Full Diluted	253,916	234,074
Year-end	241,132	231,407

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2025 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.